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Microvascular obstruction is a common repercussion of percutaneous coronary 
intervention in treating acute myocardial infarction, and results from a combination of downstream 
microembolization, ischemia-reperfusion injury, and inflammation. Ultrasound-targeted 
microbubble cavitation (UTMC) uses external therapeutic ultrasound pulsation to target 
intravascularly infused microbubble contrast agents to produce shear stresses which mechanically 
disrupt obstructing microemboli. This work aims to enhance the therapeutic effects of UTMC 
through synergistic co-administration of nitrite for enhancement of perfusion and nitric oxide 
bioavailability (Aim 1) and develop a novel microbubble agent using nitro-alkenes for therapeutic 
reduction of inflammation after ischemia-reperfusion injury (Aim 2). 
For characterization and optimization of nitrite co-therapy with UTMC, a rat 
gastrocnemius model was used with contrast-enhanced ultrasound imaging. A nitric oxide 
porphyrinic membrane catheter probe was inserted into the treatment site for real-time 
measurement of nitric oxide concentration changes. In addition to nitrite co-therapy, effects of 
administering an endothelial nitric oxide synthase inhibitor as well as varying microbubble 
concentration and therapeutic ultrasound pressure were studied. Results showed that UTMC and 
nitrite demonstrated positive synergy for enhancing nitric oxide concentration and perfusion which 
depended on functional endothelial nitric oxide synthase. 
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After a novel nitro-alkene microbubble agent was synthesized and characterized, it was 
applied in both healthy and ischemia-reperfusion injury rat gastrocnemius models. Tissue samples 
were collected after treatment for quantification of nitro-alkene delivery, changes in inflammatory 
gene expression, and contrast-enhanced ultrasound imaging was used to quantify changes in 
hindlimb perfusion after treatment. Results showed that incorporation of the nitro-alkene into a 
microbubble formulation with UTMC greatly enhanced targeted tissue delivery of the nitro-alkene 
compared to standard microbubbles co-administered with the nitro-alkene and systemic infusion 
of the nitro-alkene alone. In addition, nitro-alkene microbubble UTMC resulted in greatly 
enhanced perfusion as well as decreases in inflammatory gene expression. 
In summary, both of these applications of enhancing UTMC therapy demonstrate 
significant mechanistic interactions with endogenous nitric oxide metabolism and may serve to 
enhance nitric oxide bioavailability through different pathways. They may also improve the 
relevance of UTMC in treating the biological sequelae of microvascular obstruction without 
compromising its mechanical function in disrupting microemboli. 
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Preface 
Nitro-alkenes and nitro-fatty acids are used interchangeably in this work. Ultrasound-
targeted microbubble cavitation is referred to as UTMC. 
 1 
1.0 Basics of Ultrasound 
This chapter serves as a background to the ultrasound (US) component of ultrasound-
targeted microbubble cavitation (UTMC). Fundamental principles of ultrasound technology are 
discussed, with additional details regarding harmonic imaging due to its relevance to microbubble 
(MB) contrast agents. Use of MB contrast agents in imaging and their characterization and 
interactions will also be discussed but primarily with an imaging focus. Their various 
compositions, functionalizations, and applications will be discussed in a later chapter. Applications 
of US imaging in various clinical contexts will be discussed as well, albeit briefly because of the 
vast and diverse literature which is ever-expanding. Therapeutic US without the combination of 
MBs will also be briefly discussed briefly given its differences in mechanisms and applications 
compared to UTMC. 
1.1 Basic Principles of Ultrasound 
Sound is at its essence, a longitudinal wave involving the compression and rarefaction of 
particles. It requires a source, such as a vibrating object, as well as a medium through which to 
propagate. For example, acoustic speakers that one might find at a musical concert generate sound 
through vibration of a membrane, which then propagates through air as its medium, before being 
received in the ears of the audience. Sound waves have general wave properties such as frequency, 
or the number of cyclical pressure changes occurring at a point in space over a unit of time (with 
units of cycles per second, or hertz abbreviated Hz), peak pressure, which is the greatest 
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compressive or rarefactive pressure reached over the course of a cycle of the sound wave (with 
units of pressure in pascals abbreviated Pa), and propagation speed, which is the speed of the sound 
wave traveling through the medium itself, which is determined by physical properties of the 
medium especially density and stiffness (with units of velocity such as meters per second).  
As its name implies, ultrasound (US) is sound with frequency in excess of the upper limit 
of human hearing (approximately 20 kHz), similar to how ultraviolet light is light with frequency 
greater than that of violet light. In clinical contexts, the overall range of frequencies of US used 
may vary from 1 MHz to 20 MHz, depending on the source consulted [1, 2]. Additional methods 
of describing US arise from its application, such as using pulses of US at a time. Descriptions for 
pulsed US may include the number of cycles, or oscillations of compression and rarefaction, pulse 
length, or the time needed for a pulse to pass a point in space (which is based on the frequency of 
the pulse and number of cycles), as well as the pulse period, which is the time from the start of one 
pulse to the next, given that there may be a pause between pulses. For more complicated US pulses, 
the term duty cycle may also be used, which refers to the fraction of one pulse period in which the 
US is active. An example of a full description (and also the US scheme used in many treatments 
described in this dissertation) is 1.5 MPa at 1 MHz with 5000 cycles and a 3 s period. Additionally, 
pulse repetition frequency (PRF), or the number of pulses transduced per unit time, is also a 
measure that may be used. Given that US has both therapeutic and imaging applications, these 
parameters will affect varying aspects of each application. 
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1.2 Ultrasound Transducers 
US waves are produced by transducers which contain piezoelectric elements that convert 
electrical signals into vibrations. Modern US transducers favor artificial ferroelectric ceramics, of 
which lead zirconate titanate (PZT) is the most common. The arrangements of these materials in 
combination with others such as various plastics including polyvinylidene difluoride (PVDF) have 
been explored as well. PVDF may be polarized and chemically treated to enhance its piezoelectric 
properties. More recently, capacitive micromachined US transducers have been developed using 
micro-electromechanical systems, allowing for a wider range of shapes and dimensions. US 
transducers may employ a wide range of numbers and arrangements of these elements for various 
effects, with the simplest being the single-element transducer, with one element for transmitting 
US and one for receiving. Other designs include the annular array, the linear array, and even curved 
arrays [3, 4]. 
Although further detail regarding more complex designs of US transducers will not be 
covered in this dissertation, the key idea is that many of these designs aspire toward characteristics 
of an US transducer with ideal compatibility with human imaging, which include having a 
characteristic acoustic impedance (which is the ratio of pressure to volume flow, and also the 
density of the medium times the speed of sound, generally representative of the resistance of a 
material to the transmission of sound) matching that of the human body, being highly efficient in 
the production of US pulses and highly sensitive in receiving pulses, and having a wide range of 
amplitude pressures (dynamic range) as well as frequencies.  
The majority of work described in this dissertation was performed with a single element 
transducer for therapeutic US delivery, and a linear array transducer for simultaneous imaging. 
 4 
1.3 Basic Concepts in Ultrasound Imaging 
The basic principles of US imaging have remained relatively unchanged since its earliest 
developments. Imaging US uses a pulse-echo approach which is coupled with a visual display. In 
this method, the US transducer transmits pulses into the body, and then receives any reflected 
waves (echoes) and converts them into an image which may then be interpreted. Reflection of US 
waves known as echoes occur at the boundary between materials of different acoustic impedances, 
with the strength of the echo dependent on the difference in acoustic impedances. Conversely, 
materials with the same acoustic impedance will not generate an echo, and the US waves will 
merely pass through the boundary [5].  
In the context of the human body, impedances of various tissue components and mediums 
have been calculated and translated into percentages of reflection of US at their boundaries. Soft 
tissue boundaries and soft tissue to fluid boundaries have very low percentages of reflection (up to 
2% reflected), while soft tissue to hard tissue boundaries (such as fat to bone) have very high 
percentages of reflection (up to 50% reflected). The soft tissue to air boundary, such as from pleural 
membrane to pleural space, or at the skin surface, will reflect almost all US waves and prevent 
imaging of more distal structures. It is for this reason that coupling of the US transducer to the skin 
surface using gel is required, as well as strategic placement of the transducer to avoid unwanted 
reflection by bones [1, 6].  
For these reflections, if the interface between the two mediums is a large, smooth surface 
orthogonal to the wave propagation direction, the reflection (called specular reflection) will travel 
directly back to the transducer. However, if the angle of incidence for the US waves is not 
orthogonal to the surface, the resulting echo will return from the boundary at an angle equal to the 
angle of incidence. In addition, the remaining transmitted beam will be refracted, or deviated in 
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direction, in an amount dependent on the difference in velocity of US between the two mediums 
of the boundary as detailed by Snell’s law of refraction. These concepts are especially relevant to 
the imaging of foreign objects inside the body, as in the case of a needle, which will have a strong 
reflection against the soft tissue but may be missed by imaging depending on its angle of insertion 
[1]. 
Another behavior of US when encountering a rough or irregular surface, or reflectors 
smaller than the wavelength of the US pulse, is scattering, in which echoes are produced in a wide 
range of directions which reduces the overall intensity of the signal which returns to the transducer. 
The signal that does return generates an image of staticky irregularity known as speckle, which is 
a representation of the texture in various structures of the body such as the organs or muscle, or 
even red blood cells in vessels. Analysis of the speckle signal in itself is an entire subject of 
research which will not be further detailed here [4]. 
In all, these processes of reflection, refraction, and scattering all contribute to the 
diminishing of the US waves in intensity in a process referred to as attenuation. In addition to those 
detailed, other processes such as absorption of the US waves by particles (resulting in vibration 
and the production of heat) in a manner similar to friction, will limit the depth to which US waves 
may penetrate [1, 7].  
Frequency of the US beam is directly related to its attenuation, that is higher frequency US 
waves will be more susceptible to attenuation than lower frequency waves. This is because high 
frequency waves consist of more compression and rarefaction events for the same amount of 
distance than low frequency waves. These events, which we have described will generate heat 
through absorption of the US energy by particles of the medium, and therefore reduce the energy 
of the US wave, while lower frequency waves will lose less energy over the same distance. As 
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such, lower frequency US is used to visualize deeper structures while higher frequency US is 
limited to more superficial structures [2]. 
In addition to depth of penetration, frequency also governs axial resolution of imaging US. 
Axial resolution is defined as the minimum distance between what can be distinguished as two 
separate points (representing reflectors) in the direction parallel to US wave propagation. In short, 
higher frequency US will result in greater numbers of compression and rarefaction over a given 
distance, which will result in a greater capacity to generate distinguishable echoes for each 
reflector which are separated by more wavelengths (because the wavelengths are shorter). In 
contrast, lower frequency US (with greater wavelengths given the same velocity) will result in 
muddied, overlapping echo signals for two closely positioned reflectors, which, when detected by 
the transducer, will not be distinguishable as two separate echo events, which results in the 
visualization of a single reflector, rather than two separate reflectors [8].  
Another conceptual explanation for this is in terms of time, such that to distinguish between 
two separate echo events (generated by closely positioned reflectors), an echo separation time is 
necessary. A lack of an echo separation time results in the detection of only one event, and only 
one descriptor. Therefore, higher frequency US, with a shorter time between cycles, is capable of 
generating a smaller time between echo events, and therefore superior echo separation, and is 
capable of returning distinct signals for smaller distances between axially positioned reflectors. 
Mathematically, this concept of axial resolution is calculated to be half of the spatial pulse length, 
which is the product of the number of cycles in a pulse and the wavelength [8]. 
With these concepts of frequency, attenuation, and axial resolution, it is apparent that there 
is an exchange between depth of visualization and visual resolution as frequency changes. That is, 
lower frequency US will have greater depth of visualization due to less attenuation as the waves 
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travel through tissue, while having poorer resolution due to the longer wavelengths, while higher 
frequency US will have less depth of visualization but greater axial resolution. This determines 
what types of US are suitable for different applications, such as visualization of deeper patient 
organs versus a needle used for superficial vascular access. 
In contrast to axial resolution, lateral resolution refers to the minimum distance that two 
reflectors may be placed apart perpendicular to the direction of the US beam and still be 
distinguished as separate events. While in general terms the lateral resolution is improved with 
narrowing of the US beam width, the width itself will vary with distance from the US transducer 
surface. At the transducer surface, the width of the beam is approximately equal to the transducer 
width. As distance from the transducer surface increases, the beam will first converge until it is 
approximately half of the transducer width (this distance is called the near-zone length) and 
encloses what is referred to as Fresnel’s zone. After this distance, the beam will diverge and return 
to and even possibly exceed the width of the transducer in what is called the far zone (Fraunhofer’s 
zone) which reaches a distance from transducer to reflector that is twice the near-zone length. This 
phenomenon occurs due to the slightly phase-shifted travel paths of multiple US waves resulting 
in patterns of constructive and destructive interference. In addition to this pattern of lateral 
resolution changes which occurs in simple, unfocused US transducers, transducers may be focused 
as well either by curving their surfaces or through use of multiple element arrays, resulting in a 
focal zone of decreased width relative to the transducer width [8]. 
Aside from axial or lateral resolution, temporal resolution refers to the minimum time 
between consecutive image frames. This is particularly relevant when US is used to image 
structures in movement, such as the heart. Although temporal resolution, or framerate, may be 
manually programmed during recordings of US live imaging (referred to as cine-loops), temporal 
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resolution in general terms may be improved by reducing the depth or distance which pulses must 
travel, reducing the width of the imaging frame, and reducing the number of scan lines, which are 
the segments which compose of the final US image. 
1.4 Ultrasound Imaging Modes 
Brightness-mode imaging (also referred to as B-mode imaging) is the most common mode 
of medical US imaging. As its name implies, brightness displayed on a screen corresponds to the 
received signal from the pulse-echo approach previously described. In brief, transmitted pulses of 
US into the human body are then reflected back to the transducer, which then processes the signal 
from many pulses in sequence and combine them to generate an image. This image construction 
occurs in real-time and may produce the appearance of continual movement with the 
improvements in temporal resolution made in modern equipment, allowing physicians to use US 
to visualize movement of tissues and medical equipment in imaging-guided procedures. In 
addition, it is possible to change various parameters of the US pulse to modify the imaging outputs 
in areas such as depth, which involves changing the focus and time delay in receiving US echoes 
smoothly. This is also called dynamic focusing, as the US beam is always in focus even as echoes 
are received from structures of different depths. The US transducer structure and its resulting beam 
pattern determines the shape and quality of the resulting images. For example, element arrays 
which create a beam focus allow structures placed at the focal distance to be visualized with greater 
visual clarity [6]. 
Doppler US imaging involves characterization of moving reflectors or boundaries relative 
to the transducer. This is based on the Doppler effect by which the relative direction of movement 
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of a reflector such as a tissue boundary will affect the frequency of reflected US waves. Many 
modern Doppler US imaging systems are coupled with a B-mode scan and are referred to as color 
Doppler or color flow Doppler imaging due to their use of the colors red and blue to represent 
blood flow away or toward the receiving transducer, respectively. It is noted that these colors may 
also be used to represent magnitude of flow, with blue representing high and red representing low 
flow. In brief, B-mode imaging is used to localize a region of interest for Doppler imaging. Echoes 
from this region are isolated and analyzed for frequency shift. The most common application of 
Doppler imaging in clinical practice is analysis of blood flow with red blood cells being the moving 
targets. In those cases, it is important to orient the transducer parallel to the direction of motion to 
maximize the Doppler shift. Aside from color Doppler imaging, spectral Doppler analyzes a 
specific region and returns a velocity profile (line tracing) rather than visual indicators of flow. 
Spectral Doppler analysis may either be pulsed or continuous, with the tradeoff of continuous 
spectral Doppler analysis being an enhanced threshold for maximum flow detection in exchange 
for precision in localization of flow [5, 9]. 
Harmonic imaging, as it is pivotal to the imaging of microbubble contrast agents central to 
this dissertation, will be described briefly as well. Harmonic frequencies are frequencies which are 
integer multiples of the original frequency of the transmitted US pulse (which is also referred to 
as the first harmonic). Accordingly, the second harmonic of an US pulse, or wave, has twice the 
frequency as the first harmonic. This phenomenon occurs as US waves traveling through tissue 
become distorted and interact with each other in constructive and destructive interference. Some 
sources note that this may have been originally discovered by accident, that the pulse-echo 
technique applied to deeper tissue locations resulted in a significant second harmonic frequency 
signal. The received signal may then be filtered for specific frequencies of the harmonic 
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components, resulting in the exclusion of noise, and improvement of various aspects such as lateral 
resolution, reduced artifacts, and improvement in signal-to-noise ratio. The reason for harmonic 
imaging’s relevance to microbubble contrast agents is that the microbubbles, due to their size, 
oscillate at a similar frequency to that of the harmonic frequencies of imaging US pulses. This 
concept will be further discussed in the section on microbubble contrast agents [10-12]. 
1.5 Summary of US Imaging 
In all, US imaging is a versatile, mobile, and highly adaptable mode of imaging which has 
contributed significantly to the improvement of clinical practice, from diagnosis to intervention. 
Even now, advances are being made to expand the capacity of US imaging such as super-resolution 
US imaging, US tissue elastography, among others. In this dissertation, US was utilized in its B-
mode imaging and therapeutic capacities (which is also the subject of another section’s 
discussion). Imaging of rat hindlimbs was performed in both B-mode (mainly for transducer 
alignment) and contrast (harmonic) modes for evaluation of microvascular perfusion using 
microbubble contrast agents (which also doubled as therapeutic agents). Said microbubble contrast 
agents will be discussed in a later chapter. 
1.6 Therapeutic Ultrasound Without Microbubble Contrast Agents 
Although the subject of this dissertation involves therapeutic US applied in conjunction 
with microbubble (MB) contrast agents referred to as ultrasound-targeted microbubble cavitation 
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(UTMC), it would be remiss of us to disregard the therapeutic applications of US in absence of 
said MBs given its role in various fields of physical therapy, rehabilitation, and medical practice. 
While this is an entire field of study, we will summarize the biophysical mechanisms of therapeutic 
US and its various applications. 
Therapeutic US has typically been classified into two regimes based on intensity. Low 
intensity (around 0.1 to 3 watts per square centimeter) has applications in facilitating and 
stimulating various normal physiological processes, usually in response to various soft tissue or 
superficial injuries, or also to sensitize the skin for superficial delivery of various therapeutic 
agents. High intensity (usually greater than 5 watts per square centimeter) therapeutic US serves 
the purpose of selectively destroying target tissues [13-15]. 
Similarly, the biophysical effects of therapeutic US may be divided into thermal and non-
thermal effects. Thermal effects, as the name suggests, are based on heat energy produced by the 
interaction between US waves and tissue. As we discussed earlier in the various interactions 
between US and its medium of propagation, loss of energy through heat is a significant component 
of US attenuation due to the waves causing vibrations of particles in a manner akin to friction. 
High frequency US, because it entails more compression and rarefaction (both of which cause 
particle vibration) events per distance, will attenuate over a shorter duration and lose energy in the 
form of heat more readily than lower frequency US. This phenomenon is called acoustic 
absorption. As in other contexts of heat transfer from an energy source to a medium, the rate of 
heat absorption is described by both the intensity of the source as well as a coefficient characteristic 
of the medium. In this case, additional factors mediating this relationship include density of the 
tissue and its specific heat capacity. Various types of tissue, with different structural compositions, 
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will have different heat capacities. An early report estimates absorption to account for the majority 
of attenuation in the context of biological tissues [13, 16].  
This concept of heat transfer to tissues through US waves has historically been thought of 
being key to its applications, for example in physiotherapy, where the target connective tissues 
(being highly collagenous) have high heat absorption coefficients and may be targeted selectively 
by therapeutic US. Other similar targets may include synovium and joint capsules, muscles and 
their fascia, tendons and tendon sheaths, and major nerves. Benefits thought to arise from this 
application of heating include improvements in blood flow, decrease in stiffness, decrease in 
muscle spasms, and overall pain relief in the patient [15, 17].  
However, this perspective has been challenged in more contemporary studies of therapeutic 
ultrasound, which have localized changes in blood flow due to heating to be predominantly in the 
skin. In addition, increased blood flow has resulted in greater circulation of cooler blood to further 
diminish the warming effect. Studies involving radioactive tracers in human subjects have shown 
that the heating effect produced by US is also completely dwarfed by moderate exercise. While it 
has been proposed that higher intensities of US would also result in greater effects of heating, said 
intensities would no longer be therapeutically appropriate due to the pain that would likely be 
elicited in the patient. In addition, the idea of US heating improving flexibility of human 
connective tissue has not been found to be significant in human studies, and the effect size found 
in animal trials has led to discrepancies in therapeutic feasibility, leading many to believe that 
purely thermal effects of US are unlikely to be beneficial [15, 18]. 
Despite flaws in earlier assumptions made regarding the benefits of therapeutic US, more 
recent clinical applications have broadened and flourished, possibly in part due to the interest 
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generated by said earlier studies. Three broad areas of modern therapeutic US include high 
intensity focused US (HIFU), US-enhanced drug delivery, and shockwave lithotripsy (SWL).  
HIFU, as earlier noted in the application of high intensity US to destroy target tissues 
through heat, has been applied to a wide range of localized pathologies including cancers, benign 
prostatic hypertrophy, glaucoma, fibroids, and myocardial ischemia, among others. Not only has 
HIFU been found to cause tissue necrosis, it may also serve a cauterizing purpose for hemostasis, 
and has found additional use in emergency care for trauma control. In addition to these primary 
effects, the inflammation and necrosis caused by HIFU has also served as an immunogenic 
stimulant in eliciting further physiological responses to tissue damage. These immune responses 
have been thought to additionally contribute to the efficacy of HIFU against various malignancies, 
specifically in protecting against additional tumor growth. Typical HIFU applications operate in 
frequencies between 1-10 MHz and at the most common intensities between 1500 to 3000 watts 
per square centimeter. Certain newer clinical devices are capable of delivering up to 10000 watts 
per square centimeter. Newer piezoceramic and piezo-composite materials have further enabled 
development of HIFU therapies, along with array transducers which may further focus the US 
waves for enhanced effect. Other physical mechanisms of HIFU therapy include development of 
higher harmonics (as discussed earlier, being multiples in frequency of the base harmonic), which 
are much more readily absorbed (and therefore generate heat) in target tissues. Whereas 
previously, development of higher harmonics and therefore increased absorption was seen as 
undesirable for imaging purposes, the opposite is true for HIFU where absorption is the goal, 
resulting in a nonlinear conversion between US intensity and heat generation due to these 
mechanisms [19]. 
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US-enhanced drug delivery involves enhanced transport of drugs over various biological 
barriers in the human body. These barriers may range from scales including cell membrane 
disruption and transport, to vascular and extravascular compartments, to even penetration of 
thrombi for delivery of thrombolytic drugs. Although many studies involving the concept of 
sonoporation, or poration of membranes by sound, have used MB contrast agents in applications 
including delivery of genetic molecules to pathologic tissue and delivery of chemotherapeutic 
drugs to tumor models in animals. Frequencies of US used in these applications are much lower 
than for HIFU, and typically range around the low to mid kHz, up to 1-2 MHz. Transducers used 
are also not designed for high intensity performance as in HIFU, and do not necessarily require 
focusing. However, miniaturization is a direction of future transducer design development, 
especially for direct intravascular applications. Because many of the mechanisms of US-enhanced 
drug delivery, such as cavitation and microjetting, are identical to those involving MB contrast 
agents, these topics will be discussed in a later chapter [18, 20, 21]. 
 Lithotripsy, as the name implies, is the destruction of various types of stones, or 
accumulated mineralizations, in patient organs, most commonly kidney stones. US regimes for 
lithotripsy are typically short bursts of high intensity US similar to HIFU, with peak pressures 
reaching up to 140 MPa. As opposed to HIFU, intensities and durations of US in lithotripsy are 
limited by potential tissue injury. Many different designs of lithotripters have been implemented 
clinically, such as piezoceramic spherical lithotripters which employ an array design for the 
capacity to aim the resulting US beam. While mechanisms such as cavitation are also relevant to 
lithotripsy, other stone based physical mechanisms have been described including erosion, shear, 
and compression, due to the interaction between the fluid and stone surfaces. All of these processes 
are manifestations of the various combination effects of fluid jets resulting from cavitation, 
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generated cavitational bubbles collapsing and producing shockwaves, and material behaviors of 
the stones themselves such as fatigue, crack production and propagation, and fragmentation [18]. 
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2.0 Microbubble Contrast Agents and Therapeutics 
This chapter will introduce the concept of microbubble (MB) contrast agents used with US 
imaging. This will include the principles of their physical interactions with US waves and the 
various MB behaviors induced by said interactions. The physical characterization of MBs will also 
be discussed such as material properties, composition, and methods of synthesis. Especially 
relevant to this dissertation will be the various methods and directions in functionalization of these 
MBs to endow them with therapeutic properties. The directions, therapeutic agents used, and 
relevant clinical applications will conclude this chapter. 
2.1 Contrast-enhanced Ultrasound Imaging 
In the previous chapter, the various forms of basic US imaging were discussed, including 
B-mode imaging and Doppler US imaging. Although the utility of the various modes was 
described, they have many limitations as well. In clinical scenarios where monitoring of tissue 
perfusion is the goal, neither of these two broad methods of US imaging are ideal. B-mode imaging 
is not sensitive to distinguishing change or extent of perfusion. Although larger vessels may be 
visible in the imaging plane, enabling imaging guided vascular procedures such as catheter 
placement, tissue perfusion itself is not visible due to both the size limitations of detecting 
microvascular blood flow, as well as the limited differences in physical properties between the 
bulk tissue and smaller blood vessels. In addition, Doppler US, while it may detect blood flow and 
characterize said flow with velocity, is mainly limited to evaluation of larger blood vessels with 
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higher flow rates. Again, the low volumes and flow rates involved in typical physiologic perfusion 
are not detectable and are subject to the effects of various imaging artifacts. It is noted that while 
MB contrast agents were also later used with Doppler US imaging and did result in improved 
visualization and detection sensitivity for smaller blood vessels due to increased backscattering of 
the US waves off of contrast agents, visual artifacts such as blooming (over-exaggerated width of 
the imaged vessel compared to B-mode imaging due to scattering) and motion artifacts (tissue 
movement producing stronger signals than from the MB contrast), as well as general background 
noise [1, 7, 22, 23]. 
In addition to the limitations of the various other modes of US imaging, the desire for 
enhanced clinical utility was also motivation for the development of more sophisticated contrast-
enhanced imaging. For other modalities of medical imaging such as computed tomography and 
magnetic resonance imaging, contrast utilization to not only observe perfusion but also emphasize 
focal lesions and other patterns of pathology have greatly assisted in medical diagnosis. It is only 
relatively recently that US imaging also developed agents which could be administered to patients 
to improve diagnostic information. Given that US itself is becoming a staple of not only bedside 
and outpatient point-of-care contexts, but also in intra-operative contexts and in dedicated 
therapeutic applications, development of US contrast agents, namely MB agents, has become a 
burgeoning field [23, 24]. 
2.1.1 Early History of Microbubble Agents 
For the MB agents themselves, similar to many other advancements in science, their origin 
lies in fortunate accidents. The earliest discovery of the utility of MB agents in US imaging was 
made by Dr. Claude Joyner in the 1960’s. Dr. Joyner, a cardiologist, observed transient increases 
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in US signal intensity when performing a chemical dye injection into a patient’s left ventricle. His 
later investigations showed that these increases were due to the accidental formation and injection 
of small air bubbles forming at the catheter tip. As such, the earliest MB applications were 
essentially handmade in the most basic sense, resulting from fluid agitation in the presence of room 
air. Although these makeshift MBs did function, the inconsistency in their roughshod synthesis 
limited repeatability and proper scientific study, although these early steps paved the way for later 
discoveries, such as the stabilization of these bubbles by albumin (which occurred when blood was 
included in the agitated mixture), leading to the first pharmaceutically officiated contrast agent, 
Albunex™ [23, 25, 26]. 
2.1.2 Basic Physical Principles of Contrast-enhanced Ultrasound Imaging 
As previously discussed regarding the basis of US reflections being the differential in 
physical properties at the interface between two mediums, the fundamental source of MB contrast 
agent utility arises from two main responses of MBs to US waves. One is reflection at the bubble 
surface arising from the differences in acoustic impedance between the gas inside the MB agent 
and the surrounding blood or tissue. Generally, MB contrast agents are composed of a gas core 
stabilized by a shell (although as the earliest and most primitive forms of MB agents were merely 
agitated saline, those resulting gas particles were extremely short-lived due to the lack of a 
stabilizing shell). Because the difference in impedance between the MB and surrounding blood is 
very high, there is a strong, almost complete backscattering effect of US waves when encountering 
the MBs. However, because of the extremely small MB size and their scarcity in circulation, the 
actual amount of US which is directly reflected and returns to the transducer is insufficient for 
strong contrast-enhancing. The other most important aspect of the MBs is that they are echogenic, 
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meaning they are compressible and will be forced into oscillation along with the US wave itself if 
the size of the MB is sufficiently smaller than the wavelength of the US wave. In essence, during 
the compressive positive half cycle of the US wave, the MB will decrease in size, and later increase 
in size during the rarefactive negative half cycle of the US wave. Similar to a musical instrument, 
this MB behavior is frequency-dependent and reaches a peak at the resonance frequency, which 
has been shown to be inversely related to the MB particle size. As a result of this behavior, not 
only do MBs passively reflect US waves, but they themselves behave as small resonating sources 
of sound, resulting in a true enhancement of the US signal [27, 28]. 
With these two main mechanisms in mind, there is a range of MB responses to US waves 
based on the pressure amplitude of the wave itself. At relatively low amplitudes of US pressure, 
MB size is linear to the applied acoustic pressure as typically expected. The expansion and 
compression of the MB is the same in this behavior regime, and the MB shell integrity is relatively 
stable due to the regular movement it experiences. When US amplitude (pressure) is further 
increased, MB behavior begins to deviate from the previous pattern. Compression reaches a limit 
before expansion as smaller bubble volumes begin to resist further compression while further 
expansion of larger MBs require less energy, and the relative extent of these two phases becomes 
unequal, resulting in what is referred to as nonlinearity. In addition, the MB size is no longer 
linearly related to the applied US pressure. Due to this nonlinearity and deviations in MB response, 
distortions of the original stimulating wave occur, and MB oscillations result in formation of higher 
multiples of the original base frequency through constructive and destructive interference. This is 
familiar to us as the development of harmonic frequencies, with the most notable harmonic being 
the second. Human tissue and blood, being relatively solid and not gas-filled microparticles, do 
not demonstrate this type of behavior, and therefore the resulting signals produced by MBs may 
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be separated from that arising from surrounding tissue. Lastly, with even further increases in US 
amplitude, there has been an abrupt increase in US scattering of the MBs followed by a loss of the 
MB signal. This occurs as nonlinearity in the MB oscillation is greatly exacerbated, resulting in a 
loss of the periodic nature of MB behavior when driven by a periodic waveform. This is associated 
with rupture of the MB shell and release of the gas as well as potential fragmentation of the MB 
shell and production of smaller daughter MBs. This behavior is also highly nonlinear similar to 
the prior. The released free gas then proceeds to dissolve in the surrounding liquid (blood) at a rate 
dependent on the type of gas and its chemical interactions with blood [28-31].  
Although there are many forms of terminology for the various behaviors described, for our 
purposes we will refer to the second behavior as stable cavitation and the last behavior with MB 
rupture as inertial cavitation. Of course, the change in MB behavior between the various regimes 
described is continuous depending on the US pressure applied, and there is no all-or-nothing type 
response in that even at high pressures, only a partial population of circulating MBs may be 
ruptured depending on the numerous other factors which may affect, distort, or disrupt the applied 
US signal in a practical application. With these behaviors being the primary basis of the physical 
behaviors of MBs experiencing US stimulation, other concepts important to discuss are 
temperature increases, microstreaming and micro-jetting. In Chapter 1, absorption of US energy 
leading to increases in temperature was discussed as a main component of attenuation. With MBs, 
this concept still holds true, and excitation of the MBs with US waves results in this absorption 
and therefore dissipation of energy as a result of friction associated with viscosity and damping 
forces with oscillation. Generation of higher harmonics, particularly the second harmonic, by MBs, 
also enhances the heating effect. In addition, this heating effect is distinct from the heat produced 
during the inertial collapse of the MBs during inertial cavitation. The violent cavitation events may 
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generate extremely short-lived conditions within the center of the MB reaching up to thousands of 
degrees Celsius. In these extreme conditions, highly reactive radical chemical species such as 
hydrogen peroxide may be produced, although said production has been limited to excitation 
frequencies of 20 to 50 kHz in observation [24, 32]. 
Microstreaming is the concept of momentum from the oscillating MB transferring to 
surrounding fluid. This phenomenon may occur on a small scale around MBs undergoing stable 
cavitation (without collapse) and is of particular interest to clinical application when in close 
proximity to biological surfaces, such as the vascular endothelial compartment, or red blood cell 
membranes. In theory, these micro-streams may result in shear stresses along cellular surfaces, 
which have been though to contribute to not only uptake of extracellular compartment contents by 
cells, as well as mechanical effects [31, 33]. 
Micro-jetting on the other hand arises from more violent non-spherical oscillations at large 
amplitudes of US. During these oscillations, MBs may deform from their normal spherical shape 
into toroidal shapes when close to a rigid surface, which may produce a high-speed micro-jet 
directed toward the surface. It has been identified that these micro-jets may puncture and produce 
transient holes in cellular membranes, termed sonoporation, in in vitro studies. It is less clear 
whether this mechanism occurs in vivo given the differences and rigidity of tissue environments. 
However, recent high-speed microscopy work has shown that these various phenomena of fluid 
movement around oscillating MBs may produce endothelial invaginations which may be more 
significant for mechanotransductive pathways [28, 32, 33].  
Lastly, two additional phenomena of MBs that have been observed experimentally are 
primary radiation forces and secondary radiation forces. Primary radiation force is also called the 
Bjerknes, which describes the tendency of an unfixed object in the path of a propagating US beam 
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to translate in the direction of the beam. In practice, this may be applied to target MBs into specific 
tissue areas and even possibly stimulate cellular uptake, although in vivo experiments have shown 
that this is not entirely feasible due to the requirement of having a very high bubble to target (cell) 
ratio as well as damping effects of blood on MB activity. Secondary radiation force, which is also 
a Bjerknes force, involves interactions between MBs, nearby particles, and other MBs. This 
interaction involves MB attachment to a nearby surface which reflects sound radiating from the 
pulsating bubble, as well as attraction to other nearby particles, resulting in a proximity that may 
enhance the effectiveness of other behaviors such as micro-jetting and microstreaming. In all, these 
various behaviors are what dictate the elicited biological effects of targeted MB stimulation on a 
microscopic level. The various macroscopic physiological effects of the vast aggregation of these 
miniscule events and their interactions with various pharmacologic agents is the focus of this 
dissertation [10, 28, 31]. 
2.1.3 Enhanced Detection of Ultrasound Signals 
Previously, the capability of using second-harmonic imaging to detect MBs specifically 
was discussed. However, to fully isolate the MB signal amidst the scattered tissue signals, 
additional steps may be taken. One example aside from tuning the US receiver to the specific 
second harmonic frequency produced by the MBs, is through the use of a narrow band US pulse. 
Although this will decrease the resulting image resolution due to the decreased range of 
frequencies, it is specific to MBs in that fewer tissue scattered harmonic signals are generated. In 
addition, the pulse inversion method of imaging further improves upon the limitations faced by 
harmonic imaging and allow for lower US power to be used during continuous imaging of MBs. 
In essence, this technique involves sending two pulses in rapid succession into the tissue, with the 
 23 
second pulse being an inversion of the first (essentially the opposite such that their sum would 
cancel each other out). As these two pulses travel through the tissue and eventually encounter the 
MB agents, they generate echoes which become nonlinear based on the previous principles 
discussed. Therefore, the echoes are no longer perfect opposites of each other, and their sum is no 
longer zero. It is this non-zero summation signal which returns to the transducer for detection and 
is recognized as signal only generated from encountered MBs. In contrast to using a narrow band 
signal, the pulse inversion method is not restricted to specific frequencies, and as a fuller range of 
frequencies may be used, a much improved, high-resolution image of the MB echoes may be 
produced. As such, weaker echoes may also be detected, even at lower US intensities where MBs 
are not necessarily destroyed. Currently, the pulse inversion method is largely the preferred method 
of imaging MBs [25, 27, 29]. 
A different method of imaging, used in the present work in this dissertation, is burst-
reperfusion imaging, also called intermittent imaging. This technique relies upon the MB behavior 
of rupture after stimulation by high pressure US. Essentially, a pulse is applied which bursts all 
MBs in the imaging field, followed by a wait period to allow for new MBs to replenish the imaging 
field circulation. It has been established that the speed at which MBs are replenished to an 
asymptote of maximum brightness is directly correlated to hemodynamic parameters in 
microvascular perfusion. This technique is unique to US imaging because no other imaging 
modality has the capacity to instantaneously eliminate all contrast from its visual plane. While this 
is similar to sensing the technique of detecting the transient echo of destroyed MBs (also known 
as loss-of-correlation imaging, transient scattering, power-enhanced scattering, and stimulated 
acoustic emission), typically higher concentrations of MBs are needed for consistent images. Other 
variations on these techniques, especially pulse inversion or phase inversion mode imaging, have 
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been recently developed and implemented. Power pulse inversion involves repeating the inverted 
pulse sequence multiple times and taking the average of the resulting signal, thereby improving 
the signal-to-noise ratio. Similar to Doppler imaging, the B-mode image may also be displayed in 
the background for localization of the MB signal. Another technique uses pulse inversion as well 
as changing the US amplitude pressure, allowing for detection of non-linear signals in the second 
harmonic at improved sensitivity. This has been implemented as contrast pulse sequences (CPS) 
and is used in this dissertation work. Yet another approach uses both conventional Doppler 
imaging as well as the phase inversion pulse sequence to distinguish between slow and stationary 
MBs as well as indicate the direction of MB flow in larger vessels with conventional red and blue 
tints and is coined as Vascular Recognition Imaging [24, 27, 29, 31]. 
2.2 Microbubble Properties and Compositions 
After discussing the various physical principles behind the function of MB contrast agents, 
we will now detail the various properties, characterizations, and compositions of these agents. As 
the composition and structure of these MB agents, from the types of lipids and gases used, to their 
size, and shell chemical structure, are all intrinsically tied to their various purposes, function, and 
enhanced therapeutic potential, the development of novel MB agents is an expansive field of 
ongoing research.  
For all MB contrast agents, survival in the circulating environment is a key optimization 
parameter. Namely, to enhance longevity, passage through the pulmonary vascular beds was 
necessary to enable re-circulation of the contrast agent. In addition, stability through the pulmonary 
environment was also necessary to prevent gas transport of the MB gas component resulting in 
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patient exhalation of the gas. To address this, a shell was necessary for the MB agent. This was 
typically a lipid or polymer (or a mixture of both) coat which stabilized the gas core of the MB 
against dissolving into the surrounding fluid medium. Aside from serving as a stabilizing 
surfactant, the shell also prevented attachment of the MB to the vascular endothelial compartment 
of the pulmonary circulation. Another aspect to avoiding entrapment in the pulmonary 
microcirculation is size, and as such, MB particles were required to be on scale or smaller than red 
blood cells (around 4-5 microns in diameter). Because with such miniscule size comes an 
extremely high surface-to-volume ratio, and because room air is highly soluble in the surrounding 
medium (room air being high in nitrogen content, and patients often having decreased levels of 
nitrogen gas in their bloodstream due to receiving inhaled oxygen), these early-generation MB 
shells were highly unstable and short-lived. To address these fundamental issues in stability, two 
approaches were taken. One was replacing the chemical species of the MB gas core with a more 
stable alternative. This typically involved fluorocarbon gases rather than air. Fluorocarbon gases 
have much lower solubility in aqueous mediums compared to room air species, and as such, many 
later developed clinical agents used some form of fluorocarbon or carbon-species based gas. In 
addition, high molecular weight gases have greatly reduced tendencies to diffuse through the MB 
shell membrane and are also biologically inert. The in-house MB agents synthesized in the work 
of this dissertation followed in this trend, using perfluorobutane as the preferred species for the 
MB gas core. The other direction of improvement, rather than addressing the contents, was 
improving on the outer coating, or shell, of the MB. The earliest MBs had crude, simply agitated 
shells of human albumin mixed with various contaminants from whole blood. Later, synthetic 
approaches were taken with a mixture of various protein and polymer components. Common 
polymers used for this application were in the polylactide-co-glycolide family. Due to the 
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numerous chemical offshoots of these materials, this will be covered in an additional sub-section 
on coated gas MBs [23, 31, 33]. 
Despite what seems to be a boundless array of possibilities for MB contrast agents, the 
general classification of these MB agents into families may be simplified into the following 
groupings. 
2.2.1 Coated Gas Microbubbles 
Coated gas MBs are the most common type of MB agent utilized in most imaging and 
contrast-enhanced US applications. As mentioned earlier, one of the earliest iterations of this form 
of MB came about by agitating saline with a small amount of human blood mixed in, resulting in 
air bubbles coated with albumin. This resulted in prolonged contrast enhancement because the 
albumin barrier increased the MB lifespan considerably due to reducing the interface tension 
between the gas core of the MB and the surrounding medium (usually blood or saline). Due to 
commercialization and mass production of these products, newer iterations were developed, 
although human serum albumin (HSA) remains a popular choice and is used in products such as 
Albunex and Optison (which are both available for clinical use). Not only is denatured HAS 
flexible in the shell to allow for sufficient MB response to the US waves and pressure changes 
when sonicated, but it is also biologically inert due to the denaturation process destroying any 
immunogenic (antigenic) components of the protein itself. However, as with all protein products, 
there are always theoretical risks with the transference of viral or prion infections, and therefore 
the origins of the shell components have been mandated to be disclosed clearly to all patients 
potentially receiving these agents. Aside from HSA, phospholipids are a popular choice, including 
in the therapeutic in-house synthesized MB agents used in the work for this dissertation. For 
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phospholipids, the size and thickness of the shell for the MBs formed are determined by the species 
of lipids used. Typically, these MB formulations require agitation with a gas-liquid interface 
present to form the actual MBs, rather than preserving pre-formed MB particles such as with a 
lyophilized powder which may be frozen and stored. One benefit of using a precise phospholipid 
mixture is that the resulting MB particles are remarkably stable and consistent in size. In addition, 
phospholipid coatings are much more stable than protein coatings during sonication as well as 
during circulation, improving upon MB echogenicity as well as longevity in circulation. Adding a 
polymer brush layer conjugated to the phospholipid species further improves biocompatibility as 
well as stability. Due to the various pre-existing conjugation techniques to common polymers such 
as polyethylene glycol, multiple layers of experimental agents may be added for goals of 
improving echogenicity, stability, and therapeutic benefit [29, 34]. 
Another type of MB shell construction involves rigid polymeric species which are superior 
in creating a leakproof, gas-tight shell which is biodegradable. In comparison with protein or lipid 
shells, polymer shells are thicker and stiffer. Given that the contrast agent properties of MB agents 
rely on their response to US sonication and in compression and expansion, these polymer shell 
MBs are less responsive and therefore less efficient in producing a contrast enhancing effect. 
However, the benefit of using polymer bubbles is that the shell characteristics are more readily 
controlled, allowing for specific pressure thresholds of rupture, which may be utilized in a 
therapeutic context. Other methods of stabilization for these coated MBs include use of a 
carbohydrate matrix to stabilize the MB in its prepared solution, which then dissolves in the 
bloodstream, leaving behind a revealed lipid coated MB, such as the case with Echovist and 
Levovist, which utilize galactose and palmitic acid in these roles. In addition, rather than using 
physical agitation to form the MBs, hypobaric pressure application with electrical shocks may also 
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produce phase-changing effects which result in production of particles, such as with EchoGen, 
which utilizes a liquid-in-liquid emulsion containing a perfluorocarbon gas in the liquid phase [32, 
35-37]. 
Although we have briefly touched upon the most common compositions of coated gas MBs 
in this section, a later section will expand upon these ideas in further detail and discuss further 
specifics of the chemical species used. 
2.2.2 Other Types of Microbubble Agents 
Other categories of MB agents aside from coated gas MBs are phase-shifted emulsions, 
echogenic liposomes, and cavitation nucleated MBs. Phase-shifted emulsions, as the name implies, 
consists of an emulsion of volatile fluid droplets and lipid shell components (surfactant molecules). 
Typically, the volatile component has a boiling/vaporization point close to the normal temperature 
of the human body (37 degrees Celsius), resulting in formation of the MBs either directly after 
injection or after sonication at sufficient intensity. The main advantages of this technology include 
stability during storage and administration, as well as the ability of the agent to diffuse into 
compartments which are not typically accessible by fully formed MB agents. This type of agent 
may also be referred to as liquid nanodroplets or nanoparticles, due to the droplet nature of the 
liquid emulsion while in solution or circulation. The transformation of the phase shift due to US 
stimulation allows for superior imaging or even therapeutic leverage using these agents for 
compartments such as the interstitium or tumor masses. Echogenic liposomes are a lipid bilayer 
(as opposed to a monolayer for the typical coated MBs) which encapsulate both liquid and gas. 
This type of agent offers enhanced stability compared to phospholipid MBs due to the bilayer, as 
well as improved delivery of therapeutic agents due to the increased amount of non-aqueous 
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substances that may be contained. However, these liposomes have decreased gas content compared 
to conventional MBs, and therefore are less echogenic on imaging as well. Therefore, higher 
concentrations of liposomes are needed for the equivalent amount of contrast enhancement on 
imaging and different pulse regimes may be necessary for rupture, although the acoustic qualities 
themselves of the liposomes (in terms of the efficiency of scattering US rather than directly 
absorbing US) may actually be superior to conventional MBs [21, 34, 38, 39]. 
As mentioned in Chapter 1, the concept of cavitation is of itself independent of any MB 
agents, and therefore the concept of endogenously sourced MBs will also be discussed here. 
Cavitation, once again, refers to the phenomenon of rarefactive phases of US waves drawing out 
dissolved gas from the solution medium. This gas may then form MBs, which then behave akin to 
the agents previously discussed. Various parameters may affect this process, such as temperature, 
diffusion, and pressure. This cavitation is typically seen only at higher pressures of US than those 
used for only imaging, and instead at those used for HIFU applications such as surgical ablation. 
The bubbles may then undergo violent inertial collapse, resulting in damage to the surrounding 
tissue. In thinking of the development of these bubbles as cascade events of the buildup of gas 
molecules, the application of MB contrast agents may also be thought of as reducing the threshold 
necessary for this to occur or reducing the cavitation threshold. Because these MB agents are 
exogenously seeded into the circulation and provide a basis for the formation of larger bubbles, 
these MB agents and nanoparticles allow formation of bubbles at much lower US intensities, 
although the exact mechanisms for this are yet unclear [28, 31, 33, 34]. 
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2.2.3 Microbubble Agent Preparation Methods 
Preparation of a MB agent involves whatever steps are necessary to transition from a stock 
packaged solution to one which is ready for infusion into the patient. The earliest method of 
preparation involved vigorous agitation of a fluid sample with gas enclosed and remains extremely 
popular due to its simplicity and lack of technical demands. Nowadays, this may be achieved 
through either mechanical agitation or through high intensity US dispersal of a gas into a MB 
coating solution. Characteristics of the agitation including duration, rate, and energy input all affect 
the resulting MB particles, including concentration and distribution of size. Other methods include 
simply resuspending particles in solution prior to injection, given pre-formed MBs or liposomes 
(single-layered membrane preparations). As mentioned before, dissolution of crystalline 
carbohydrates and phase change of volatile liquids are also methods for MB agent preparation. 
Other preparation methods include high shear emulsification (which may often be mechanical), or 
membrane emulsification, which involves extrusion of a liquid through finely sized pores in a 
membrane and into a suspension of the coat material. However, this method, as well as agitation 
and sonication, do not produce the most uniform populations of MB particles. More recently 
developed methods have been designed to offer more control over particle uniformity, and include 
ink jet printing (which extrudes fluid through mechanical nozzles), which uses only liquid 
components (therefore requiring additional subsequent steps to evaporate select volatile 
components resulting in bubble formation), electrohydrodynamic atomization, which involves a 
stream of fluid being focused in an electrical field, which then breaks the fluid into droplets. 
Coaxial electrohydrodynamic atomization involves two coaxial streams of fluid, which are placed 
within one another, resulting in the encapsulation of one fluid stream. Dispersal of the fluid stream 
into particles then results in formation of MBs and has been successfully demonstrated with 
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phospholipid and polymer coated gas MBs, as well as liquid filled capsules. Another more recently 
developed method for MB production which also reports the highest MB particle uniformity is 
through microfluidic devices, which involves focusing a jet of gas through a microscopic orifice 
into a flowing stream of fluid. As the gas-liquid interface passes through the orifice, the medium 
interface becomes unstable, and MB particles are naturally pinched off and deposited into a 
separate compartment. Addition of therapeutic components through this mean may also be 
accomplished through positioning various thin layers of oils, drugs, or other aqueous solutions at 
various positions along the columns of gas and fluid [34, 35, 37]. 
2.3 Principles of Therapeutic Microbubble Agents 
The previous part of Chapter 2 discussed the basic principles behind contrast enhanced US 
imaging (CEUS), the early development of MB agents, the various behaviors of MBs when 
targeted by an US field, methods behind enhanced detection of contrast MB signals, and a cursory 
discussion of the various types of contrast MBs and their methods of preparation. This part of 
Chapter 2 will trend more toward therapeutic aspects of MBs, including more specific details 
regarding their chemical composition, previous methods in functionalization of MBs (note that 
functionalization refers to any sort of modification of a pre-existing MB or design of a MB with 
therapeutic applications in mind aside from serving as a contrast agent in US imaging), as well as 
an overview of the general principles behind optimization of MBs and their behaviors. The last 
topic will delve briefly into molecular chemistry for the various interactions between agents used 
and their behaviors as part of a membrane, although the focus of this dissertation lies rather in the 
implementation and application of said therapeutic MBs in an animal model. 
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2.3.1 Formulations and Methods of Synthesis for Microbubble Shells 
As an expansion to the previous section discussing various types of coatings for coated gas 
MBs, this section will discuss all the compositions mentioned in further detail as well as include a 
few additions not previously mentioned. In all, these are protein, surfactant, lipid, polymer, and 
polyelectrolyte types of shells. 
2.3.1.1 Protein Shells 
Protein shells were the first implemented coatings for gas MBs as discussed, with human 
albumin being the first formulation that was formally approved by the US Food and Drug 
Administration under the name Albunex. Albunex MBs were generated by the sonication of a 
heated albumin solution in an atmosphere of room air, resulting in air MBs ranging from diameters 
of 1 to 15 microns across. Notably, however, these MBs were stable for up to 2 years with 
refrigeration. To disrupt the native molecular structure of proteins and to facilitate formation of 
membranes which would encapsulate air, the albumin solution used was heated to denature its 
contents [40]. The resulting protein shell is described as a mono-molecular layer of both denatured 
and native albumin molecules which interact in multiple orientations, mainly deriving its structural 
stability from the disulfide bonds (formed between cysteine residues) which are built during the 
cavitation or sonication process [41]. Because disulfide bonds are covalent in nature, they are 
relatively inflexible, and as a result the albumin gas MBs are also relatively inflexible during US 
sonication (which would therefore limit their echogenicity as previously discussed) [42, 43]. To 
improve upon the stability and longevity of the MB, the gas species of the MB core was later 
replaced with a perfluorocarbon gas as previously discussed, resulting in increased longevity in 
vivo. Present iterations of this form are marketed under the name Optison™, which is approved 
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for contrast echocardiography, or for the use of delineating the boundaries of the various cardiac 
cavities as well as observing myocardial perfusion [44]. 
Aside from albumin, proteins in general perform favorably when used in shells for gas 
MBs. This is likely due to their amphipathic nature (of having both positive and negative electrical 
charges on a single molecule), which results in them being highly surface active (which means 
they have a tendency to reduce the surface tension of any fluid, such as saline, in which they come 
into contact) [45]. As with albumin MBs, other protein species are typically stabilized by the same 
disulfide bridges between cysteine residues (which are conveniently found on most proteins). In 
addition, the protein avidin has also been previously incorporated into the albumin MB, which is 
notable due to the capacity for avidin to form biotin mediated bonds to other large molecules as a 
form of loading the MB with various therapeutics [46]. This concept will be discussed later in 
further detail. 
2.3.1.2 Surfactant Shells 
Surfactants are a term for a group of organic molecules which generally serve to reduce 
surface tension between two compartments or mediums, in this context being fluid and gas. These 
molecules are typically amphiphilic, meaning they have both hydrophobic and hydrophilic 
structures, which result in their organization at the interface usually between an aqueous 
compartment and a nonpolar compartment (gas in our case). Organization of these surfactants into 
micelles (single layer organizations of these molecules usually with the hydrophilic head pointing 
outward) is common, the behavior of which lends toward their use in coatings for gas MBs.  
Two species of synthetic surfactants, SPAN-40 (sorbitan monopalmitate) and TWEEN-40 
(polyoxyethylenesorbitan monopalmitate) have been used in combination to form stable MBs with 
room air. These molecules, as we discussed, are comprised of a sorbitol-derived group (which is a 
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carbohydrate, and therefore having polar characteristics), as well as a palmitic acid-derived group 
(which is a fatty acid, and also a main component of palm oil, therefore having nonpolar 
characteristics). Interestingly, these molecules are also used as industrial emulsifiers for cosmetics 
and food products. Sonication was once again the method used to generate MBs with these 
molecules in combination, although interestingly it was tested that the stability of the resulting MB 
shells after sonication was significantly stronger than the film of the surfactant molecules in 
solution prior to sonication. Another group had reported stable MBs formed using sucrose stearate 
(once again, a carbohydrate with a fatty acid), although these MBs were limited in further clinical 
utility [47-49]. 
2.3.1.3 Lipid Shells 
Lipids are perhaps the most interesting and most useful types of shell formulations for gas 
MBs both in imaging and drug delivery applications. Lipid bubbles may be found in nature, 
generated on beaches and in rivers as stabilizations of acyl lipids and glycoproteins, as well as in 
the human body, as natural lung surfactant which forms stable MBs in extracted lung lavage 
solution. Phospholipids, being amphiphilic, are an extremely popular choice, and are found in 
commercial products including Definity™ (Lantheus Medical Imaging) and Sonovue® (Bracco 
Diagnostics). The orientation of phospholipids around gas MBs are that their acyl chains 
(nonpolar) face the center with their phosphate headgroups facing outward [50, 51]. 
In essence, the favorability of phospholipids for MB stabilization arises from two main 
phenomenon; one is their ability to exist in a liquid-crystalline state with behavior similar to the 
fluid phase (in a manner akin to the fluid mosaic model of cellular membranes, which also mainly 
consist of phospholipids), and that low surface tension associated with the arrangement of 
phospholipids in that fluid state avoids formation of a Laplace overpressure on the gas core of the 
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MB which would typically force the gas core to dissolve. This way, having such low surface 
tension avoids creating that Laplace pressure on the gas core, allowing it to remain undissolved in 
solution, and thereby stabilizing the MB. The second phenomenon is the tight packing of the acyl 
chains resulting in significant hydrophobic attractive forces as well as van der Waals interactions 
between the chains due to their significant length, which also gives the phospholipid membrane a 
high degree of stability, and is also not dependent on the formation of chemical bonds such as with 
the disulfide bridges in protein shells. While the disulfide bridges rely on the presence of generated 
superoxide radicals during the sonication process, synthesis of phospholipid membranes is not 
restricted to such a process, allowing for various alternative synthesis methods [52-55]. 
In all, phospholipid shells are not only cohesive, they are also extremely pliable and weak 
in the manner of their construction. Therefore, because there is no actual structural covalent 
entanglement as with proteins or polymers, phospholipid shells are compliant and are capable of 
undergoing significant amounts of compression and expansion and have minimal damping 
(friction-like behaviors) and are also self-healing around an extent of fragmentation. These 
characteristics make phospholipid shells extremely favorable for CEUS imaging. In addition, 
because lipid species are easily modified in their headgroups or conjugated to other molecules, 
creation of functionalized MBs for applications such as drug delivery have also been explored, 
though this is subject to additional steps in synthesis and processing of the MBs themselves [35, 
56, 57]. 
2.3.1.4 Polymer Shells 
Polymer shells are much more restrictive than phospholipid shells due to their molecular 
nature and construction. Typical polymer shells consist of a thick region of cross-linked physically 
entangled polymer species. As discussed, this makes these shells much less echogenic than protein 
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or lipid counterparts. In addition, polymer shells may fracture like a cracked egg without complete 
disintegration during sonication, which results in escape of the gas core while the shell may remain 
intact. 
Various methods of synthesizing polymer MBs have been investigated in previous 
literature. One method involves spraying both air and an alginate solution into a reservoir of 
calcium solution, resulting in adsorption of the alginate to the gas-liquid interface and hardening 
upon exposure to the calcium solution. In a fashion distantly similar to electrospinning, 
characteristics of the resulting MBs depended on flow rate from the extruding syringes [58]. 
However, typical diameters resulting from this method were too large for IV administration, being 
between 30 to 40 microns across. Another method involved emulsification and evaporation steps 
with ethylidene units [59]. Resulting size and texture characterization with a Coulter counter and 
through scanning electron microscopy showed that the resulting polymer MBs had a range of size 
restricted to 1 to 2 microns in diameter, with smooth surface texture and no defects. Biodegradable 
polymers such as polylactide-co-glycolide (PLGA) have also been explored for MB synthesis 
through procedures such as multi-phasic emulsification followed by sublimation of a volatile 
solvent, resulting in a variety of internal morphologies (such as honeycomb-like structures) with a 
smooth exterior [60]. Gases used for polymer MB applications are similar to the other shell 
material compositions and include room air and perfluorocarbon species such as perfluoropropane. 
Animal trials using these PLGA microbubbles showed successful left ventricular opacification 
(which is an application similar to clinical use in human patients) with increased stability 
demonstrated by the perfluorocarbon gas-core MBs. Other species of polymers used include poly-
vinyl alcohols, which are chemically cross-linked at the gas and fluid material interface using high-
speed stirring (8000 rotations per minute) rather than sonification of the material solution, and 
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rather than varying the mechanical parameters of the agitation to control the resulting MB 
parameters, temperature was lowered instead to decrease the MB shell thickness. These poly-vinyl 
alcohol MBs were notable in that they were stable for several months after synthesis and were 
capable of being functionalized with hydrophobic therapeutic molecules, charged polymer species 
(with DNA being one such species), and targeted ligands for cell surface molecules. Again, ink-
jet printing is a more recent development in polymer MB printing technology, with dispersal of a 
polylactic acid co-polymer species into an aqueous solution along with an additional non-solvent 
core species which was later removed to create the hollow MB morphology [61, 62]. 
2.3.1.5 Polyelectrolyte Multilayer Shells 
Polyelectrolyte multilayer shells are a relatively new development of a hybrid class of MB 
shell coating. This composition involves the deposition of various electrolyte species onto the 
surface of pre-formed lipid or protein MB shells with the help of an additional substrate coating 
layer of either charged surfactant molecules or proteins between the electrolyte species and the 
original MB. Typically, this is achieved through a layer-by-layer technique, with subsequent layers 
having opposite charges being referred to as polyionic pairs. Shchukin et al. were the first to 
demonstrate this technique of polyelectrolyte multilayer deposition using the polymers of 
polyallylamine and polystyrene as a polyionic pair, resulting in a coating that is both uniform and 
provides the MB with additional stability. Other groups have developed additional material 
compositions using this technique, including the use of other polyionic pairs for the deposition 
layers including the cationic trimethylammonium propane and poly(L-lysine) as the other species 
for the polyionic pair. This technique may also be used to protect various functional molecules 
which are imbued into the inner layers, such as the coating of a DNA imbued layer with a later 
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polyallylamine hydrochloride layer, which serves to protect the DNA molecules from enzymatic 
degradation in the circulating biological environment [63-65]. 
2.3.2 Molecular Imaging with Microbubble Agents 
This application of functionalized MBs will be described briefly here, because while it is 
an expansive field of research of its own, it is not the particular focus of the work in this 
dissertation. In essence, molecular imaging with MBs involves surface modification of the MB 
with a specific ligand prior to injection into subject circulation, resulting in adhesion of the MBs 
by virtue of their surface modifications to specific molecular or rather cellular targets in the 
vascular endothelial compartment which express those specific ligand receptors. By leveraging 
specific ligand-receptor pairs which are upregulated in particular conditions or pathologies, this 
results in an enhanced, informative, selective contrast methodology which may serve the purpose 
of quantifying pathological changes in vasculature. Pathologies which are particularly relevant to 
this type of quantification and which have been well developed for this application of 
functionalized MBs include angiogenesis, inflammation, and atherosclerosis [35, 66-68]. 
The technique of imaging molecular targeted MBs typically involves injection of the 
targeted MBs, a time delay to allow for adhesion and circulation of the MBs, followed by recording 
and determination of the video intensity of the specific region of interest. This first measured 
intensity is then recorded. A destructive US pulse (destructive in the sense that it will result in total 
MB rupture, without damage to the tissue environment) is then applied, and MBs in circulation 
will then flow back into the field of view for the US, replenishing the depleted region following 
the destructive pulse. Video intensity for this replenishment is then recorded as well and taken to 
be the video intensity for freely circulating MBs without significant adhesion due to the lack of a 
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time delay following the destructive pulse. The subtraction of these two video intensities then 
becomes a quantification of the ‘stuck’ MBs, which typically require time to find and adhere to 
their molecular targets. In this way, the extent of MB adhesion between different pathologic groups 
of comparison and the difference in video intensities becomes a measure for pathologic severity, 
which is taken to be represented by the prevalence or concentration of the specific ligand receptor 
in question, which directly influences the extent and amount of targeted MB binding. 
MBs are particularly suited for this type of application in comparison to other types of 
contrast due to their particular size, which limits their presence to the circulating vascular space, 
but does not preclude them from smaller vessels of the microcirculation (up to capillary beds), 
their lifespan in circulation (which is on the order of 10 minutes), which results in sufficient half-
life for imaging purposes but does not persist unduly resulting in saturation of the viewing field 
and allows for a return to normalcy for the patient (and relatively quick imaging sessions on the 
physician and technician schedule), and also the capacity to apply destructive pulses of US to 
immediately remove all contrast from the field of view to apply techniques such as the subtraction 
of the contribution from freely circulating MBs, as previously described. This is again a unique 
characteristic of MB contrast agents as opposed to fluoroscopy or MR contrast imaging, in which 
a dye is injected but is not able to have its presence completely removed at the discretion of the 
imaging practitioner [36].  
In addition, physical behaviors of the MB when sonicated by US as we previously 
described also contribute toward the utility of MBs as molecular imaging agents. In particular, the 
radiation force, or directional influence of applied US fields targeting circulating MBs, as well as 
the radial expansion of MBs themselves against the distal boundaries of the vascular compartment, 
allow for more direct physical interception of the MBs against the endothelial wall. In addition, 
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oscillation of the MBs during sonication results in expansion of the MB shell, which may also 
allow for the leveraging of techniques such as the obscuring of the molecular ligands by other 
components such as a polymer brush layer (through PEGylation of the phospholipid species) and 
the later reveal of said ligands due to shell expansion and a sort of parting of the brush layer with 
sonication, which then facilitates binding using the surface ligands. It is these additional details 
which allows for innovative designs and mechanisms of molecular imaging focused MBs, 
improving upon the sensitivity and accuracy of these techniques in tracking pathological or 
physiological changes in the vascular space [69, 70]. 
2.3.3 Therapeutic Agent Delivery with Microbubbles 
Delivery of therapeutic agents using MB vehicles is perhaps the most heavily researched 
application of modern MBs, including the work of this dissertation. As mentioned before, payload 
delivery using MBs is intertwined with the technique of ultrasound-targeted microbubble 
cavitation in that the therapeutic value of the MBs would be incomplete and lacking without the 
US sonication. Although ultrasound-targeted microbubble cavitation is a therapeutic technique in 
its own right, with specific benefits, many of the biophysical effects of ultrasound-targeted 
microbubble cavitation impart significant benefits to delivery of therapeutic agents from the MBs 
as well. These include the phenomenon of sonoporation, or the poration of the endothelial barrier 
(cell membranes facing the vessel lumen) by oscillating or rupturing MBs, as well as the 
fragmentation and impact of the MBs themselves. This phenomenon will be discussed in the later 
ultrasound-targeted microbubble cavitation chapter [71]. 
Many of the MB agents used in these therapeutic applications are either commercially 
available for purposes of contrast enhancement (as previously discussed) or are derivatives thereof. 
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However, there has been a growing movement toward the development of MB carriers designed 
specifically to carry and deliver therapeutic agents with greater efficacy and efficiency. The two 
most common types of therapeutic agents delivered by these MBs include genetic material and 
drugs. 
Delivering genetic material to the human body has been a longstanding challenge in 
biomedical engineering, with the additional caveat of targeted delivery raising even more barriers. 
This is mainly because for effective treatment, that is having sufficient exogenous genetic material 
present for actually producing quantifiably modified expression of said genes, is limited by the 
large amounts of genetic material needed. In addition, genetic material in the bloodstream is 
rapidly degraded and cleared with extreme prejudice by the reticuloendothelial system and 
circulating nucleases. Hence, MB agents are needed to not only protect the genetic material from 
degradation prior to reaching its target site, but also to deliver adequate amounts of the genetic 
material to the specific location of interest [72]. 
Targeted drug delivery holds a similar rationale to delivery of genetic material, although 
many drugs are much less sensitive to immediate degradation in the bloodstream compared to 
genetic material. However, they are similar in that ideally the drug will be released into the local 
circulatory microenvironment after destruction of the bubble through ultrasound-targeted MB 
cavitation, which is also selective for location based on direction of the beam. One key difference 
between drugs and genetic material is that drugs are often incorporated within, beneath, or inside 
liposomes attached to the MB shell, rather than electrostatically bound to the MB surface. Again, 
the MB agents are used to protect, deliver, and target the drugs, with the additional potential effects 
of protecting the drug from first pass hepatic metabolism, which often covalently modifies or 
degrades certain chemical structures. 
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In a manner similar to previous, well-written reviews on this subject matter, we will 
organize the delivery of therapeutic agents into specific types of MB shell compositions, similar 
to the previous sections, namely discussing protein, lipid, and polymer MB shells. 
2.3.3.1 Protein Microbubble Shells 
As previously discussed, the main manner of structural integrity in protein shells for MBs 
is in the form of disulfide bridges forming cross-linking bonds between protein molecules. These 
bridges are formed during the sonication process of MB synthesis. As this is a relatively 
straightforward and simple process, the incorporation of macromolecules into these structures is 
also relatively straightforward. The macromolecules are most commonly incorporated into the 
shell material during the crosslinking phase of the sonication stage of synthesis, with an alternative 
being simple adsorption, or attaching the macromolecules to the protein surface through 
electrostatic interactions, which may be more amenable to charged macromolecules such as 
nucleic acids. As typical MB sizes are on the order of single digit microns in diameter, the presence 
of these loaded macromolecules does little to disrupt the acoustic behavior of the MB, allowing it 
to remain contrast enhancing during US imaging. 
One example of this in application is the incubation process of a target macromolecule with 
the protein solution followed by simple agitation with the gaseous core agent. A previous study 
performed this using a solution of albumin and fructose incubated with adenoviral vectors agitated 
and mixed with perfluoropropane, resulting in adenovirus loaded MBs, which were then injected 
into rats with successful delivery and translation of the protein products observed in the animal 
myocardium. This study, performed by Shohet et al., was one of the earliest studies demonstrating 
the feasibility of this simple approach [73]. 
 43 
Another similar application using rapamycin loaded albumin MBs performed by Kipshidze 
et al. emphasized another benefit of using albumin MBs for drug delivery purposes in a disease 
context in that albumin MBs have adhesive interactions with sites of pathogenic vessel injury, 
resulting in targeted delivery without specific ligand enhancement of the MBs, and also notably, 
without MB destruction using ultrasound-targeted MB cavitation techniques [74]. The mechanism 
of loading the therapeutic agent onto the MBs was not discussed by the authors, although one may 
hypothesize that their success was the result of electrostatic and hydrophobic intermolecular 
forces. It is also significant to note that this method has the disadvantage in efficiency of the drug-
loading process, in that expensive or scarce drugs/substances may preclude the process of 
incubation which relies upon sufficient concentration of the therapeutic agent in solution. In 
addition, the presence of negative ionic charges on both the proteins comprising the shell material 
itself and on macromolecules (such as other proteins or in the phosphate backbone of nucleic acid 
chains) may also lower the efficacy of these techniques. 
A different approach involves the direct incorporation of the therapeutic agent within the 
protein shell of the MBs during formulation rather than incubation and subsequent adsorption of 
the therapeutic agent [75]. Although there have been some studies validating this approach, 
limitations of evaluating its efficacy include a lack of proper controls in said studies especially of 
groups consisting of injection of unloaded MBs with a co-injection of free therapeutic agent in 
solution. Other obstacles include reaching sufficient efficiency of release of the therapeutic agent 
from the protein shell after MB rupture. Comparisons against commercially available transfection 
agents revealed that loaded protein MBs had significantly lower efficacy for cell transfection. 
As previously mentioned, polyelectrolyte multilayer deposition techniques have 
introduced new potential for protein MBs to be modified for carrying genetic material. Examples 
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of intermediate coating compositions (used as a bridge between the protein shell material itself 
and the genetic material) include negatively charged albumin as well as polyammonium 
hydrochloride [64, 76-78]. Results of studies investigating polyelectrolyte modified bubbles 
showed that the MBs themselves experienced greater longevity and circulating half-life of up to 7 
hours, and that the MBs remained viable in their response to sonication (and resulting cavitation 
behavior). In addition, the coated MBs showed that the purpose of protecting the genetic material 
with the intermediate coatings was indeed achieved, with polyammonium hydrochloride and DNA 
coated MBs revealing minimal degradation. These new techniques in modifying protein MBs for 
superior payload protection and delivery continue to be investigated with further goals of 
improving transfection efficiency and payload capacity. 
2.3.3.2 Lipid Microbubble Shells 
Lipid MBs are one of the more popular choices for targeted delivery of a therapeutic agent, 
as previously mentioned, due to their great capacity for chemical modification, favorable 
intermolecular interactions with many chemically active species of molecules, and resilient 
acoustic behaviors after modification. Because lipid and protein MBs may share certain types of 
synthesis procedures as previously discussed, such as simple sonication or agitation, direct 
incorporation of the therapeutic agent into the lipid shell without additional chemical modification 
steps is one of the most simple and common methods of modifying the lipid shell. One previous 
investigation demonstrated this through simple incubation of luciferase in the MB solution prior 
to formulation, followed by injection into rats with therapeutic ultrasound applied to the thorax 
[79]. This resulted in significant delivery of the luciferase enzyme and detection of the enzyme 
activity (thought to be mediated by destruction of the MBs) although loading efficiency, as always, 
is an ongoing target for improvement. 
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Another strategy of incorporating therapeutic agents into lipid MB shells involves 
acoustically active lipospheres, which are essentially lipid MBs with a thick inner coating of oil 
surrounding the gas core. With this thick coat of oil comes the capacity to incorporate hydrophobic 
agents without significant disruption to shell integrity, while ensuring their release upon MB 
destruction. Unger et al. first described this process in 1998, in a study which investigated the 
loading of paclitaxel (a hydrophobic anti-cancer drug) onto these acoustically active lipospheres 
[80, 81]. Resulting measurements showed a high efficiency of incorporation with no significant 
disruption to parameters such as MB size or acoustic behavior. However, it was noted that there 
were reductions to MB stability. Later studies further investigating and refining this technique 
have utilized previously described US radiation force and various pulse sequences to mechanically 
intercept the circulating MBs against the endothelial wall for drug deposition after MB 
fragmentation, with success both in vitro and in vivo [82]. Aside from paclitaxel, this concept is 
applicable to a wide variety of clinical contexts and therapeutic agents. 
Both of these techniques, whether incorporation into the lipid shell, or development of a 
hydrophobic inner layer, involve intrinsic modification of the lipid MB. In contrast to this, a 
different direction of lipid MB modification is limited to the surface, whether through direct 
attachment or through an additional carrier system. Advantages of surface modifications only are 
that the stability and echogenic properties of the MB shell are less likely to be affected. 
In some contexts, modification of the lipid shell is favorable to promote surface 
modification at a later synthesis step. One example of this is the introduction of charged lipid 
species into the lipid shell, which are by themselves not intrinsically bioactive, for the purpose of 
using electrostatic charges to later load a charged therapeutic agent onto the surface. One example 
of this was the use of cationic lipids for the purpose of binding genetic material (plasmid DNA) as 
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reported by Christiansen et al. in 2003 [83]. Not only has this approach been used with plasmid 
DNA, it has also been successfully applied to antisense oligodeoxynucleotides in anti-tumor 
applications both in vitro and in vivo. Similar to previous in vivo loaded-MB studies, the authors 
concluded that US stimulation of the MBs was a significant driving factor in the success of payload 
delivery, and interestingly enough even free genetic material was seen to be delivered more 
successfully in the absence of any MB vehicles. 
Again, no discussion of modified lipid MBs would be complete without the mention of 
polyelectrolyte multilayer membrane assemblies, as their application has again been demonstrated 
with lipids just as with protein MBs [63]. As with protein MB shells, lipid MB shells were 
successfully modified to carry plasmid DNA for delivery after sonication. However, it was found 
that the addition of these layers to the lipid MB shell did have damping effects on the oscillations 
of MBs during US stimulation which resulted in improvements for MB stability. Therefore, this 
novel approach toward MB modification holds significant potential in the area of lipid MB 
modification as well for targeted gene delivery. 
As mentioned, various chemical linkers and carrier systems have been developed for 
surface modification of lipid MBs. One common system is the biotin-avidin linker system, in 
which biotinylated lipids are incorporated into the MB shell [84]. The avidin molecule, which is 
capable of binding four different biotin groups, is then incorporated as an intermediate step 
followed by addition of a biotinylated therapeutic agent. Therefore, this process forms an avidin 
bridge between the therapeutic agent and the MB surface. Not only may this process be used for 
therapeutic molecules, but liposomes themselves may also be biotinylated for attachment to the 
lipid MB surface. Having mean diameters on the order of hundreds of nanometers, these liposomes 
showed extremely high binding efficiency to the lipid MB surface, allowing for significantly 
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increased concentrations of the therapeutic agent in modified MBs. Sonication of liposome-linked 
lipid MBs in vitro showed significant deposition of a dummy drug molecule. This approach has 
also been applied to liposomes containing genetic material, with the resulting structure termed as 
lipoplexes. These genetic material containing liposomes have been showed to be released from the 
vehicle lipid MB after MB destruction without significant disruption to the lipoplex structure. 
Early studies have shown that containment of genetic material in these structures enhances 
therapeutic efficacy of the material delivery. However, clinical relevance of this approach has yet 
been limited.  
It has generally been a previous pattern that delivery of genetic material using various non-
MB vehicles (cationic vehicles) have high efficiencies in vitro with a failure to produce 
quantifiable results of significant transfection in vivo, due to what many hypothesize to be 
immediate clearance in circulation by the reticuloendothelial system. Therefore, attachment to a 
lipid MB vehicle is thought to reduce this clearance, promote longer time in circulation and 
therefore increase likelihood of delivery to the proper tissue target, thereby improving efficiency 
of delivering genetic material to cells. 
2.3.3.3 Polymer Microbubble Shells 
The development of polymer MBs for drug delivery is less extensive than that of lipid or 
protein MBs. However, there has been evidence showing that polymer MBs are still a promising 
option, as one study showed that hard polymer shell MBs resulted in greater transfection rates 
when loaded with genetic material than an equivalent lipid MB, although polymer MBs often 
require higher therapeutic US pressures due to their stiffness [85]. These higher pressures and the 
differences in polymer shell behavior upon fragmentation has been hypothesized to be the cause 
of this greater efficiency, as their cavitation and rupture may be more violent than equivalent 
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behavior in lipid MBs, resulting in greater poration of genetic material into cells. In addition, 
polymer MBs offer the advantage of incorporating both hydrophobic and hydrophilic 
macromolecules without the need for an additional structural matrix. 
Examples of previous investigations of modified polymer MBs for genetic material 
delivery include a study by Seemann et al. in 2001, where the double emulsion technique was 
applied to form poly-lactic-co-glycolic acid MBs in the presence of plasmid DNA complexed with 
polylysine, protamin sulfate, or polyethylenimine cationic polymers, resulting in successfully 
loaded polymer MBs [86]. However, it was also documented that release kinetics for the genetic 
material from these polymer MBs was slow, with only 10% of the encapsulated genetic material 
released after stimulation by US of 10 minutes. These MBs were further evaluated by another 
group for use with plasmid DNA for delivery to a rodent tumor model. Application with US 
treatment resulted in successful signal of the genetic material within the tumor, but not surrounding 
tissue. Later encapsulation of anti-tumor genetic material was also performed, showing that 
application of the loaded polymer MBs with therapeutic US stimulation resulted in successful 
slowing of late-stage tumor growth, showing the overall potential of this technique. 
More recently, various other applications of polymer MBs have surfaced as well, such as 
use of poly(lactic-co-glycolic) acid MBs in conjunction with iron oxide nanoparticles resulting in 
the formation of multifunctional polymer MBs for use in dual-mode US with magnetic resonance 
imaging [39, 87]. Not only are these MBs dual-purpose in their imaging, but they have also been 
loaded with doxorubicin, an anti-tumor drug with adverse systemic effects. The investigating 
group showed that varying concentrations of iron oxide particles incorporated into the polymer 
MB shell did not significantly affect the capacity for doxorubicin encapsulation nor functional 
capacity of the polymer MBs during US imaging. These novel agents were used in a model for 
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treatment of metastatic malignancy in lymph nodes while also assessing various tumor 
characterization markers including blood vessel density, micro-lymphatic vessel density, and 
tumor proliferation index. 
Furthermore, along these lines, incorporation of various nanoparticle species with polymer 
MBs for application with other imaging modalities including optical fluorescence, magnetic 
resonance, and even computerized tomography have been investigated [39]. As stated, iron oxide 
nanoparticles providing additional contrast for magnetic resonance imaging has been investigated 
by several groups. In addition, radioactive fluorine-labeled lipids have also been incorporated for 
use in positron emission tomography. Another recent study showed that gold nanoparticles and 
quantum dots (which are nanosized semiconductor crystals) may also be incorporated into 
functionalized polymer MBs successfully, allowing for development of dual mode contrast agents 
and simultaneous clinical applications of contrast enhanced multi-modal imaging with potential 
theranostic applications as all of these polymer MB multi-contrast agents may be loaded with 
various therapeutic agents for targeted drug delivery as well [88, 89]. This is especially useful for 
pathologies where localization is limited to an imaging modality aside from US, while US imaging 
is simultaneously required to validate the delivery and MB presence at the local site. 
2.3.4 Basic Principles of Microbubble Optimization and Design 
This section briefly discusses various topics relevant to the design and optimization of lipid 
MBs for the purposes of compatibility with novel molecules. The concepts covered represent an 
intersection of many different disciplines, from biochemistry to physics, considering how MB 
function entails both acoustic properties in response to US stimulation such as for imaging 
purposes as well as biomechanical interactions with endothelial physiology. This section is mainly 
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relevant to the work in this dissertation involving design and fabrication of the novel nitro-fatty 
acid lipid MB, and much of those processes drew inspiration from the material to be discussed. 
Each sub-section will discuss a different topic covered in cursory detail to be investigated further 
at the reader’s discretion. 
2.3.4.1 Hydrophobic Tail Chain Length 
As previously discussed in the general overview of lipid MB structure, many of the 
phospholipid species commonly used in lipid MB shells are amphiphilic, in that they contain both 
hydrophilic and hydrophobic structures. The hydrophobic structures are commonly acyl chains, 
which are long hydrocarbon tail groups that may either be saturated or unsaturated depending on 
the extent of hydrogen-carbon bonding. Typically, these hydrophobic tail groups face the interior 
of the lipid MB, and immediately border the gas core.  
These tail groups are of immediate relevance when considering MB properties that are 
significant for performance such as longevity in circulation, half-life in storage, and stability (both 
when freely circulating and when sonicated by US pulses).This is because the essential mechanism 
of MB instability is the escape of the gas core from the lipid shell resulting in gas dissolution and 
disappearance of the MB for all functional purposes, as well as the loss of structural integrity of 
the lipid shell itself, which also results in an exposed gas core. Therefore, gas permeation through 
the phospholipid shell, including permeation through these hydrocarbon chains, is a key 
mechanism contributing to the loss of MB stability [56]. 
Aside from affecting stability, length of the hydrocarbon tail group also significantly 
affects the physical properties of the lipid MB itself. Parameters such as yield shear and surface 
viscosity both increase directly with the length of these hydrocarbon chains, as previously shown. 
The deformability and flexibility of the lipid shell under physical stimulation not only affects its 
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echogenic properties which allow it to serve as a contrast agent for US imaging, but also the 
threshold for MB rupture, which is a key behavior for therapeutic applications of MBs as 
previously mentioned, including drug delivery. The source of this increased stability in the shells 
formed by longer hydrocarbon chain group phospholipids is thought to derive from increases in 
attractive forces and hydrophobic interactions (van der Waals forces) between adjacent 
phospholipid molecule tails [56, 90, 91]. 
The concept of hydrophobic chain length affecting permeability of the lipid shell to gas 
escape into the surrounding aqueous mechanism was confirmed by previous studies investigating 
a series of various hydrocarbon chain lengths in an empirical setting. It was found that the primary 
mechanism for MB stabilization are through reduction of surface tension and presenting a physical 
barrier to gas permeation, although these were thought to not be the only contributing mechanism 
as discrepancies in MB behavior between theoretical force-modeling approaches and the 
experimental results existed. Microscopic studies of deforming lipid MBs also showed that lipid 
MBs composed of hydrophobic chains with length greater than 17 carbon atoms demonstrated 
significant lipid membrane folding behaviors and development of lipid projections with their own 
radii of curvatures. These behaviors are consistent with a membrane of negligible surface tension, 
and that the overall MB was in a constant state of change between various deformations which 
were significantly smaller than the overall radius of the MB. Carbon chain lengths of up to 24 
atoms were investigated, with longer chain lengths resulting in increased stability. Lipids with 
chain lengths shorter than 17 atoms also demonstrated a behavior of excess lipid shedding, while 
those with lengths longer than 17 atoms did not demonstrate this shedding, and would deform as 
described instead, prior to suddenly returning to a more regular sphericity, indicating possible 
sudden formation of smaller vesicles in the deformation process in a sort of zippering effect due 
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to the stronger intermolecular forces. This is also because the longer hydrophobic chain 
phospholipids have stronger interactions with not only resist the typical formation of aggregate 
leaving structures, but also because the crumpled surface morphology is an energetically 
unfavorable state [90, 91]. 
Another study focused on improving the persistence and longevity of circulating lipid MBs 
in vivo again investigated the effect of acyl chain length on these stability measures [91, 92]. Again, 
various phospholipid species were investigated ranging from chain lengths of 16 carbon atoms to 
24 carbon atoms. Similar to the previously mentioned study, stability generally increased with 
increasing acyl chain length; however, for the longest chain length investigated of 24 carbon 
atoms, MB stability dropped unexpectedly. In addition, an US phantom imaging model was used 
to investigate a stimulated circulation environment for the lipid MBs with contrast-mode US used 
in burst-reperfusion imaging to assess replenishment of the imaging field with new MBs. It was 
again noted that increase in persistence was associated with increase in acyl chain length, again up 
to 18 carbons in length. However, imaging persistence did not increase when further increasing 
the acyl length, including up to 24 carbons in length, suggesting that previous passive dissolution 
experiments do not quite share the same mechanics of MB dissolution as an actively circulating 
MB environment. However, when using an in vivo rat kidney model of contrast-enhanced US 
investigation for lipid MB persistence, stability increased with chain length up to 22 carbons in 
length, while further increase to 24 carbons resulted in decreased persistence.  
This study also investigated presence of surfactant molecules in the lipid MB on stability 
and did indeed verify that presence of surfactant proteins resulted in increased stability in lipid MB 
shells as well. Notably, this study proposed that significant mismatch in chain length between the 
main lipid shell component phospholipid and other components such as the emulsifier species 
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resulted in significant decreases in MB longevity and a less stable MB surface microstructure. The 
emulsifier investigated was DSPE-PEG, which is the same emulsifier that was later used in the 
therapeutic MB applications of this dissertation work [93, 94]. 
Other studies on physicochemical properties of MBs have also raised implications of their 
efficacy in drug delivery, including the main property of acyl chain length. Specifically, longer 
chain lengths have been found to result in longer time necessary for re-stabilization following any 
rupture in the lipid shell and also longer time to full collapse after initial mechanical disruption 
due to stronger intermolecular forces. Increases in acyl chain length also result in increased in-
plane rigidity, which influences factors such as cavitation response and shear stress necessary for 
MB disruption and rupture. Investigations of lipid MB phospholipid component parameters on in 
vivo performance have also been performed, with the main results that longer acyl chain length 
MBs resulted in improved tissue delivery and biological basement membrane permeation of large 
molecular MB payloads, but not for smaller molecular payloads. It was also found that acoustic 
energy of the stimulating US pulse on the MBs modulated the relationship between lipid shell 
parameters and delivery efficacy, suggesting that using the proper US regime and acoustic pressure 
is just as important for effective in vivo therapeutic benefits [95]. 
2.3.4.2 Presence of PEGylated Emulsifier Molecules 
Naturally occurring MBs are stabilized by surfactant molecules comprised of lipids and 
glycoproteins. For example, in many water systems these lipid and glycoprotein molecules are 
derived from decomposition of multi-cellular organisms. Addition of emulsifier molecules is also 
a common practice in synthesis of lipid MBs in a laboratory setting. One of the most common 
types of emulsifiers is the attachment of the hydrophilic polyethylene glycol head group to the 
phosphate group of phospholipid species. Not only does this head group prevent coalescence of 
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multiple MBs while in preparation, it also prevents adsorption of various substances including 
blood plasma proteins onto the surface of the MB while in circulation. Additionally, having this 
polyethylene glycol form a brush layer around the outside surface of the MB also prevents 
phagocytosis of the MB to a degree. 
Various theories for behavior of these modified emulsified components in lipid shells have 
previously been presented. These include consideration of the shell as a homogenous structure 
with relatively even dispersion of the emulsifier molecules, as well as polycrystalline distributions, 
where clustering and partitioning of different molecular structures occurs, resulting in the 
formation of specific domains on the surface structure of lipid MBs. 
One specific previous study investigated the behavior and miscibility of PEG-40 stearate 
as an emulsifier in phospholipid shells [94]. This is of particular relevance to the work of this 
dissertation because PEG-40 stearate is the same emulsifier featured in all therapeutic MBs used 
in this work. The work of this study further re-affirmed that surface distribution of emulsifier 
components and other lipid species is not only heterogenous, but that these so-called network 
domains are increasingly found in MB shells with longer lipid acyl chains. Therefore, inclusion of 
these emulsifier groups does not result in a uniformly distributed shield of the polymeric brush 
layer over the entire MB, nor will modifications of these surface lipid species result in uniform 
distribution or targeting for molecular agents. However, it was noted that emulsifiers still did 
provide benefits in terms of structural stability and longevity of the MBs over an absence of any 
emulsifier use. 
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3.0 Ultrasound-targeted Microbubble Cavitation Principles and Applications 
Previously we have discussed US in its imaging and therapeutic modalities, as well as MB 
contrast agents and their therapeutic modifications. In this chapter, these two topics will be 
combined into ultrasound targeted microbubble cavitation (UTMC), which is a combination 
therapeutic-diagnostic (theranostic) technique which serves many purposes. We will begin with 
an overview of this technique and basic mechanisms which relate to its therapeutic applications, 
and then discuss several clinical applications of UTMC. The general directions of applying UTMC 
therapy include cancer therapy, gene and drug delivery, thrombolysis, and cardiovascular disease. 
Although the last two subjects are often considered together (due to pathologies requiring 
thrombolysis often being co-morbid with cardiovascular pathologies), various other techniques 
such as gene and drug delivery may be applied toward cardiovascular disease as well. There will 
be a specific emphasis placed upon the last two topics, especially thrombolysis, because the 
context in which the work of this dissertation was initiated was in treatment of microvascular 
obstruction by micro-emboli, which is relevant to both thrombolysis and cardiovascular disease. 
Lastly, other applications of UTMC not included in the list above will be discussed briefly at the 
end of the chapter. 
3.1 Ultrasound-targeted Microbubble Cavitation Basic Overview 
US targeted MB cavitation (UTMC) has been referred to by a range of different labels, 
including US targeted microbubble destruction, US-exposed MB therapy, and US-induced 
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cavitation, among others. All of these names encompass a therapy which, at its essence, consists 
of two components: therapeutic US and MBs. By directing the external US transducer toward an 
intended target site which contains circulating MBs, this technique results in MB oscillation and 
destruction (with stronger US pulses), which lead to biomechanical effects in the local tissue 
environment. One distinction which has been made lies between destruction and cavitation in 
nomenclature. As previously discussed regarding the range of possible MB responses as the 
acoustic pressure of the sonicating US pulse increases, MB destruction does not necessarily occur 
at relatively lower pressures. Therefore, UTMC is an umbrella term that describes both stable and 
inertial (destructive) cavitation responses. In addition, although cavitation in the absence of MBs 
refers to the coalescence of gas into bubbles during the rarefaction phases of US, presence of MBs 
results in pre-formed nuclei for further cavitation, thereby reducing the necessary pressure, or 
cavitation threshold, necessary for this process. Along these lines, while US pulses by themselves 
have an extent of therapeutic capacity, these effects are greatly enhanced by circulating MBs, 
whose mechanical behavior acts as the immediate effector on biological targets including cells, 
membranes, and material such as blood clot. 
3.2 Basic Mechanisms of Ultrasound-targeted Microbubble Cavitation 
The main mechanisms of UTMC to be discussed here are cavitation, radiation force, and 
sonoporation. These may interact and combine to result in a myriad of other behaviors which 
contribute to the efficacy of UTMC therapy in vivo. Cavitation refers to the oscillation and possible 
destruction of MBs when targeted by US pulses. Radiation force involves the displacement of MBs 
along the direction of the US beam. In this way, cavitation and radiation may be leveraged together 
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to first direct MBs toward their intended target followed by destruction and release of the contained 
therapeutic payload, resulting in delivery of the therapeutic agent to the tissue site and 
concentration of the agent in the local vicinity. 
Sonoporation refers to the disruption of a cellular membrane by UTMC generated shear-
stress. This mechanism functions in conjunction with both radiation and cavitation and is the result 
of applying the MB oscillatory forces to a biological membrane. Studies using extremely high-
speed imaging and incubations of MBs with cells have demonstrated the temporal and spatial co-
registration of UTMC application with resulting cellular intravasation with a model drug, followed 
by re-sealing of the membrane [96-98]. Investigations varying the physical parameters of the US 
pulse used have shown that there is a lower limit of MB radial expansion necessary for 
sonoporation to occur; this behavior therefore depends on the characteristics of the stimulating 
pulse [99]. It has been found that for a fixed pulse frequency, this oscillation threshold increases 
as pulse duration decreases. Cellular membrane mechanics for sonoporation have been modeled 
using materials engineering approaches for failure, although this work will not be further discussed 
here [100, 101]. In essence, it is known that MB oscillation resulting in sonoporation may facilitate 
delivery of therapeutic agents to the targeted cells, while downstream mechanotransductive events 
(such as nitric oxide production in the vascular endothelium) may follow [102].  
Sonoprinting is another UTMC mediated delivery technique which has subtle distinctions 
from sonoporation [103, 104]. While sonoporation refers to the formation of pores, or microscopic 
holes in the cellular membrane, sonoprinting instead entails the surface deposition of therapeutic 
agents such as nanoparticles onto cell membranes, which are later assumed to be endocytosed by 
the cell. Sonoprinting has the benefit of avoiding the violent MB behaviors associated with high 
acoustic pressure US, including phenomenon previously described such as micro-jetting, MB 
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fragmentation (which has also been referred to as lipid shedding), and sonoporation. Rather, low 
acoustic pressure US is used, and has actually been found to enhance and favor alternative cellular 
behaviors such as endocytosis. A disadvantage of sonoprinting is that the therapeutic agent is 
required to be fixed to the surface of the therapeutic MBs, whereas sonoporation has been shown 
to result in successful intravasation of therapeutic molecules not fixed on the MB surface, but 
rather circulating in conjunction with MBs. Sonoprinting also involves direct physical deposition 
in that surface contact of the MB with the target is assumed and necessary. Target surfaces 
including cell membranes and cellulose tubes have been successfully deposited with nanoparticles 
using this technique. Lastly, a major difference between sonoporation and sonoprinting is that 
sonoporation relies upon fluid movement through the sieve-like holes formed by MB oscillations 
for delivery of molecules into cells. This may become more difficult and less reliable in the case 
of larger molecules. However, sonoprinting results in the direct deposition of these molecules onto 
cellular surfaces, resulting in improved feasibility for larger molecules including polystyrene and 
mRNA-lipoplexes [103]. 
Sonoporation and sonoprinting are both mechanisms of UTMC interaction on a cellular 
level. However, UTMC applications to blood vessels have shown evidence for an additional 
interaction of increasing vascular permeability by temporarily modulating vascular integrity. 
Rather than targeting a single cell, this refers to the effects of rarefaction and compression on an 
entire vascular tissue environment, including the endothelial boundary and the various basement 
membrane components of blood vessels. High-speed imaging studies have shown that expansion 
and contraction of MBs in a blood vessel result in circumferential deformation of the vessels, and 
by definition, increases in strain and potential gaps between adjacent cells [98, 99]. In addition, 
oscillating MBs have been shown to actually traverse through the endothelial layer after being 
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attached to the vessel wall, and invaginations of the vessel endothelium have been observed in the 
absence of the oscillating MB after contraction. This concept of a leaky endothelium is thought to 
also result from partial delamination of the endothelial layer and contributes to therapeutic efficacy 
of various drug and gene delivery applications of UTMC therapy. 
Stimulation of endocytosis and uptake of material was previously mentioned in the 
description of sonoprinting and is a veritable means by its own right toward the application of gene 
or drug delivery by UTMC therapy. This mechanism is the interaction between the mechanical 
forces of MB oscillation and endocytotic pathways. Previous studies have shown much evidence 
for this phenomenon, such as the upregulation of clathrin-coated pits, endocytotic vesicles, and 
endocytotic markers in cells exposed to UTMC with low intensity US, without evidence of 
concurrent sonoporation or other cellular membrane disruption [102, 103]. This was further 
supported by work showing the inhibition of cellular uptake of low and high molecular weight 
dextrans during low intensity UTMC after the administration of clathrin and caveolin inhibitors. 
ATP depletion, which inhibits endocytosis, was also used to demonstrate the mechanistic 
significance of endocytotic uptake in molecular delivery of UTMC. However, while mechanistic 
in vivo studies regarding endocytotic uptake are still limited and inconclusive regarding its 
improved efficacy for material delivery in UTMC, there are potential benefits of using low 
intensity US in UTMC, including decreased inflammation and potential cellular damage which 
may occur with sonoporation and high intensity US. 
Another mechanism that is hypothesized to be related to various mechanisms of transient 
cellular and endothelial permeabilization is the formation of extracellular hydrogen peroxide. This 
has mainly been studied in the context of low intensity US. Previous investigations have shown 
that low intensity UTMC results in a significant increase in production of hydrogen peroxide [105, 
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106]. Simultaneous permeabilization of cellular membranes was also measured using influxes of 
calcium ions. This phenomenon is distinct from the transport of ions across the cell membrane 
through endogenous ion channels. Other studies on reactive oxide species have also shown 
increases in macromolecular permeability of cellular membranes in the presence of hydrogen 
peroxide even without the UTMC stimulus. However, the authors did not explicitly propose any 
mechanisms for the relationship between hydrogen peroxide and membrane permeabilization. 
3.3 Applications of Ultrasound-targeted Microbubble Cavitation 
This section will discuss select applications for UTMC, namely toward treatment of 
Alzheimer’s disease (with blood-brain barrier permeabilization), cardiovascular disease, and 
thrombolysis. Previous sections have discussed various MB modifications for gene and drug 
delivery. The range of possible applications and contexts for those general uses of UTMC are too 
many to list here, although the common themes and mechanisms for successful delivery using 
UTMC have been listed in the previous section. Cardiovascular disease and thrombolysis are 
subjects of immediate relevance to the work detailed in this dissertation. 
3.3.1 Blood-brain Barrier Disruption and Alzheimer’s Disease 
Interest in using UTMC and focused US in the context of the neurovascular unit has been 
growing significantly in recent times. Given the versatility of UTMC, these applications have been 
varied in their goals, from increasing permeability to drug delivery to modification of the local 
environment in aspects such as gene transcription profile. 
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3.3.1.1 Blood-brain Barrier Background 
The blood brain barrier is a structure common to all organisms which possess a complex 
central nervous system. It is the boundary between the intravascular compartment and the 
parenchymal interstitial compartment of both the brain and the spinal cord and is composed 
primarily of cerebral endothelial cells. Aside from the tight junctions which seal the margins of 
adjacent endothelial cells, which prevents the occurrence of paracellular transport, the endothelial 
cells are also in contact and communicate with other neural cell types including microglial cells, 
astrocytes, and pericytes. The endothelial cells themselves also express a wide range of transport 
channels and proteins for substances necessary for cellular metabolism including glucose and 
amino acids. Endocytosis from the endothelial cell surface (and transport across the cell layer, 
termed transcytosis) is another mechanism for the movement of macromolecules as well. In 
essence, the blood brain barrier serves the function of regulating the substances which may be 
transported into the central nervous system, including brain parenchyma, and is also therefore the 
greatest barrier in delivery of various therapeutic agents to the brain. The reverse is true as well, 
with the blood brain barrier also serving to actively remove metabolic waste products which are 
potentially toxic with excessive accumulation. The blood brain barrier also serves to create and 
stabilize a distinct fluid compartment of the interstitium of the central nervous system which is 
notably varied from the somatic interstitial fluid in that the central nervous system relies on precise 
ionic and molecular concentrations for proper synaptic function. 
Given its paramount role in regulating brain metabolism, it comes as no surprise that blood 
brain barrier dysfunction is thought to play a key role in the etiology of several pathological 
processes. Examples of this include Alzheimer’s disease, where transport of the beta-amyloid 
protein is defective resulting in accumulation of the protein in the brain fluid compartment and 
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eventual deposition of insoluble protein plaques as well as increases in oxidative stress. Although 
this is particularly nuanced by the additional role of the brain-cerebrospinal fluid barrier which 
also participates in clearance of said protein products in the brain, it stands that there are direct 
connections between impairment of barrier transport function and development of key disease 
markers. In addition, the integrity of the blood brain barrier is also thought to naturally decline 
with age, which is also relevant to the development of Alzheimer’s disease. Another example is 
obesity, where blood brain barrier transportation of leptin, a signaling protein, is impaired, 
resulting in dysfunction of various signaling pathways regulating appetite.  
In relation to clinical applications of UTMC, most if not all treatments are not targeted to 
the blood brain barrier with intent to restore or improve its function [107]. Rather, the blood brain 
barrier is taken as an obstacle toward delivery of therapeutic agents to the brain parenchyma, given 
its role in impeding transport of large foreign molecules. The goals of these therapeutic agents may 
then be varied, whether toward treatment of brain tumors or removal of amyloid plaques. Other 
applications of general US in treatment of brain pathologies include delivery of neuroprotective 
agents in ischemia-reperfusion injury, and gene delivery in Huntington’s and Parkinson’s diseases. 
As such, the role of the sonicated MB in overcoming the blood brain barrier is achieved through 
the various physical mechanisms of action including sonoporation, radiation forces, and 
cavitational forces. 
3.3.1.2 Blood-brain Barrier Disruption in Alzheimer’s Disease 
One of the earliest studies for blood brain barrier disruption using UTMC was performed 
at an US frequency of 690 kHz, with confirmed results by electron microscopy and negligible 
damage to brain parenchyma [108]. Since then, various other studies have focused on the 
investigation of various US frequencies due to the major distortion of the US pulse by the skull. 
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Given our understanding of the effects of lowering US frequency on phenomenon such as 
attenuation and distortion, lower frequencies have been found to be distorted less when passing 
through the skull. An additional benefit of using lower US frequencies is that tissue absorption of 
US energy is decreased as well, resulting in fewer thermal changes in brain parenchyma (which is 
obviously favorable), while remaining suitable for blood brain barrier disruption due to the low 
threshold of energy necessary. A later study sought to apply this type of low frequency US beam 
(260 kHz) to a rabbit model to demonstrate successful intravasation of injected contrast through 
the blood brain barrier with minimal adverse effects [109]. Not only would this US regime not 
necessitate more complex US equipment and transducer arrays, but it would also preclude the need 
to create a surgical skull window to allow superior access of the beam to brain parenchyma. The 
results of the study demonstrated successful disruption of the blood brain barrier to the extent of 
successful delivery of large molecules to the brain. Histologic analysis of brain tissue, including 
red blood cell extravasation indicative of hemorrhage, and immune cell presence indicative of 
inflammation, showed minimal aberrative activity. Characterization of the time scale of the 
disruption and of its temporary nature was also documented. In comparison to other studies using 
higher frequencies of US for disruption where primary transport was through widening of the 
blood brain barrier endothelial cell tight junctions, this study demonstrated significant vacuoles in 
the endothelial cells which were thought to provide transport for the target molecular agents used 
through transcytosis. 
Later studies further elaborated on these advances, as successful blood brain barrier 
disruption became more consistent, to incorporate therapeutics relevant to Alzheimer’s disease. 
One such example is the delivery of antibodies against the beta-amyloid proteins, which were 
shown to improve beta-amyloid clearance when previously directly injected into the brain [110]. 
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Given that this process was surgically invasive and essentially infeasible in human patients, 
disruption of the blood brain barrier presented an alternative mode of delivery. In one study, a 
focused US beam was applied during simultaneous injection of Definity™ MBs in a transgenic 
mouse model of Alzheimer’s disease during simultaneous magnetic resonance imaging [110]. 
Because injection of contrast and its subsequent appearance in the brain during magnetic resonance 
imaging was indicative of successful blood brain barrier disruption, this monitoring allowed for 
the localization of the US beam for targeted treatment. The authors found that not only was the 
delivery of the beta-amyloid antibody into the brain successful, but hemispheric pair-wise design 
of the treatment showed improved clearance of insoluble beta-amyloid plaques from brain 
parenchyma. 
One notable later investigation in the application of UTMC to Alzheimer’s disease did not 
focus on delivery of a therapeutic agent to the brain; rather, it relied upon the UTMC itself and 
disruption of the blood brain barrier targeted to the hippocampus in an animal model with the aim 
of modifying disease progression related behaviors indicative of memory impairment. This study 
continued the use of magnetic resonance imaging guided focused US, and targeted the 
hippocampus using the rationale that increases in neuronal plasticity were previously 
demonstrated, albeit in healthy mice that did not display impairment of memory functions [111]. 
Again, Definity™ MBs were used during sonication at 1.68 MHz US frequency targeting two 
locations in the hippocampus on one side per animal, followed by gadolinium-based contrast 
infusion for T1-weighted magnetic resonance imaging to confirm blood brain barrier disruption. 
This treatment was performed once per week for three weeks, followed by a Y-maze analysis, 
amyloid plaque analysis, and immunohistological analysis.  
 65 
The authors’ results demonstrated that the magnetic resonance guided UTMC alone 
resulted in improvement in cognitive task performance, reduced amyloid plaque burden, as well 
as increased neuronal plasticity without the addition of other therapeutic agents. There were no 
adverse effects found on the animals’ typical behaviors or general health, nor indications of brain 
parenchymal damage on histological analysis. Potential mechanisms listed by the authors for these 
positive results included increased transport of endogenous immunoglobulins into the 
parenchymal compartment as a result of blood brain barrier disruption, leading to increased 
amyloid clearance, as well as activation of various neural cell species including astrocytes and 
microglia, which are known to phagocytose beta-amyloid plaques.  
In addition to these mechanisms, the authors also tracked the population of immature 
neurons in the dentate gyrus of the hippocampus, the increase of which is associated with memory 
functions and general improvement of cognitive behavior in models of Alzheimer’s disease. It was 
shown that UTMC was able to stimulate the proliferation and development of these cells as well, 
although the mechanisms are not precisely understood. Previous studies without MBs and only 
focused US stimulation found that such treatment increased production of brain-derived 
neurotrophic factor, which also serves to mediate hippocampal neuroplasticity, as a potential 
mechanism for this phenomenon. Other potential explanations include upregulation of Akt 
signaling in the neurons stimulated by UTMC, which has previously been shown to occur with 
local blood brain barrier disruption. This results in increased activity in signaling pathways also 
related to neurotrophic receptors, therefore resulting in improved survival of these immature 
neurons. 
Another study which similarly applied only focused UTMC in the absence of additional 
therapeutic agents across the entire mouse forebrain in a model of Alzheimer’s disease reported 
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significant cognitive functional improvements after treatment [112]. The US regime used was a 
0.7 MPa pressure 10% duty cycle (percent of time the US is active) pulse, with five treatments 
over a six-week period. Sham controls with only MB infusions were performed as well. All groups 
received behavioral testing for spatial memory in the Y-maze task, followed by histological 
analyses of brain tissue for changes in amyloid plaque burden and evidence of cellular damage or 
inflammation. 
This study’s results supported the previous study described, as UTMC alone was shown to 
activate microglial phagocytosis of beta-amyloid protein, resulting in creased plaque burden in 
treated mice, as well as improvements in spatial memory during the cognitive tasks. The authors 
also discussed the alternative possibility that enhanced blood brain barrier disruption prevented 
the deposition of additional insoluble plaques, giving off a similar appearance as improvement. 
Safety measures and the absence of adverse effects of the UTMC were confirmed again as well. 
Notably, the authors also address potential barriers in translation of this therapy to human patients 
in that thickness of the skull and depth of potential targets for UTMC would require significant 
adjustments to the US parameters. In addition, timing of the UTMC application relative to disease 
progression would need to be taken into consideration, such as whether to apply UTMC during the 
prodromal stage of Alzheimer’s disease. In addition, to avoid potential excessive immune 
activation such as with microglial cells, a stepwise approach to covering greater volumes with 
UTMC may need to be adopted. However, in all, the lack of additional therapeutic agents applied 
in this animal model study for Alzheimer’s disease again demonstrated the significant therapeutic 
potential of UTMC. 
As the significant therapeutic potential and translatability of UTMC became more and 
more widely recognized after these studies, diversification of the models used and endpoints 
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evaluated surfaced. One example of an alternative model of Alzheimer’s disease related cerebral 
damage featured the use of aluminum chloride in drinking water given to wild-type rats, which 
were then treated with a regime of low intensity pulsed US [113]. Cognitive behavioral tasks of 
the Morris water maze and elevated plus maze were performed in animals following treatment, 
along with histologic measures of beta-amyloid deposition as well as measures of aluminum 
related damage. Their results showed that the pulsed US regime resulted in retained memory 
function over the course of aluminum chloride administration, as well as attenuated accumulation 
of aluminum as well as beta-amyloid 42 expression in the brain. This study demonstrated that 
pulsed US (even without MBs) was capable of protecting against an agent known to be associated 
with increased risk for development of Alzheimer’s disease and other types of neurotoxicity. 
Aside from measures of plaque burden and immunohistological markers from brain tissue 
indicative of immune cell activity, recent studies have moved to more sophisticated measures of 
microvascular changes due to UTMC such as transcriptomic analysis. One such study applied 
UTMC for blood brain barrier disruption in the dorsal hippocampus and followed changes in 
transcription up to 24 hours post-treatment [114]. The study found that after UTMC treatment, 
there was a transient increase in proinflammatory cytokine transcription, potentially promoting the 
localization and movement of leukocytes across the disrupted blood brain barrier, as well as 
activating microglial cells and astrocytes. The authors noted that while chronic activation of these 
inflammatory pathways has been implicated in various disease processes, acute activation has 
instead been associated with neuroprotection and homeostatic regulation against acute stresses 
such as ischemia. In all, the authors summarized that these changes result from the oscillation of 
MBs against the vascular endothelium and may explain for the beneficial effects of UTMC 
treatment in the context of neurovascular disease models.  
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These results were noted to be compatible with additional mechanistic studies for UTMC, 
including upregulated presence of caveolin, a protein involved in transcytosis across the 
endothelial barrier, which was shown in this study as well [115]. Although this study was not 
performed with an animal model of Alzheimer’s disease, and instead used wild-type Sprague-
Dawley rats instead, the implications raised by this type of analysis open avenues for future study 
specifically in a disease context, given the potential role of inflammatory events in the disease 
pathogenesis. In addition, the interactions between UTMC therapy and these inflammatory 
pathways may also reveal different mechanistic implications for the efficacy of UTMC in such 
disease models as discussed in the previous studies mentioned. 
Given the main obstacles of further translation of UTMC for treatment of Alzheimer’s 
disease pathology discussed, such as larger brain size and increased skull thickness in human 
patients relative to the small rodent models previously investigated, continued investigation of this 
area transitioned toward work with larger animal models. One such study utilized an aged beagle 
model, which featured several distinctions from previous transgenic rodent models of Alzheimer’s 
disease [116]. One key difference is that aged beagles (and other species of dogs) naturally develop 
the amyloid pathology observed in Alzheimer’s disease, with corresponding cognitive decline, 
whereas the transgenic rodent models were engineered to overexpress select proteins. In this way, 
the canine model represented an aged, pathologic brain rather than merely overexpressing the 
amyloid protein in an isolated context in the absence of other possible accompaniments to disease 
etiology associated with the aging process. In addition, the larger brain size of the beagle model 
presented a more similar physical environment to human patients in that the greater depth of 
penetration that the US waves would experience prior to reaching their therapeutic destination 
would allow for the use of the low frequency US waves previously investigated such as in the 
 69 
rabbit model without development of standing waves, which are essentially stationary waves that 
oscillate with respect to time but whose peaks do not translate in space. This phenomenon may 
develop as the result of resonance and wave interference, and due to the accumulation of the US 
waves effects at the same node locations, adverse biological effects may occur such as the 
increased development of free radicals and oxidative species. The greater depth of the beagle brain 
also presents a similar challenge in treatment as human patients, which would facilitate the 
development of similar US regimes feasible in the similar size scales. 
For the blood brain barrier disruption UTMC treatment, a single-element, focused 
transducer was used. Similar to previous discussion, lead zirconate titanate (PZT) was the material 
used for the transducer. The US pulse regime was a collection of 10 ms bursts with frequency of 
280 kHz (similar to the study of blood brain barrier disruption in the rabbit model, which used a 
frequency of 260 kHz) with a pulse repetition of 0.33 Hz with a change in position for each second 
across a millimeter scale grid. The estimated amplitude for the treatment ranged from 0.8 to 1 MPa 
(in free field, without attenuation from penetration through the skull), starting with the lower 
estimate and increasing in 0.016 MPa intervals until cavitation signals from injected MBs were 
detected. For the MB agent, Definity™ MBs were used once again, titrated to a concentration of 
0.02 mL per kg of animal bodyweight. This treatment proceeded until an entire hemisphere of the 
brain was treated, followed by computerized tomography and magnetic resonance imaging with 
gadolinium-based contrast. 
The study results demonstrated consistent safety and efficacy with previous experiments 
in smaller animal models. All of the blood brain barrier treatments were extremely well tolerated 
by the animals, and three out of the five animals in each treatment group showed lower beta-
amyloid load in the treated hemisphere. However, despite these results, the main takeaway from 
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this study was the safety rather than efficacy of the focused UTMC treatment, as the authors noted 
larger sample sizes would be necessary for further comment on statistical significance. 
The last study to be discussed in this section represents the final stage in the translational 
development of this UTMC therapy for blood brain barrier disruption, and also the start of a new 
area of clinical investigation, that is, application of UTMC for blood brain barrier disruption in 
human patients in a phase I safety trial [117]. Five patients were enrolled with a mean age of 66 
years, and previous positron emission tomography had demonstrated significant amyloid burden 
past the standardized uptake value ratio cutoff for all patients. A similar treatment protocol as 
previous studies was performed, with simultaneous UTMC treatment during magnetic resonance 
imaging with contrast for confirmation of blood brain barrier disruption. T1-weighted gadolinium 
magnetic resonance images were obtained immediately after sonication and showed a small 
window of contrast enhancement at the location of the US beam, with disappearance of said 
window at 24 hours after the treatment, suggesting that the blood brain barrier disruption was 
indeed transient and had no significant adverse effects that were of immediate notice. The primary 
US target was white matter in the frontal lobe (more specifically, the dorsolateral prefrontal 
cortex). All patients were successfully discharged the morning after the US procedure with no 
significant adverse events including hemorrhages, edema, or death. Again, Definity™ MBs were 
used in combination with the focused US beam. 
While there were no significant functional improvements whether in cognitive 
performance or in observed amyloid burden before and after the treatment, this did not detract 
from the study’s success or scientific value, as the primary goal of this study was for evaluation of 
safety and feasibility in human patients, to which end the study was extremely successful. The 
authors noted that the study had limitations of sample size and target selection, as the blood brain 
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barrier disruption was limited to a relatively small area in this preliminary study. In addition, more 
sophisticated targets with additional functional implications in Alzheimer’s disease pathology 
would warrant further investigation in the future. In addition, no therapeutic agents were used in 
this investigation, which may further enhance the value of UTMC and its role in blood brain barrier 
disruption. 
3.3.2 Toward Treatment of Cardiovascular Disease 
Given the wide range of pathologies which fall under the umbrella term of cardiovascular 
disease, this section will be divided into two main sub-sections of drug and gene delivery for non-
acute conditions, and sonothrombolysis using UTMC, which is often directed toward acute 
conditions, such as acute coronary syndrome. It is noted that both applications may be combined, 
such as in the work of this dissertation, through the use of therapeutically modified MBs in 
applications of thrombolysis, as the preserved mechanical performance of the MBs result in their 
therapeutic cavitational activity simultaneously with the drug delivery resulting from MB rupture 
after US sonication. 
3.3.2.1 Cardiovascular Drug and Gene Delivery 
Similar to the difficulties presented by the blood brain barrier, vascular tissue is similarly 
compartmentalized and highly regulated and restricted in the substances which may traverse this 
boundary to enact therapeutic effects. Therefore, one of the main goals of UTMC in cardiovascular 
applications of drug delivery are again disruption and permeabilization of this barrier to allow for 
enhanced transport of therapeutic agents. In addition, cardiovascular disease may also present 
various types of pathologic tissue, such as the buildup of atherosclerotic plaque, which is 
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composed of lipids, cholesterol, cellular debris, and calcified tissue, in the walls and lumen of 
affected vessels. In this context, and in the context of diseases such as cardiomyopathies, peripheral 
vascular diseases, and rheumatic heart diseases, the therapeutic target often presents beyond the 
vascular endothelium. Aside from the physical barrier that this cell layer presents, other 
characteristics of the physical microenvironment that limit therapeutic delivery include blood flow 
itself, which may reduce lumen concentration of the therapeutic agent. Many larger blood vessels 
such as the aorta and coronary arteries also possess elastic lamina which present significant 
resistance to permeabilization, and their endothelial linings are highly resistant to shear stresses 
due to the high-pressure, high-flow conditions of the immediate environment. In addition, 
compliance and muscular activity of these vessels are highly coordinated with endogenous 
homeostatic systems such as the nitric oxide pathway and adrenergic pathways, disruption of 
which may result in significant adverse effects upon cardiac function and local tissue perfusion. 
Early applications of targeted delivery to cardiovascular tissue using UTMC involved cellular 
studies with targeted MBs to adhesive proteins expressed by said vascular cells. One example was 
ICAM-targeted liposomes conjugated with vascular stem cells delivered to ex vivo murine aortas 
in the presence of continuous US, which demonstrated successful extravasation past the vascular 
endothelium and subsequent stem cell deposition confirmed in the intimal layer. Although no US 
associated damage to the tissue was reported, there was also extremely limited delivery of the stem 
cells beyond the first elastic laminae. Increase of the peak US pressure from the 0.15 MPa used to 
0.23 MPa with actin-targeted liposomes labeled with fluorescent calcein resulted in strong signal 
from the intima to the adventitia, as well as within the smooth muscle layer, which suggests greatly 
enhanced transendothelial delivery [118]. 
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Further success with UTMC for drug delivery to the myocardium was experienced by many studies 
targeting a wide range of both molecular growth factors and genetic material as payloads for 
therapeutically modified MBs. This resulted in therapeutic outcomes ranging from enhanced 
revascularization and angiogenesis through transmyocardial delivery of vascular endothelial 
growth factor (VEGF), as well as plasmid DNA delivery with loaded MBs to rat myocardium 
resulting in significantly increased target gene expression relative to untreated samples [119].  
From these early studies emerged predominant strategies toward the targeting of MBs to major 
pathologic and inflammatory molecular markers. Both ICAM-1 and VCAM-1 (vascular cell 
adhesion protein) have been popularly targeted by conjugation of their respective antibodies on 
the surface of MBs, resulting in localization of circulating MBs to specifically activated vascular 
endothelial cells. In addition, P-selectin, another cellular adhesion protein upregulated in 
conditions of endothelial inflammation, has been successfully targeted by modified MBs, with the 
adhesion characterized by increased shear stress necessary to dislodge the successfully adhered 
MBs. Combinations of these antibodies have also been applied to MBs for even greater efficiency 
in localization compared to MBs selective for single species of molecular targets [120, 121]. 
In addition to endothelial targets, intraluminal thrombi have also been the subject for 
localization of modified MBs. As a surrogate marker for thrombi, platelets with their surface 
glycoproteins, have been the subject of thrombolytic drug delivery applications with modified 
MBs, such as against GP IIb/IIIa targeted MBs. Fibrin itself has also been the target of modified 
therapeutic MBs. Conjugation of drugs such as plasminogen activator to these MBs has resulted 
in significantly enhanced thrombolysis in vitro [121]. In contrast to drug delivery, gene delivery 
to cardiovascular targets faces additional barriers such as degradation of the genetic material by 
the immune system or blood enzymes, electrostatic repulsion by cellular membranes, degradation 
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by intracellular compartments such as lysosomes, and penetration of the nuclear membrane for 
successful transcription. Current advances in gene therapy toward treatment of cardiovascular 
disease have distinguished two main categories for delivery vectors for genetic material: viral 
vectors and non-viral vectors. As the names suggest, viral vectors encompass many different 
families of viruses including adenoviruses, retroviruses, and lentiviruses [122-125]. Examples of 
viral vector applications include the delivery of calcium channel genes to coronary arteries 
resulting in the prevention of ventricular arrhythmias, silencing of phospholamban gene expression 
(a calcium channel regulator in cardiomyocytes) resulting in treatment and slowed deterioration in 
heart failure, although viral vector approaches in gene therapy in general have been subject to 
criticism due to their potentially unpredictable nature and the capacity to develop mutations in the 
genetic material and during the gene insertion process, potentially resulting in devastating adverse 
effects [126, 127]. On the other hand, non-viral vector gene therapy involves the use of 
macromolecules and molecular constructs including the liposomes, particles, and polymers that 
have been partially discussed in the previous section on therapeutic modifications of MBs for gene 
delivery [128, 129]. Although naked DNA may also be used directly, this is unpopular due to the 
high rates of deterioration and low targeting efficiency after circulation in the subject vasculature. 
Therefore, many of the conjugated constructs also serve the purpose of protecting the genetic 
material from exposure to destructive mediators such as enzymes and phagocytic immune cells.  
Other strategies for enhancing delivery efficacy of genetic material include conjugation of 
constructs to antibodies targeting specific molecular components of cardiac tissue, such as cardiac 
myosin, which resulted in successful enhancement of in vitro transfection [130]. However, these 
generally biologically inert non-viral constructs are tasked with the main obstacle of penetrating 
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the physical barrier of the cellular membrane, something which viral vectors are innately equipped 
to handle [131]. 
Therefore, in this context UTMC provides an efficient solution to the delivery of genetic 
material through overcoming the physical barrier of cellular membranes through the many 
mechanisms previously discussed, including sonoporation, radiative forces, inertial cavitation, and 
increased endothelial permeability. Indeed, studies have shown that use of UTMC successfully 
increases transfection efficacy of both plasmids and short hairpin RNA both in vitro and in vivo 
[132-134]. Use of UTMC to enhance gene therapy also confer advantages of low toxicity (as the 
material components of most MBs are biocompatible and the gas core species will diffuse to be 
exhaled by the subject), low immunogenicity (compared to viral vectors, which may trigger a host 
immune response after delivery), decreased invasiveness (due to external US application and 
injections of MBs being extremely non-invasive to the subject), and improved targeting (due to 
external manipulation of the US beam for selection of a location for MB cavitation and subsequent 
release of genetic material). Due to all these reasons, UTMC is highly favored as a recent 
development and tool for enhanced gene therapy. One such example is the TFPI-2 gene, which is 
involved in the processes of atherosclerosis, thrombosis, and re-stenosis following intervention. 
Previous investigation has demonstrated the successful delivery of the gene with SonoVue as the 
MB agent, with increased efficacy even compared against an adenoviral vector [135]. Other gene 
targets include the TB4 gene, which stimulates differentiation of immature cardiac progenitor 
cells, naked plasmids which have been incubated with liposome formulations as previously 
described, fibroblast growth factor for stimulation of myocardial angiogenesis, and tissue 
plasminogen activator gene plasmids for treatment of thrombotic disease [136]. 
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Viral vectors have also been successfully shown to be enhanced with adjuvant UTMC 
therapy. Although viruses have the innate ability and machinery to penetrate through the cellular 
membrane, their efficacy may still be improved through the mechanisms of UTMC such as 
sonoporation in a synergistic manner [137, 138]. Moreover, UTMC may enhance the specificity 
of viral targeting due to increased concentration of viral activity to cavitation regions, as well as 
increased spread of the viral vectors through increased permeability of the endothelial barrier. This 
increase in transduction efficiency has been demonstrated with retroviral vectors to over 5-fold 
increases in transduction for various types of cells [139]. Further experiments on transgene 
expression in vivo showed similar results with infusion of therapeutically modified MBs into the 
myocardial microvascular beds followed by rupture with high intensity US pulses at 1.3 MHz 
[140]. Therapeutically modified MBs have also been shown to confer a cloaking effect on the 
immunogenicity of injected viral vectors, as systemic administration of viral vectors has previously 
triggered host innate immune responses that were potentially concerning. In addition, certain types 
of viruses (such as retroviruses) require their own viral envelope membrane to successfully 
integrate and penetrate the cellular membrane for payload delivery [141]. However, previous 
studies of envelope-deficient retroviruses which were loaded into MBs still resulted in successful 
delivery and transfection using UTMC, suggesting that MB lipid shells may possibly perform 
similar roles, or are enhancing cellular mechanisms of material incorporation such as endocytosis 
[142]. In further mechanistic studies regarding the delivery of partially inactivated viral vectors 
with UTMC, one group developed pegylated adenoviruses which were essentially prevented from 
interacting directly with the cellular membrane based on steric hindrance from the polymer brush 
layer [143]. Use of these modified viruses with UTMC still resulted in successful delivery into the 
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cytosol of cells, hence suggesting that mechanisms of sonoporation alone are highly capable of 
mediating viral particle delivery. 
3.3.2.2 Thrombolysis 
Thrombolysis, or the destruction of blood clot, is relevant to many pathologies including 
acute coronary syndromes, stroke, pulmonary embolism, and peripheral vascular disorders. 
Although there exist endogenous mechanisms for prevention and resolution of thrombosis, 
including signaling from endothelial cells and hematologic systems such as the tissue plasminogen 
activator pathway, development of thrombi that overwhelm these defenses often require medical 
intervention to prevent potentially irreversible damage. Use of US to dissolve thrombus has been 
a long-sought after solution to this issue, which has more recently become refined with the 
development of UTMC and various elaborations on this minimally invasive technique. The 
mechanisms of efficacy of UTMC in performing thrombolysis have their foundations in the same 
physical mechanisms previously described that are attributed to the efficacy of UTMC in other 
applications as well; these cavitational and radiative forces may leverage the explosive nature of 
MB destruction to instead cause maximal impact on the surface and penetration into the depths of 
thrombus material to not only cause disruption of the thrombus mechanical integrity but also to 
increase the available surface area for activity of both endogenous and exogenous molecular 
thrombolytic therapies. In this section, the application of UTMC for thrombolysis in various 
pertinent clinical applications will be discussed. (It is noted that the context of microvascular 
obstruction, because of its central nature to the work in this dissertation, will be reserved for 
discussion in a later chapter.) 
It is first to be noted that US alone has been shown to have thrombolytic effects. Low 
frequency US has been delivered both transcutaneously and intravascularly (via a catheter-based 
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system) to destroy arterial thrombotic obstructions and has been demonstrated to be successful in 
a number of previous studies in coronary arteries and vein grafts [144-146]. The US frequencies 
used have ranged from 20 kHz to 2 MHz, both in continuous and pulsed regimes of delivery. In 
addition, many of these studies have sought to use therapeutic US alone to enhance the efficacy of 
a simultaneously delivered thrombolytic agent to significant effect. In one example, 26 kHz US at 
an output of 18 watts per square centimeter was applied to thrombotic rabbit femoral arteries as an 
adjuvant therapy to streptokinase administration [147]. The study’s results showed that use of both 
therapeutic US and streptokinase together resulted in over a 50% increase in the number of rabbits 
successfully recanalized compared to streptokinase alone. Improved results using the same model 
showed even greater increases at over 90% recanalization rate for the animals when frequency of 
the US was further increased to 37 kHz.  
UTMC has also shown highly positive results for thrombolysis, of course. However, the 
mechanism of UTMC in thrombolysis has been strongly suggested to be mechanical, not biological 
in nature. One previous study showed that UTMC resulted in increased thrombolysis than US 
alone with urokinase infusion [148]. However, measured D-dimer levels, which are molecular 
markers of enzymatic thrombolysis, were non-elevated with UTMC. While the residual particle 
size was indeed smaller, similar to sizes seen in biological thrombolysis, the lack of D-dimer 
elevation suggested that the UTMC merely mechanically reduced the thrombi to smaller sizes.  
One area in which UTMC has demonstrated significant clinical utility is in the treatment of stroke. 
Stroke, or ischemic stroke, is the event of neuronal cell death due to obstructed blood flow through 
the cerebral vessel supplying the local region, commonly due to a thrombotic event. This may lead 
to death, or sustained neurological damage, leading to potential disability. The current prevailing 
treatment for stroke is infusion of recombinant tissue plasminogen activator, which is a biological 
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thrombolytic agent unfortunately accompanied by increased risk for subsequent hemorrhage. With 
developing medical technology, thrombectomy, or the intravascular procedure of non-invasive 
surgical thrombus removal, has become an alternative to recombinant tissue plasminogen activator 
(rtPA) therapy. However, this technique is limited to specific treatment centers and also by vessel 
size, as vessels with diameters smaller than 2 mm are generally inaccessible to the equipment. 
Therefore, UTMC based thrombolysis has been explored as an additional minimally invasive 
therapy toward treating stroke. Because the injected MBs themselves have no innate biological 
function or adverse effect, there is no increase of hemorrhage as in the case with rtPA therapy, nor 
is there a size limitation for access as in the case of thrombectomy because the size of the MBs (on 
the order of single digit microns) is much less than most vessels of the major cerebral vascular 
system. A meta-analysis of randomized controlled trials and case-control studies as well as a recent 
clinical trial have both concluded that thrombolysis with UTMC, termed sonothrombolysis, is a 
viable therapeutic strategy for treatment of stroke and demonstrates no significant adverse effects 
in the patient [149].  
In one most recent meta-analysis of pre-clinical animal studies, a number of successful 
aspects of sonothrombolytic therapy were emphasized [149-151]. General trends included the 
favor toward intra-arterial administration of treatment MBs over intravenous administration, 
targeted MBs over non-targeted MBs for patency and recanalization rates, and adjuvant rtPA 
therapy with concurrent sonothrombolysis over sonothrombolysis alone. Outcomes of 
sonothrombolysis with UTMC included lower infarct volumes, better TIBI scores, patency rates, 
and vascular volumes of treated versus untreated hemispheres. However, there were some negative 
results reported as well suggesting that sonothrombolysis with rtPA treatment was ineffective in 
certain scenarios of thrombi with high platelet concentrations. With the main adverse effect of 
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stroke intervention being hemorrhage, sonothrombolysis has been shown to not increase cerebral 
hemorrhages relative to control; however, the meta-analysis notes that the other treatment groups, 
including rtPA (which is known to be accompanied by an increased risk of hemorrhage), also did 
not show increased cerebral hemorrhage. The meta-analysis proposes several potential reasons for 
this, with one being the lack of an ischemic phase prior to treatment in animal studies. With the 
development of multimodal imaging techniques, as well as combination theranostic (therapeutic 
and diagnostic) interventions, the combination of magnetic resonance imaging with therapeutic 
US continues to be a strong source of innovation for treatment of stroke just as it has been for 
treatment of Alzheimer’s disease and in disruption of the blood brain barrier. Specifically, 
magnetic resonance guided high frequency US (HIFU, as previously described), has become a 
targeted, minimally invasive method for thermal heating and ablation. Both the size and extent of 
ablation depend on the delivered thermal dose, which is determined by the characteristics of the 
US wave used due to the mechanical principles of attenuation and absorption as previously 
described [152]. Although several human clinical trials for unfocused US alone with rtPA for 
treatment of stroke have been either unsuccessful or prematurely terminated due to an unacceptable 
rate of adverse events, there are those who feel that the use of rtPA and the use of unfocused beams 
(which may generate standing waves, a phenomenon of stationary nodes and antinodes due to 
waveform interference) resulted in such adverse events which would be addressed through the use 
of HIFU. Preliminary in vivo studies have shown viability for this technique in thrombolysis in 
animal models such as a carotid rabbit model [153]. In addition, HIFU with injected MBs, an 
additional factor not studied in the clinical trials previously mentioned, further reduced the US 
energy required for successful recanalization of the occluded vessel. One further advantage of 
HIFU with magnetic resonance guidance is the treatment of hemorrhagic stroke, which may be 
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caused by trauma to the head, cerebral aneurysm rupture, and hypertension, among other factors. 
This results in a need for thrombolysis as well, as otherwise the resultant clots from the hemorrhage 
often require craniotomy and aspiration for surgical removal. Catheter based magnetic resonance 
guided HIFU has also been shown to enhance thrombolysis in such cases, while also potentially 
augmenting CSF circulation and improve hydrocephalus. 
One other clinical area to mention for the use of US for thrombolysis is in acute pulmonary 
embolism [154]. Pulmonary embolism, which has generally been limited to systemic 
anticoagulation for treatment, may result in hemodynamic instability, severe hypoxia, right cardiac 
ventricular failure, and death. Although use of systemic anticoagulation therapy results in an 
improvement in overall mortality, again, as in the case with stroke, increased risk for major 
hemorrhage is a significant factor in weighing the risks for its application. Again, in parallel with 
interventions for stroke previously discussed, catheter-based techniques for treatment of 
pulmonary embolism have also been developed. The goal being to remove the obstructing thrombi 
from the pulmonary circulation, this involves mechanical disruption of the thrombus using 
fragmentation, suction, and torsion. Additionally, delivery of thrombolytic agents in the immediate 
vicinity of the catheter device is also possible, resulting in a direct distribution of the agent to the 
thrombus surface. However, peri-procedural complications and procedural-related deaths have 
still occurred, and the therapeutic contribution of the catheter intervention alone (versus 
thrombolytic agent administration with the catheter intervention) is still not fully understood. One 
device designed specifically for this need is the EkoSonic® Endovascular System, which is a 
combination of a multi-sidehole drug infusion catheter outside of a core wire consisting of several 
US elements [155]. This device was approved by the FDA in 2008 for intravascular applications. 
One clinical trial for US thrombolysis in acute pulmonary embolism is the ultrasound accelerated 
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thrombolysis of pulmonary embolism (ULTIMA), hypothesized that use of US thrombolysis 
would result in improvement in right to left ventricular ratio compared to systemic anticoagulation 
alone [156]. The treatment arm of the trial consisted of an US thrombolysis combination therapy 
with rtPA administration, and resulted in a highly significant improvement in right ventricle to left 
ventricular ratio at 24 hours after therapy (therapy lasting 15 hours), while the control group 
receiving systemic thrombolytic therapy showed no such improvement at that time, only managing 
a later catch-up effect. Ventricular ratio at 90 days after therapy and systolic function of the right 
ventricle were both assessed to be in favor of the US thrombolysis group, and only minor adverse 
events of some hemorrhaging were observed. A later meta-analysis noted that the previous study, 
as well as an aggregate of other clinical studies on patients with acute pulmonary embolism treated 
with US thrombolysis, demonstrated significantly lower rates of major bleeding events than seen 
in systemic thrombolytic therapy by almost five times [157]. It was noted that the newest catheter 
devices are capable of delivering the high frequency US (2.2 MHz) needed for successful 
disruption of thrombus and delivery of the concurrently administered thrombolytic agent. 
Additionally, one of the most recent US thrombolysis trials showed no incidences of intracranial 
hemorrhage, with significant improvement of hemodynamic status. Overall, US thrombolysis with 
local thrombolytic agent delivery has been shown to have significantly improved prospects for 
patients with acute pulmonary embolism [158, 159]. 
3.4 Summary 
This chapter was an introduction to the concept of UTMC, with several examples of notable 
clinical applications for the technique. While the work in this dissertation remains at a pre-clinical 
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animal model stage, the further refinement of UTMC itself still warrants investigation and 
innovation with novel therapeutic agents and biological applications. Now that much of the 
relevant concepts and techniques involving US, both imaging and therapeutic have been discussed, 
the next few chapters will mainly detail the biological contexts in which UTMC operates, which 
will also be relevant to the disease and animal model context of the work in this dissertation. 
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4.0 Microvascular Obstruction Background and Clinical Implications 
In this chapter we will discuss the concept of microvascular obstruction as a pathological 
condition as well as a therapeutic target for UTMC. Although microvascular obstruction is not 
directly addressed in the work of this dissertation (an ischemia-reperfusion injury model is instead 
used), it has been the target for the previous work in the author’s laboratory. However, many of 
the pathological changes which occur in MVO are sought to be captured in the ischemia-
reperfusion disease model, including processes such as inflammation and oxidative stress. In 
addition, for further translation of this work, including transitioning to larger animal models and 
even human patients, MVO and the no-reflow phenomenon remain to be the target pathologies. 
Therefore, this chapter will consist of the pathophysiology of microvascular obstruction, its 
underlying mechanisms, its occurrence in human patients, current treatments for microvascular 
obstruction (including with UTMC), and its implications on patient outcomes. 
4.1 Microvascular Obstruction Pathophysiology 
Coronary artery disease is the pathological deterioration of the capacity for the coronary 
arteries to supply blood to myocardial tissue. One specific form of coronary artery disease is when 
there is an acute, sudden obstruction of an epicardial vessel, due to a combination of thrombosis, 
embolization, plaque disruption, and vascular spasm, and is called acute myocardial infarction. 
The resulting myocardial ischemia may result in permanent damage to the heart if left untreated, 
although modern medicine has developed percutaneous coronary interventions to prevent such 
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occurrences [160]. Percutaneous coronary intervention involves patient catheterization and the 
deployment of various wire, catheter, balloon, and sheathe type devices to the heart to store blood 
flow to the occluded artery. However, despite these advances, there is a phenomenon in which 
ischemic myocardial tissue fails to reperfuse (or reflow) after successful recanalization of the 
epicardial artery, termed no-reflow. Another source defines no-reflow as inadequate perfusion of 
myocardial tissue without evidence of a mechanical obstruction to perfusion for that specific 
region. This term for the phenomenon described was first coined in 1967 in the setting of cerebral 
ischemia and has persisted since [161]. The occurrence of no-reflow has also been accompanied 
by terms such as the no-reflow region, which refers to the area in which no-reflow occurs, and 
microvascular obstruction, which is essentially synonymous with no-reflow but places emphasis 
on the contribution of deranged microvasculature conditions to the phenomenon [162]. Nowadays, 
no-reflow has been used to refer to the physiological state of absent myocardial perfusion 
following successful epicardial recanalization, while microvascular obstruction is referred to as 
the underlying mechanism resulting in the no-reflow condition [162]. Microvascular obstruction 
refers to the obstruction of vessels fewer than 200 microns in diameter. In addition, 
pathophysiology of microvascular obstruction in relation to epicardial vessel atherosclerotic 
disease and obstruction has been well documented, with plaque erosion from epicardial vessels 
shown to have strong implications in development of microvascular obstruction in patients [163, 
164]. 
There has been a distinction of two overall types of microvascular obstruction resulting in 
no-reflow: myocardial infarction reperfusion no-reflow and interventional no-reflow. In the 
myocardial infarction reperfusion type, the underlying source of injury results from ischemia-
reperfusion and endothelial injury due to ischemia [161]. Briefly, endothelial injury is caused by 
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a wide range of factors including oxidative damage from reactive oxygen species, inflammation, 
excessive intracellular calcium influx, and a loss of mitochondrial membrane integrity. The 
resulting damage causes endothelial swelling and protrusion, as well as myocardial edema, which 
result in bulging of tissue into the vascular compartment and thereby causing microvascular 
obstruction. Of course, vasospasm and distal embolization from the epicardial event site may also 
exacerbate the damage described above. The second type of microvascular obstruction described 
as interventional refers to the scenario in which percutaneous coronary intervention and 
deployment of stents and balloons results in fragmentation and distal embolization of the main 
thrombus, as well as the release of atherosclerotic debris, which is highly inflammatory [161]. This 
deployment of debris results in significant activation of platelets and inflammatory cells, which 
further contribute to the obstructions which develop in the downstream microvasculature in a 
combination of mechanical plugging and biological aggravation of endothelial health. These 
various processes will be described in further detail in following sections. 
Another type of classification for microvascular obstruction separates cases into structural 
and functional obstruction [165]. Structural obstruction is due to factors such as endothelial 
swelling and myocardial edema causing vascular compression and obstruction, or damage to 
capillary integrity which renders them unfunctional after prolonged ischemia (and development of 
an ischemia lesion). Functional microvascular obstruction, on the other hand, refers to transient 
factors such as vascular spasm, ischemia-reperfusion injury resulting in a build-up of neutrophils 
and platelets, and distal microembolization [165]. Structural obstruction is generally irreversible, 
whereas functional obstruction is reversible to an extent. In human patients, there have been four 
main components of microvascular obstruction, described as distal embolization, ischemic 
myocardial injury, ischemia-reperfusion injury after successful percutaneous coronary 
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intervention, and previous individual vulnerability for microvascular injury [165]. Distal 
embolization may occur both from an epicardial thrombus as well as an atherosclerotic plaque and 
is the downstream circulation of various atherothrombotic particles ranging from tens to hundreds 
of microns in size. Such emboli are thought to range from 20 to 200 microns in size, although 
microemboli greater than 200 microns may result in severe obstruction [165]. Ischemic myocardial 
injury commonly consists of cellular swelling and bulging, including the development of luminal 
endothelial protrusions. In addition, erythrocyte extravasation is extremely common due to the loss 
of structural integrity in cellular junctions and widening endothelial gaps, which further contributes 
to myocardial swelling and edema, further compressing the microvasculature.  
Reperfusion-ischemia injury will be described again in a later chapter, but in the context 
of microvascular obstruction, occurs after successful epicardial recanalization. Sudden return of 
blood flow also results in a massive influx of inflammatory cells, neutrophils, and platelets to the 
previously ischemia area [166]. Due to the buildup of toxic metabolites and waste products during 
the period of ischemia, activation of these cells typically occurs, which only results in the feedback 
loop of further production of various antagonistic products by neutrophils, such as reactive oxygen 
species, free radicals, proteolytic enzymes, and pro-inflammatory signaling mediators which may 
cause not only endothelial damage, but also further amplify this signal and pattern of activity to 
other immune cells in the body after circulation [167]. Damaged endothelial cells may then release 
various vasoconstrictive mediators, which may result in vascular spasm and exacerbation of 
microvascular obstruction [167]. Specifically, some of these molecular mediators include 
interleukin-1 beta, tumor necrosis factor-alpha, selectin, and superoxide radicals [167]. 
Interleukin-1 beta has been shown to be associated with ischemia-reperfusion injury and 
inflammation. Tumor necrosis factor-alpha has been shown to be associated with decreased 
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coronary flow reserve (which increases vulnerability to microvascular obstruction as there is less 
capacity for additional recruitment and vasodilation of the coronary vessels) [167]. Selectin is a 
cellular adhesion molecule expressed on endothelial surfaces and is relevant to mechanical 
obstruction. Superoxide radicals, which are formed by the enzyme xanthine oxidase of neutrophils, 
also contributes toward inflammation through damage of cellular proteins and genetic material. 
Another mediator of endothelial injury is vascular endothelial growth factor (VEGF) when 
produced in a metabolically deranged context. VEGF may be produced in response to hypoxia 
during myocardial infarctions, and while it typically complexes with cadherin to stabilize 
endothelial cellular junctions, during ischemia, this signaling molecule dissociates its own receptor 
molecule from the cadherin junction complex, resulting in increased endothelial permeability 
[167]. 
Other aspects of reperfusion injury aside from cells and molecular mediators is the change 
in electrolyte concentrations of the extracellular fluid compartment during and after ischemia 
[167]. During ischemia, there is an accumulation of sodium ions due to an increase in hydrogen 
ions produced by anaerobic metabolism, an accumulation of calcium ions due to a sodium calcium 
exchanger’s overactivity, and extrusion of accumulated sodium ions through the sodium potassium 
ATP dependent transporter is impaired, again due to lack of ATP and anaerobic metabolism. In 
all, this leads to cardiomyocyte swelling and mitochondrial permeability, which results in sudden 
rupture when there is a drastic and sudden change in extracellular osmolality during reperfusion 
and influx of typical extracellular fluid to the region [167]. For predisposing factors and 
vulnerability to microvascular injury, vascular disease factors such as diabetes, 
hypercholesterolemia, and other genetic conditions involving oxidative stress are implicated due 
to the role of oxidative stress and inflammation in the development of microvascular obstruction 
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pathology [167]. In addition to these factors, microvascular obstruction continues to present 
additional adverse effects which continue on to affect patient prognosis. These are thought to 
include hemodynamic obstruction of the delivery of various molecular mediators involved in the 
recovery process and remodeling of the ischemic lesion into a myocardial scar, as well as limiting 
of circulation and localization of various cellular participants in post-infarct remodeling such as 
macrophages, which phagocytose cellular debris and promote infarct healing [161, 162, 166, 168, 
169]. 
4.2 Diagnosis of Microvascular Obstruction 
Microvascular obstruction, as we previously defined, is a deficiency in perfusion of 
myocardial tissue despite patency in the proximal epicardial vasculature. It may be caused by a 
wide range of contributing factors, including ischemic damage promoting the release of toxic and 
vasoconstrictive factors, myocardial edema, endothelial swelling, distal microembolization from 
the epicardial atherothrombotic event site, and neutrophil and platelet activation and aggregation. 
Typically, microvascular obstruction occurs at the core of the ischemic region, although its 
pathology may spread to surrounding myocardial tissues within the first 48 hours. The prevalence 
of microvascular obstruction is different depending on the study population referenced. For the 
population of all patients receiving a catheter procedure, microvascular obstruction may be as low 
as 8-10%. However, for the population of only patients experiencing an acute myocardial 
infarction with ST elevation, previously investigated incidence of microvascular obstruction has 
been as high as 60% [166].  
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The diagnosis of microvascular obstruction most commonly requires the use of an imaging 
modality, of which there is a wide range of options available. These include angiography, US 
echocardiography, cardiac magnetic resonance imaging, and nuclear scintigraphy. As previously 
mentioned, the Thrombolysis in Myocardial Infarction (TIMI) flow grading system is used to 
assess microvascular blood flow on angiography. For contrast echocardiography, use of MB agents 
is included, with the rate of myocardial MB uptake being the quantitative measure [170]. However, 
this is a less consistent measurement due to greater dependence on consistency in MB contrast 
infusion, operator skill, and acquisition of an optimal acoustic imaging window. Another method 
used is through electrocardiography, especially changes in ST segment elevation after 
percutaneous coronary intervention. Studies have shown that with successful myocardial 
reperfusion following intervention, there should be a rapid decrease of ST elevation (assuming 
myocardial infarction with ST elevation) [161, 166]. A drop of ST elevation less than 70% after 
one-hour post-intervention is therefore taken to be a sign of microvascular obstruction and has 
been shown to be highly specific (91%) as well as sensitive (77%). Intracoronary guidewires and 
catheters have also been used to measure coronary blood flow rate, flow reserve, and also therefore 
microvascular function and possible obstruction. Microvascular obstruction is associated with 
alterations in observed flow characteristics, specifically reversal in systolic flow, reduced 
anterograde flow during systole, and rapidly decelerating diastolic forward flow. Because 
microvascular obstruction is at its essence a derangement of hemodynamics and capillary damage 
on the microvascular level, these velocity patterns are associated with such hemodynamic changes. 
Intracoronary pressure measurement using double lumen catheters has also been performed with 
two measurement points. A significant pressure gradient may also be investigated as potential 
microvascular obstruction. 
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Cardiac magnetic resonance imaging remains the most comprehensive method of 
diagnosing and assessing microvascular obstruction [171]. Cardiac magnetic resonance imaging 
utilizes infusion of gadolinium-based contrast agents to delineate the infracted region, and the 
appearance of microvascular obstruction to this contrast imaging may change depending on the 
timing of the magnetic resonance image acquisition with the instance of contrast administration. 
In early stages, microvascular obstruction is identified as a defect in perfusion in the core of the 
infarcted region, essentially a hypointensity on T1-weighted imaging typically 2 to 5 min after 
contrast administration [171]. If the microvascular obstruction is particularly severe, this 
hypointensity and absence of contrast enhancement may persist up to greater than 10 minutes after 
contrast administration, which is then referred to as late microvascular obstruction. Compared to 
early microvascular obstruction imaging, late microvascular obstruction has much greater spatial 
and contrast-enhancement resolution, and also fully encompasses the left ventricle [171]. As such, 
the filling in, or washing in of the gadolinium contrast into the microvascular obstruction region 
at the core of the infarct zone varies based on each individual case, and the prognostic significance 
of this timing is yet undetermined [171]. 
Another development of severe microvascular obstruction is described as intramyocardial 
hemorrhage and occurs after the development of microvascular obstruction in the infarct zone core 
and may expand even after successful percutaneous coronary intervention [171]. The cause of 
intramyocardial hemorrhage is the accumulation of vascular endothelial damage and loss of 
intercellular junction integrity, resulting in extravasation of red blood cells into the interstitial 
myocardial space. Due to this lack of compartmentalization between the bloodstream and tissue 
interstitium, this inundation is accompanied by severe ischemia reperfusion injury, and is also 
highly correlated with the overall infarct size [171]. Other factors contributing to intramyocardial 
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hemorrhage and possibly exacerbating its severity include presence of collateral flow (to mitigate 
ischemic damage by having supplementary pathways for blood to reach the infarct zone), extent 
of necrotic damage (also related to timing of percutaneous coronary intervention), extent of distal 
microembolization, and individualized risk factors including lifestyle factors such as 
hypercholesterolemia, smoking, and diabetes, among others [171]. 
Diagnosis and assessment of intramyocardial hemorrhage is once again achieved through 
cardiac magnetic resonance imaging, and intramyocardial hemorrhage is typically observed as a 
hypointensity within the infarct zone in T2-weighted imaging [171]. This is because the 
paramagnetic characteristics associated with the hemoglobin molecule and its various metabolic 
decomposition products shortens the T2 relaxation time after sequences. In addition, T2*-weighted 
imaging may also be used to identify intramyocardial hemorrhaging due to the sequence marking 
hemorrhages as hypointense [171]. However, T2* images are slightly noisier than T2-weighted 
images, and the T2* signal gradually normalizes to the surrounding tissue due to tissue remodeling 
associated processes such as collagen deposition and removal of interstitial iron deposition. Further 
comparison between T2 and T2*-weighted imaging is needed in study, however, as microvascular 
obstruction without significant hemorrhage may also appear as hypointense on T2-weighted 
images [171]. 
4.3 Clinical Outcomes Following Microvascular Obstruction 
One major study pooling data from 7 randomized trials studying microvascular obstruction 
after percutaneous coronary intervention showed strong associations between microvascular 
obstruction and mortality and development of heart failure in patients after 1 year [172]. MVO 
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itself was also quantitatively analyzed using gadolinium-based contrast and cardiac magnetic 
resonance imaging. Briefly, with gadolinium contrast after myocardial infarction, there is a 
hyperintense infarct area, and then a dark region within the hyperintensity which represents 
microvascular obstruction. In the study, 1688 patients with cardiac magnetic resonance imaging 
performed after percutaneous coronary intervention for acute myocardial infarction were analyzed 
with clinical follow-ups at 6 months and 1 year after the event [172]. There were significant 
associations found between microvascular obstruction and all-cause mortality as well as 
subsequent hospitalization for development of heart failure, including a graded response when 
microvascular obstruction was separated into three categories based on severity [172]. In addition, 
it was found that MVO itself was a strong independent predictor of all-cause mortality, and that 
patients who experienced microvascular obstruction had greater infarct sizes [172]. However, even 
while adjusting for infarct size, microvascular obstruction remained significant for the mortality 
and heart failure rehospitalization previously described. In addition, area of microvascular 
obstruction also was significant in modeling, with a 1% increase in the absolute extent of 
microvascular obstruction being associated with a 14% increase in 1-year mortality and an 8% 
increase in re-hospitalization due to heart failure [172]. 
In a separate meta-analysis, presence of early or late microvascular obstruction was 
correlated against clinical outcomes including major adverse cardiac events, cardiac death, 
congestive heart failure-related re-hospitalization, and recurrence of acute myocardial infarction 
[173]. In addition, for studies in the meta-analysis which analyzed both early and late 
microvascular obstruction, a comparison between the two was also investigated for intra-study 
correlation. In addition, functional measures such as left ventricular function and volume and 
infarct size were correlated against presence of early and late microvascular obstruction [173]. The 
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results showed that early microvascular obstruction was independently associated with both left 
ventricular remodeling and incidence of major adverse cardiac events [173]. In addition, there 
were significant difference in ejection fraction and left ventricular volumes at later follow-up 
examinations for patients who presented with and without early microvascular obstruction. In 
addition, there were trends of early microvascular obstruction increasing cardiac mortality, 
incidence of future acute myocardial infarction, and congestive heart failure re-hospitalization, 
although the results were not statistically significant. 
For effects of late microvascular obstruction, which was investigated as a potential 
alternative marker to early microvascular obstruction for prognostic purposes, similar outcome 
measures were analyzed [173]. Similar to early microvascular obstruction, late microvascular 
obstruction was significantly associated with both left ventricular remodeling and incidence of 
major adverse cardiac events using multivariate analysis, with presence of late microvascular 
obstruction predicting greater declines in ejection fraction at both baseline measurement and 
longitudinally during follow-up examinations. However, most studies did not report any 
significant additional benefit of assessing presence of late microvascular obstruction to predict the 
previously mentioned functional outcome measures. The few studies which did, though, reported 
significant correlation between size of the late microvascular obstruction with incidence of major 
adverse cardiac events, and the ratio of the microvascular obstruction to infarct size was found to 
be the strongest predictor of major adverse cardiac events by one study, possibly suggesting that 
late microvascular obstruction holds stronger predictive capacity with future major adverse cardiac 
events experienced by the patient [173]. 
Another study investigating the prognostic implications of microvascular obstruction 
found that presence of microvascular obstruction was significantly associated with an increased 
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mortality at 30 days post-event (relative risk ratio of 2.1), and that 5-year re-hospitalization is also 
more frequent in microvascular obstruction patients [174]. In addition, evaluation of infarct 
regions using positron emission tomography showed that microvascular obstruction patients 
typically had larger infarcts and almost twice as many deaths at the 5-year survival mark.  
In all, microvascular obstruction has been characterized as a pathologic phenomenon which is 
extremely common and identifiable, with significant impact on patient outcomes. The following 
section will discuss current attempts at intervention for microvascular obstruction [165, 171, 174-
177]. 
4.4 Current Treatments for Microvascular Obstruction 
There have been numerous trials investigating treatments for microvascular obstruction, 
from pharmacological agents to medical devices. General consensus in the field is that there is 
currently no standardized treatment for this phenomenon, although results from various meta-
analyses and reviews have been mixed in opinion regarding suggestions for treatment [161, 178]. 
One class of drugs that have seen consistent use in applications of cardiovascular disease are 
calcium channel blockers such as verapamil, diltiazem, and nicardipine. Recent meta-analyses 
have shown significant benefits of intracoronary calcium channel blocker therapy compared to 
standard of care [179]. However, many of these studies claiming benefits were also performed in 
different clinical contexts such as atherectomy, which involves removal of atherosclerotic plaque, 
and percutaneous interventions for venous grafts rather than native coronary vessels [179]. While 
positive, and certainly demonstrating the value of these drugs, the results from these trials suggest 
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the need for a larger standardized trial investigating calcium channel blocker therapy in acute 
myocardial infarction and specific treatment to microvascular obstruction [179].  
Nitroprusside is another pharmacological agent which has been investigated for treatment 
of microvascular obstruction. Nitroprusside chemically dissociates to release a nitric oxide 
molecule (more on which will be later discussed) which leads to relaxation of vascular smooth 
muscles and vasodilation. Some studies propose that intracoronary nitroprusside infusion is 
clinically effective in treating microvascular obstruction, although application of this drug has 
varied between the various supporting studies [179]. In one case, it was documented that patients 
receiving nitroprusside experienced more rapid resolution of ST elevation, although the various 
outcome measures of flow were not significantly different between treatment groups. Another 
study investigating nitroprusside treatment in microvascular obstruction showed significant 
improvement in TIMI frame counting compared to nicorandil, another drug, although the sample 
size in this study was admittedly limited to 49 patients. However, two meta-analyses conducted on 
nitroprusside therapy for microvascular obstruction during percutaneous coronary intervention 
have suggested significant benefits. Therefore, as pharmacologic agents go, nitroprusside has 
garnered significant attention as a potential treatment for microvascular obstruction [179]. 
However, use of these pharmacologic agents was associated with improved clinical 
outcomes after resolution of microvascular obstruction. One example of this is the use of the purine 
nucleoside adenosine, which has effects on smooth muscle relaxation in the coronary blood 
vessels. One study found that while adenosine administration following thrombectomy was not 
significantly associated with clinical benefits as observed up to 30 days follow-up, at the 1-year 
timepoint, there was significantly increased beneficial remodeling of the left ventricle in the group 
receiving adenosine compared to nitroprusside or the control group [179]. In addition, this group 
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with favorable remodeling showed lower incidences of future acute myocardial infarctions and 
development of congestive heart failure [179]. 
An alternative strategy of placing a downstream device to protect against distal 
microembolization in the patient coronary arteries also failed to show any improvements in 
perfusion or reduction in infarct size. Another technique called thrombectomy, which involves 
aspiration of the main obstructing thrombus, applied before percutaneous coronary intervention, 
was investigated in a clinical trial and has resulted in positive results overall for acute myocardial 
infarction with ST elevation. However, despite being associated with a decrease in microvascular 
obstruction, long-term benefits of this additional intervention were not found in a later meta-
analysis [161, 166, 170, 178-181]. 
4.5 Treatment of Cardiovascular Pathology with UTMC 
Previously, various applications of UTMC were discussed, including its use in treatment 
of thrombotic conditions such as stroke and pulmonary embolism. Myocardial infarction with ST 
elevation is one of the main manifestations of cardiovascular disease which requires immediate 
treatment. Contemporary standards of care for acute myocardial infarction is percutaneous 
coronary intervention, as previously discussed [160]. However, as with the development of 
microvascular obstruction, as well as due to geographic limitations, treatment with percutaneous 
coronary intervention is not perfect. Other therapies include thrombolysis with pharmacologic 
agents, although such interventions are accompanied by an elevated risk of hemorrhage and poorer 
recanalization rates [179]. Therefore, UTMC, with the portable nature of US therapy and its 
relatively non-invasive nature, holds great potential in treatment of acute myocardial infarction 
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with ST elevation. As with other conditions, treatment of myocardial infarction essentially 
simplifies to an issue of UTMC thrombolysis. Many previous groups have investigated the ideal 
US regime for use in these scenarios, given the difference in clot size, accompanying thrombolytic 
agent, and treatment contexts (whether in vivo or in vitro).  
One camp of thought involved the use of low-frequency, high-intensity US, which 
demonstrated significant success in thrombolysis, even showing significant decreases in vessel 
obstruction in an in vivo canine model without signs of injury to the surrounding tissue and vessel 
walls [182, 183]. However, while other follow-up studies showed good safety and efficacy based 
on TIMI flow, the lack of improvement in recanalization rates over PCI slowed further 
development of this methodology. An alternative US regime that has been investigated is with low 
intensity but high frequency US [184, 185]. Although this type of US was unable to significantly 
cause thrombolysis by itself, since approximately 50% of the material found in MVO autopsy 
specimens is comprised of thrombus, addition of a thrombolytic agent such as tPA resulted in 
significance enhancement of thrombolysis compared to tPA alone [163, 164, 183]. Given our 
previous discussions on the mechanisms behind different regimes and intensities of US, it is 
possible that these two types of US functioned through different mechanisms. It is likely that the 
high intensity US involved destructive inertial cavitational mechanisms, while the low intensity 
US involved more stable rather than inertial cavitation, with mechanisms such as microstreaming 
causing enhancement of thrombolysis. 
These studies, performed with US alone, were soon followed by the use of contrast MB 
agents, which lowered the cavitational threshold as previously described [183]. As expected, 
addition of MB agents significantly increased the amount of thrombolysis achieved, especially 
with an additional thrombolytic adjuvant therapy on top of the UTMC. 
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Another parameter of the US pulse investigated for efficacy was pulse duration. Several 
groups demonstrated that a longer pulse length was more favorable for thrombolysis because such 
pulse resulted in increased sustained MB activity, resulting in increased amounts of cavitation 
experienced by the clot [184, 186]. This was also later confirmed in an in vivo rat study and in 
vitro microvascular obstruction model, where simulated myocardial infarction treated with a 
longer pulse resulted in improved rates of recanalization versus a shorter pulse [184, 187]. 
However, despite these positive results, pulse length faces a ceiling of limitation due to the 
presence of adverse effects such as vessel damage or hemolysis with excessive length. In all, there 
is still no single value for any of these parameters which has been determined to be optimal to this 
day. 
There have been several clinical trials for UTMC treatment of acute myocardial infarction 
with ST elevation. One trial by Cohen and colleagues applied low frequency US for 60 minutes to 
patients after pre-treatment with thrombolytic therapy [188]. Their results were generally positive 
with 64% of patients demonstrating TIMI III class flow. However, a different trial of 360 patients 
was pre-emptively halted due to a lack of efficacy of low frequency US added to thrombolytic 
agents, although no MB agents nor image-guided approach were used in this trial [189]. 
Subsequent studies which did feature the use of MB agents with US (true UTMC) found that there 
was a significant improvement in recanalization rate for patients receiving high intensity US pulses 
guided by imaging prior to percutaneous coronary intervention [185]. In addition, even patients 
receiving short pulses with high intensity showed improvements in recanalization, suggesting that 
a long pulse approach may not be necessary.  
Treatment of microvascular obstruction is slightly different than that of acute myocardial 
infarction with ST elevation. Namely, with microvascular obstruction, there is no epicardial 
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thrombus target, and several other pathologic processes are involved including ischemia-
reperfusion injury, inflammation, and oxidative stress, on top of distal microembolization as a 
result of percutaneous coronary intervention. UTMC applied toward treatment of MVO may have 
the aim of improving any or all of these measures, as well as taking a preventative approach in 
reducing the frequency of MVO occurrence after percutaneous coronary intervention. 
In multiple studies involving animal models, high intensity long pulse UTMC was found 
to significantly improve microvascular perfusion in models of microvascular obstruction [190-
192]. In addition, adjuvant thrombolytic therapy further enhanced the results of restoring 
perfusion, with further augmentation of microvascular blood flow sustaining for far longer than 
the treatment duration itself, up to 24 hours. To explain for these results, mechanistic studies in 
vitro have also been performed, including implication of nitric oxide (NO) metabolism and 
signaling [190, 191]. This will be discussed in a later chapter. For now, previous studies have 
found that UTMC-associated vascular shear stress (due to MB cavitational activity) may result in 
production of nitric oxide, which serves as a vasodilatory signaling molecule associated with 
improvements in microvascular perfusion, especially given various studies antagonizing nitric 
oxide activity to see an ablation of this effect. 
In terms of clinical trials, a first-in-human phase II trial was abridged due to occurrence of 
coronary vascular spasm in 3 out of 6 enrolled patients [193]. This trial applied a long pulse UTMC 
at 15 minutes before and 30 minutes after percutaneous coronary intervention. Although the 
precise source of the spasm was undetermined, the results were confirmed in a follow-up pig study 
involving UTMC treatment of balloon injury and thrombus injection in simulation of acute 
myocardial infarction [193]. Therefore, long pulse UTMC has been associated with potential local 
vasoconstriction and continues to be a subject of investigation given its promising pre-clinical 
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results for thrombolysis. However, using a similar US pulse configuration, a different trial reported 
on over 100 patients and did not report on any occurrence of US-induced adverse effects including 
epicardial coronary artery spasm [186]. 
For all of these experiments, safety in application of UTMC remains at the forefront of 
consideration, especially in the context of potential future clinical trials. Normal concentrations of 
MBs have been found to have minimal hematological disturbances (such as platelet activation and 
hemolysis) when used in UTMC. In addition, vessel damage has been found to be minimal in 
UTMC with the exception of some extremely high intensity experiments on in vitro tissue samples 
that were not replicated in vivo. Coronary spasm that was found in the trial of UTMC in treatment 
of MVO was unfortunate; however, utilization of the short duration, high intensity pulse in the 
previous trial for acute myocardial infarction which demonstrated significant recanalization may 
be applied to avoid this issue given that the spasm seems to be associated with an US regime with 
longer pulse length. 
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5.0 Nitric Oxide and Nitrite Physiology and Applications 
As it is applied to a biological environment, UTMC and its mechanical forces may produce 
significant effects on mechanotransductive systems of the vascular endothelium. One such system 
is that of nitric oxide, a potent signaling molecule which pleiotropically mediates a wide range of 
downstream effects. One key effect is vasodilation, as endogenous nitric oxide is a key regulator 
of hemodynamic status and smooth muscle tone in blood vessels. This, along with many other 
effects of nitric oxide, will be discussed in this chapter due to the relevance of nitric oxide to both 
cardiovascular disease as well as the bioeffects of UTMC therapy.  
Furthermore, nitrite, a chemical species closely related to nitric oxide, which is involved 
in nitric oxide metabolism in circulation, will also be discussed both in terms of its physiology as 
well as clinical applications and relevance to cardiovascular disease. One of the main portions of 
work in this dissertation involves the combination of nitrite and UTMC therapies, and the 
background established in this section will be referred back upon in the subsequent chapter 
detailing said work. 
5.1 Nitric Oxide Physiology 
The earliest sources investigating what would later be known to be nitric oxide detailed a 
so-called labile and humoral endothelium-derived relaxing factor which resulted in significant 
vascular relaxation along with other properties of inhibition of platelet aggregation and adhesion. 
Its actions were known to be mediated by the guanylate cyclase enzyme, and it was only later 
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chemically identified as nitric oxide. Nitric oxide is synthesized from the terminal nitrogen of the 
amino acid L-arginine by the enzyme nitric oxide synthase and is stereo-specific to the L isoform 
of arginine given the biological inactivity of its D-enantiomer. N-monomethyl-L-arginine and the 
methyl esterified form of L-arginine (N-LMMA and L-NAME) are known inhibitors of this 
synthesis step. The result of this synthesis is one molecule of nitric oxide and L-citrulline, the 
metabolic byproduct from the rest of the L-arginine molecule. The nitric oxide synthase molecule 
(NOS) is known to be dependent on NADPH and calcium/calmodulin [194]. 
The earliest studies of nitric oxide function in animals involved indirect study through 
application of its inhibitors such as L-NMMA. Administration of L-NMMA was found to result in 
dose-dependent, prolonged increases in blood pressure reversible by administration of L-Arginine 
in multiple vascular beds including the renal, mesenteric, carotid, and coronary vascular beds. The 
release of nitric oxide, on the other hand, was found to be dependent on both the pulsatile nature 
of flow through a specific vessel, as well as shear stress induced upon the vessel lining. Given the 
immediate increases in blood pressure after specific inhibition of nitric oxide activity, it was 
established that nitric oxide is one of the main endogenous vasodilatory systems. Other roles of 
nitric oxide have since been identified, including the presence of various other isoforms of nitric 
oxide synthase, namely neuronal nitric oxide synthase and inducible nitric oxide synthase. 
Neuronal nitric oxide synthase, as the name suggests, is mainly present on neuronal cells while 
inducible nitric oxide synthase is found in various immune cells such as macrophages and 
neutrophils and is induced by presence of bacterial endotoxins or inflammatory cytokines such as 
IL-1 or interferon-gamma. These two other forms of nitric oxide synthase are not as involved in 
management of vascular hemodynamics and will not be discussed in further detail in this 
dissertation [194, 195]. 
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The mechanism of nitric oxide in activating the enzyme guanylyl cyclase was only later 
elucidated through a complex series of biochemical experiments which led the investigators to 
hypothesize that the nitric oxide molecule binds to the heme group of guanylyl cyclase to form a 
nitrosyl-heme product resulting in molecular conformational changes of the porphyrin site though 
to modify the structure of a neighboring catalytic site which served to bind GTP (for its subsequent 
cleavage). Subsequent cleavage of GTP and production of cyclic GMP resulted in vascular smooth 
muscle relaxation (and vascular vasodilation) through several pathways. One pathway involves 
phosphorylation of myosin light chain kinase, an enzyme which phosphorylates myosin light 
chains and therefore activates actin-myosin cross-bridge cycling and muscular contraction. 
Phosphorylation of myosin light chain kinase by a cyclic GMP dependent protein kinase results in 
its diminished affinity for the calmodulin and calcium ion complex, which ultimately results in the 
stabilization of an inactive form of myosin and decreased muscular contraction [194, 196].  
Therefore, the inhibitory effect of myoglobin and hemoglobin on nitric oxide activity (by 
diluting the presence of reactive heme groups) supported these mechanistic assertions. 
Furthermore, addition of superoxide dismutase prolonged the half-life of nitric oxide while 
addition of superoxide anions decreased said half-life, which is now understood to derive from the 
reaction between nitric oxide and the superoxide anion to form peroxynitrite, a biologically 
harmful reactive oxygen species.  
Nitric oxide itself is an extremely small and lipophilic molecule. These properties allow it 
to rapidly diffuse through cellular membranes, acting as a local regulator of blood flow. As such, 
nitric oxide diffuses from the endothelial cells in which it is produced to neighboring target cells 
such as vascular smooth muscle cells. Nitric oxide is also rapidly scavenged in the extracellular, 
intravascular environment by molecules such as hemoglobin, and as such is extremely short-lived 
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and limited in its vasodilatory signaling effects to the local environment. Additionally, nitric oxide 
itself may act as a feedback regulator of nitric oxide synthase activity due to interaction between 
nitric oxide and the heme group of nitric oxide synthase. 
As discussed, one of the main roles of nitric oxide is to regulate vascular smooth muscle 
tone through its metabolism in the vascular endothelium. As such, endothelial nitric oxide is almost 
continuously produced, as shown by experiments involving constant bioassay experiments on 
effluents from perfused vascular preparations. Production of nitric oxide was also found to be 
concentrated in vessels with smaller overall diameter but possessing large amounts of smooth 
muscle (and smooth muscle associated cyclic GMP). In addition, production of nitric oxide by 
endothelial cells was shown to be dependent on shear stress of flowing blood on the endothelial 
surface, later determined to be mediated through the opening of mechanosensitive calcium 
channels and calmodulin-related signaling. Currently, it is understood that nitric oxide synthesis 
and nitric oxide synthase activation may occur through both calcium dependent and independent 
pathways, although both pathways involve tyrosine phosphorylation and other enzymatic cascade 
events. More specifically, endothelial agonists of nitric oxide production such as acetylcholine or 
bradykinin stimulate the production of inositol triphosphate, which then binds to receptors on the 
surface of the endoplasmic reticulum, causing calcium ion release from intracellular sources. 
These calcium ions then bind to calmodulin, creating a complex which activated nitric oxide 
synthase until the level of intracellular calcium decreases [196-198]. 
In a longer timescale, nitric oxide regulation of vasodilatory status also involves the 
regulation of genes involved in vasoconstricting agents and growth factors. Nitric oxide has been 
found to suppress expression of endothelin-1 and platelet derived growth factor B, both 
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vasoconstrictors, in environments of hypoxia. This is one mechanism involved in the response of 
vasoconstriction to hypoxia such as seen in pulmonary arteries [199]. 
Given its role in regulation of hemodynamic status, it is unsurprising, therefore, that the 
dysfunction of nitric oxide metabolism or impairment of its production is a key role in the 
pathogenesis of several disorders of the cardiovascular system, including hypertension, ischemia-
reperfusion injury, and atherosclerosis [197, 200]. However, the functions of nitric oxide extend 
beyond mere vasodilation. Interactions between the vascular endothelium and circulating platelets 
are also thought to be mediated by endothelial nitric oxide production. Nitric oxide has been found 
to inhibit ADP-induced platelet aggregation, while also actively dis-aggregating platelets, in 
processes mediated by cyclic GMP. Additionally, platelets themselves contain nitric oxide 
synthase and have the capacity to synthesize nitric oxide during platelet activation. This 
mechanism may serve as a natural feedback inhibition of the cascading behavior of platelet 
aggregation and thrombus formation, and this behavior is also seen in neutrophils as well. Nitric 
oxide may also work in tandem with other vasodilating agents and inhibitors of platelet activation 
such as prostacyclin, which is mediated by cyclic AMP rather than cyclic GMP [197, 200]. In 
addition, the anti-platelet properties of nitric oxide also provide an additional safeguard measure 
against unwanted thromboembolic events in the occurrence of prostacyclin blockade by common 
pharmacologic agents such as aspirin [197, 200]. 
In addition to mediating the interactions between the vascular endothelium and platelets, 
nitric oxide also has inhibitory effects on leukocyte aggregation. Not only has direct evidence been 
shown for this both in vitro and in vivo, inhibition of nitric oxide signaling also results in the 
opposite effects, including leukocyte localization, adhesion, and emigration, as well as increases 
in microvascular permeability [201, 202]. The underlying mechanism between nitric oxide and 
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inhibition of leukocyte adhesion has been shown to be dependent on the chemical reactions 
between nitric oxide and the superoxide anion, as presence of the superoxide anion activates other 
inflammatory mediators such as mast cells, which degranulate to produce signaling molecules 
which promote leukocyte adhesion. Therefore, the capacity of nitric oxide to scavenge and remove 
superoxide anions from the cellular compartment has been proposed to be one mechanism of its 
anti-inflammatory properties [203]. 
Given the various properties of nitric oxide in cell signaling as well as the role of its absence 
in the development of many disease states, modulation of endothelial nitric oxide synthase activity 
through artificial means has been a topic of much interest in cardiovascular disease research. There 
are many directions to approach the concept of enhancing endothelial nitric oxide synthase 
activity, whether through enhancing its genetic expression or through increasing the activity levels 
of existing enzymes. In terms of targeting nitric oxide production, additional molecular substrates 
of endothelial nitric oxide synthase may be administered to enhance activity. These include L-
arginine and tetrahydrobiopterin, an enzymatic co-factor. Studies have shown that administration 
of L-arginine, while theoretically intracellular levels of L-arginine should generally be saturated 
due to its concentration being significantly above the rate-limiting concentration based on enzyme 
kinematics of endothelial nitric oxide synthase, has been shown to produce significant reductions 
in blood pressure, improvements in vasodilation, and decreased endothelial damage as quantified 
by platelet and leukocyte adhesion. These benefits were especially apparent in patients with pre-
existing cardiovascular disease such as congestive heart failure, where administration of L-
arginine resulted in improvements in cardiovascular and renal function. However, despite these 
positive results, other studies have also reported that supplementation of L-arginine resulted in no 
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effects on endothelial dysfunction, suggesting that its potential benefits and therefore intracellular 
shortages have differences in etiology from endothelial dysfunction [197, 198, 200, 204].  
Simulating these effects through direct addition of nitric oxide donating molecules such as 
molsidomine, glyceryl trinitrate, and sodium nitroprusside, is another strategy for increasing nitric 
oxide bioavailability. Not only does the exogenous source of nitric oxide function essentially the 
same as endogenously produced nitric oxide, but additional pharmacokinetic details of the drugs 
themselves may actually prolong nitric oxide release for therapeutic effect. Examples of these 
types of drugs in clinical use (or previously in clinical use) include nitroglycerin, nitroprusside, 
and nitrate. Clinical studies have shown that inhibition of endothelial nitric oxide synthase, and 
therefore of endogenous nitric oxide production, may be overcome through administration of 
exogenous nitric oxide donors, resulting in not only reduction of blood pressure through 
vasodilation, but also the other various bioeffects of nitric oxide including decreased leukocyte 
infiltration and extravasation, reduced atherosclerotic lesion sizes, and reduced endothelial 
dysfunction [196, 198]. 
Aside from administration of enzymatic substrates, co-factors, or direct exogenous nitric 
oxide molecular donation, another method of enhancing endothelial nitric oxide synthase activity 
is through upregulating or artificially increasing its expression such as through genetic 
modification [205]. As previously discussed, genetic modification may occur through both viral 
and non-viral means of transferring the endothelial nitric oxide synthase gene to a target location, 
although use of the adenovirus vector is very common, and has been successfully applied to various 
in vitro tissue types including vascular tissue and smooth muscle. Other studies have shown that 
successful gene transfer of endothelial nitric oxide synthase results in improved outcomes in 
disease models such as of hypertension, ischemia reperfusion injury, and atherosclerosis [198, 200, 
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205]. Additionally, lifestyle factors may also affect endothelial nitric oxide synthase activity, such 
as the lowering of low-density lipoproteins, which have been found to affect nitric oxide synthase 
activity. Other medications such as statins, which also serve to reduce levels of low-density 
lipoproteins, may also be utilized along with estrogens, which have been found to phosphorylate 
the enzyme itself [198, 200, 205]. 
5.2 Pathways Governing Endothelial Nitric Oxide Synthase Activity 
Given the various roles of nitric oxide in maintaining a homeostatic environment for the 
vascular endothelium, the molecule itself plays several roles in affecting cell proliferation, as 
previously discussed. Not only does nitric oxide inhibit expression of leukocyte adhesion 
molecules and platelet aggregation, it also inhibits the proliferation of smooth muscle cells while 
also enhancing the proliferation of vascular endothelial cells. These bioeffects, along with the 
inhibition of matrix metalloproteinases (which affects atherosclerotic plaque stability and 
remodeling), are at essence anti-atherosclerotic properties of nitric oxide. With connections 
between atherosclerosis and derangement of hemodynamic conditions becoming more apparent, 
and as our understanding of mechanotransductive pathways improves, the role of nitric oxide, and 
the sensitivity of endothelial nitric oxide synthase to shear stress, become more central in these 
processes. 
Previously, we discussed that shear stress results in an increase in intracellular calcium, 
which complexes with calmodulin, binding to endothelial nitric oxide synthase and enhancing its 
activity. However, studies have shown that levels of nitric oxide production far exceed the 
expected values explained only by increases in intracellular calcium, and that the production of 
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nitric oxide is sustained despite a return of intracellular calcium to normal concentrations, 
suggesting that there are alternative, calcium-independent mechanisms affecting nitric oxide 
synthase activity (and phosphorylation). Previous experiments have shown that shear stress itself 
mediates phosphorylation of endothelial nitric oxide synthase through protein kinase A at various 
sites, while also up-regulating nitric oxide synthase transcription, which involves a MAP kinase 
pathway. In addition, certain regions of the endothelial nitric oxide synthase promotor (a non-
expressing gene sequence which up-regulates transcription of a particular gene), have been shown 
to be shear sensitive, along with several protein kinases including protein sub-units of the NF-
kappa B protein, which typically leads to increased expression of pro-inflammatory genes with its 
activation. 
In addition to regulation of gene expression, post-translational modification of endothelial 
nitric oxide synthase, especially phosphorylation at key sites such as Ser1177, affects its activity 
in nitric oxide production [206, 207]. Shear stress has also been found to affect several enzymatic 
pathways leading to this phosphorylation, including Akt and protein kinase A, as previously 
mentioned [208, 209]. In addition to these pathways, AMP-activated protein kinase (AMPK) has 
recently been implicated in phosphorylation of endothelial nitric oxide synthase [209]. This is 
significant, as not only is AMPK sensitive to physiological stresses including exercise and 
hypoxia, any increase in cellular metabolism which drives the conversion of ATP to AMP results 
in its activation [204, 210]. Therefore, implication of AMPK in the regulation of nitric oxide 
synthase also raises questions regarding the role of energy balance and nitric oxide metabolism. In 
addition, AMPK itself was shown to be sensitive to shear stress, including changes in shear stress 
of magnitude and pulsatile characteristics [208, 209]. In terms of the connection between energy 
metabolism of ATP and shear stress, no explicit connections have been made, although shear stress 
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exposure of endothelial cells has been associated with some ATP release as well, resulting in a 
shift in the equilibrium toward AMP (and leading to AMPK activation). In addition, exercise 
training of both animals and humans, which typically leads to increased cardiac output and 
improved capacity for vascular dilation, have been associated with increased levels of AMPK 
activation (and therefore endothelial nitric oxide synthase phosphorylation), suggesting that 
exercise and shear stress are all intrinsically related to nitric oxide metabolism and vascular health 
[209, 211]. 
In elaboration of this work, other groups have investigated the more precise mechanistic 
steps in the enzymatic pathway from AMPK to endothelial nitric oxide synthase phosphorylation, 
and have identified a novel pathway of AMPK, Rac1, and Akt (which was also previously 
mentioned) to culminate in nitric oxide synthase regulation [212]. Previous studies have also 
shown conclusively that AMPK is a mediator for vascular endothelial growth factor-mediated 
activation of endothelial nitric oxide synthase [213]. In addition, S1P, a regulator of endothelial 
function through its interaction with G protein-coupled receptors, was also found to be a significant 
mediator of AMPK activation, resulting in the advent of multiple AMP-independent pathways for 
AMPK activation [212]. This suggests that the role of AMPK is more complex than previously 
envisioned given its impression as a sort of metabolic regulator with dependence on the presence 
of AMP, and instead the AMPK pathways are significantly affected by extracellular signaling and 
stimuli which may be present in pathophysiologic states, as well as during endothelial cell 
migration and angiogenesis. In addition, another study found that nitric oxide itself serves as an 
activator of AMPK in vascular endothelial cells [214]. This positive feedback mechanism also 
results in increased phosphorylation of the Ser1177 site on endothelial nitric oxide synthase, as 
was found in isolated aorta preparations. The implications raised by these results are relevant not 
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only to physiologic production of nitric oxide, but also potentially therapeutic applications of nitric 
oxide donors given the identical natures of the molecule despite the different sources. Although 
these experiments were carried out in vitro, the results were replicated in an inverse manner with 
inhibition of nitric oxide resulting in decreased phosphorylation of AMPK [214]. However, the 
study did find that this feedback cycle was also partially dependent on intracellular calcium levels, 
as down-regulation of intracellular calcium resulted in some suppression of AMPK activity. 
Another study which focused on skeletal muscle biopsies from human participants replicated these 
results in that not only did nitric oxide increase AMPK activity, it also increased cyclic GMP levels 
and glucose transport [215]. These study results confirmed many previous investigations which 
were limited to rodent muscle samples. In addition, the source of nitric oxide in this experiment 
was from spermine NONOate, a nitric oxide donor, showing that exogenous nitric oxide sources 
participate significantly in these endogenous regulatory pathways of endothelial nitric oxide 
synthase [215]. Similar results using sodium nitroprusside have also been reported as well [198, 
200, 205, 214]. 
Lastly, and as segue to the next sub-section, a recent investigation demonstrated that nitrite, 
a biological reservoir and metabolic byproduct of various reactions of nitric oxide, also participates 
in the AMPK signaling pathway. The study demonstrated that nitrite resulted in significant 
endothelial nitric oxide synthase activation as mediated through the AMPK pathway, which may 
be a mechanism for the various protective effects of nitrites. The mechanism and clinical 
applications of nitrite will be discussed, and this concept of interaction with endogenous 
endothelial nitric oxide synthase pathways will be re-visited in a proposed mechanism of synergy 
between nitric oxide synthase activation and administration of exogenous nitrite [210]. 
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5.3 Nitrite Basic Physiology and Metabolism 
Historically, nitrite (and nitrates) have been known as byproducts of various preservation 
and flavoring applications in the food industry. However, this molecule also has a wide range of 
applications and natural functions as a participant in nitric oxide metabolism and physiology. 
Nitrite has a wide range of pathways for its chemical modifications in the human body, including 
reactions with hemoglobin, myoglobin, xanthine oxidoreductase, and various other biological 
components, and its chemical equilibrium is affected by various physiological parameters such as 
oxygenation and acidosis. 
As an overview of the nitric oxide pathways previously discussed, nitric oxide is 
synthesized by nitric oxide synthase, which uses substrates of L-arginine, an amino acid, and 
molecular oxygen. The mechanisms of nitric oxide are involved in vascular status (for 
vasodilation), immune signaling, and endothelial homeostasis. Nitric oxide may also be converted 
through oxidation into nitrite and nitrate, which are stable in blood and tissue compartments, and 
may be later reverted back to nitric oxide under different environmental conditions. Therefore, 
nitrite may be thought of as a biological reservoir of nitric oxide, which will be further expounded 
on later in this subsection. Nitric oxide synthesis through the endogenous pathway as described, 
however, is an oxygen dependent process. In conditions of hypoxia, where oxygen is deficient, 
this pathway becomes less and less favorable, whereas different pathways in nitric oxide 
metabolism and conversion gradually dominate. More specifically, the nitrite to nitric oxide 
reactions become more favorable in hypoxic conditions and may serve as a natural regulatory 
mechanism to maintain nitric oxide bioavailability in conditions where synthesis through nitric 
oxide synthase are less feasible. The importance of nitric oxide bioavailability in conditions of 
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hypoxia is emphasized in physiological processes such as hypoxic vasodilation and protection in 
settings of ischemia reperfusion [216]. 
For the general endogenous sources of nitrite in the human body, the greatest contributions 
come from endogenous synthesis of nitric oxide which becomes oxidized in blood, and from diet 
(including natural dietary supplements such as beetroot juice) [217]. For endogenously synthesized 
nitric oxide, chemical reactions converting it to nitrite include oxidation by ceruloplasmin, 
oxidation by oxyhemoglobin to produce nitrate and methemoglobin, and subsequent conversion 
of nitrate to nitrite through enzymes such as nitrate reductase, are all extremely common and occur 
regularly. Previous animal studies involving genetic knockout techniques against endogenous 
nitric oxide synthase resulted in reductions of endogenous nitrite by up to 70% [217]. Other factors 
affecting endogenous circulating levels of nitrite include exercise conditioning (which also 
increases endothelial nitric oxide synthase activity), systemic inflammation and inflammatory 
conditions (which results in increased inducible nitric oxide synthase induction and therefore 
synthesis and conversion of nitric oxide), and cardiovascular diseases such as atherosclerosis 
(which result in endothelial dysfunction and diminished activity of endothelial nitric oxide 
synthase, and therefore reduced levels of nitrite from lack of chemical conversion) [217]. Dietary 
consumption is the other major source of endogenously found nitrite in circulation. As mentioned, 
certain vegetables, such as beetroots, lettuce, or spinach, contain significantly higher amounts of 
nitrate than endogenous production in the human body. Preserved foods, such as cured meats and 
bacon, also contain significant amounts of nitrite depending on the method of production [217]. 
After dietary consumption, various processes independent of nitric oxide synthase act to render 
the consumed nitrate and nitrites biologically available in the bloodstream. As evidence of this, 
dietary nitrite and nitrate products are rapidly absorbed from the upper GI tract and become 
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detectable in plasma with significant elevation for a prolonged half-life of up to 6 hours after 
consumption [217]. Excretion through kidney filtration does apply for circulating nitrites and 
nitrates, although nitrate is also actively absorbed and concentrated in the salivary glands, after 
which it is secreted into the oral cavity. In the oral cavity, various species of facultative anaerobic 
bacteria use nitrate in their respiratory processes as a destination for electron transport alternative 
to oxygen (hence facultative anaerobic metabolism), and in doing so, reduce secreted nitrate to 
nitrite through nitrate reductase (as previously mentioned) [217]. Thus, this newly formed salivary 
nitrite is then swallowed into the stomach’s acidic environment, where it is then further reduced 
to various byproducts, and eventually nitric oxide. Various studies have also demonstrated that 
this process of nitrite formation occurs not only in the oral cavity, but also on the surface of the 
skin and in the lower GI tract. Production of nitric oxide in the gastric compartments has been 
shown to have significant cyclic GMP-dependent increases in blood flow through vasodilation 
[217]. 
However, aside from its involvement in the GI system, nitrite has been shown to have a 
wide range of other physiologic roles, including peripheral vasodilation. Specifically, nitrite has 
been shown to serve as a sort of vasodilatory mediator similar to nitric oxide in that infusion of 
nitrite into human participants resulted in significant increases in blood flow even at concentrations 
of nitrite below 1 micromolar [217]. This vasodilation and decrease in blood pressure have also 
been observed in oral consumption of nitrate (and subsequent increases in plasma nitrite). While 
in the periphery, nitric oxide is typically scavenged extremely quickly by hemoglobin-containing 
red blood cells, resulting in limitation of the range of its efficacy, nitrite is able to maintain its 
vasodilatory effects even in the presence of such conditions, although said effects still do derive 
from its conversion into nitric oxide [216]. The key factor for nitrite’s bioeffects derives from a 
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shift toward favor of its chemical equilibrium resulting in nitric oxide production correlating with 
an increase in deoxyhemoglobin, which has been shown to have nitrite reductase type activity 
[216]. This chemical reaction involves deoxyhemoglobin as well as a proton, and accordingly is 
therefore favored in conditions of hypoxia as well as acidosis (which accompanies environments 
of either poor perfusion, increased metabolic activity, or pathologic processes). Other 
interconversions between nitrite, nitric oxide, and other metabolic byproducts also occur, but will 
not be discussed within the scope of this dissertation. 
Other enzymatic sources of this nitrite reductase activity to nitric oxide also include 
myoglobin and xanthine oxidoreductase [218]. Myoglobin, or rather deoxymyoglobin, is an even 
stronger catalyst of nitric oxide production through nitrite reduction than hemoglobin and is 
heavily present in muscular compartments (of course) such as skeletal muscle or the heart [219]. 
Therefore, when muscle is active in exercise and metabolic depletion of local oxygen occurs, 
myoglobin may therefore convert nitrite into nitric oxide as described and induce effects including 
vasodilation and decreased oxygen utilization (which is physiologically favorable in conditions of 
hypoxia) [216]. Dietary supplementation with nitrate supported these results as investigated in 
healthy human participants, as oxygen consumption was significantly reduced due to metabolic 
nitrite to nitric oxide conversion in skeletal muscle, as associated with plasma nitrite metabolism. 
Xanthine oxidoreductase, on the other hand, is a part of the mitochondrial electron transport chain, 
which will not be heavily elaborated in this dissertation. However, in essence, xanthine 
oxidoreductase is a facultative oxygen reducer (to the superoxide anion) which may also utilize 
nitrite (reducing it to nitric oxide) in environments of low oxygen availability [220]. It is significant 
to note that the alternative to nitrite reduction results in production of superoxide anions, which 
are aggressive reactive oxygen species, which may result in local damage from oxidative stress, 
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while also greatly scavenging nitric oxide and reducing nitric oxide bioavailability. Therefore, in 
reducing nitrite to nitric oxide, not only does this metabolic pathway result in the formation of 
nitric oxide, it also competes against the production of superoxide, which results in a reduction of 
nitric oxide scavenging [220]. This ultimately results in increases in nitric oxide bioavailability on 
multiple levels and protection against scavenging of nitric oxide. Other effects of nitrite include 
modification of proteins have also been documented and are the subject of current investigations 
[221]. 
Specifically, mechanistic studies involving nitrite and its protective properties in ischemia-
reperfusion injury have identified correlations between nitrite-induced cytoprotection and 
increases in mitochondrial oxidative phosphorylation [222]. Specifically, nitrite causes a 
concentration and dosage dependent modification and inhibition of complex I, a component of the 
electron transfer chain. This modification of S-nitrosation results in significant inhibition of 
electron transfer, and therefore also inhibits formation of reactive oxygen species generation and 
mitochondrial permeabilization, which would typically lead to release of cytochrome c, a signaling 
mediator for apoptosis [222]. Although ischemia-reperfusion injury and oxidative stress will be 
further discussed in a later chapter, here we will emphasize the role of nitrite in protecting cellular 
mitochondria from damage, which ultimately results in protection against the endpoints of 
ischemia-reperfusion injury and oxidative damage including inflammation and tissue necrosis 
[203]. 
Extrapolation of this efficacy suggests there is strong potential for relevance of therapeutic 
nitrite to other disease settings heavily featuring ischemia-reperfusion injury, including sickle cell 
disease, myocardial infarction, microvascular obstruction, and stroke. Other more recent studies 
of therapeutic nitrite include cardiac arrest (which involves ischemia reperfusion injury in the brain 
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as well as myocardial dysfunction), where nitrite infusion resulted in significant improvements in 
hippocampal CA1 neuron preservation after simulated cardiac arrest (where control conditions 
resulted in significant neuronal death) [223]. Mechanistically, these improvements were associated 
with nitrite concentration in the hippocampus as well as nitrosothiol involved modifications of 
macromolecules in the local region, but not cyclic GMP. Development of a phase 1 clinical trial 
for nitrite therapy in these patients demonstrated safety and a lack of adverse effects such as 
hypotension or methemoglobinemia, suggesting that nitrite may be a safe candidate for further 
investigation in settings of brain injury and cardiac arrest [223]. 
5.4 Therapeutic Applications of Nitrite 
There are many applications of nitrite in various forms for many different pathologies. 
Many of these involve the effect of nitrite on vasodilation, either to restore perfusion to vessel beds 
or to combat vascular spasm. One example of this is in patients with subarachnoid arterial 
aneurysms, which may result in spontaneous hemorrhages eliciting delayed cerebral vasospasms. 
Non-human primate models of this condition showed successful prevention of these vasospasms 
with systemic nitrite administration, while the condition was also associated with low levels of 
cerebrospinal fluid nitrite concentration [224]. Another example of nitrite applied to a clinical 
pathology is in pulmonary hypertension, which is associated with abnormally increased pulmonary 
vascular resistance and poor oxygenation as a result. Inhaled nitrite (which is then converted to 
nitric oxide) administered to a sheep model of this disease resulted in successful vasodilation of 
only the pulmonary vasculature (due to the inhaled nature of the therapy) for treatment of the 
condition [225]. 
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However, more relevant to the work of this dissertation and our main clinical context of 
interest are the roles of nitrite in settings of ischemia-reperfusion injury and cardiovascular disease. 
Endogenously, nitrite has been shown to have strong involvement in cardiac models of ischemia 
reperfusion injury, concurrent with other mechanistic work suggesting its predominance in 
conditions of hypoxia. Specifically, both endogenous and exogenous levels of nitrite (natural and 
therapeutically induced) have been shown to have protective effects in the face of ischemia 
reperfusion injury in various tissue settings including the heart, liver, brain, and kidney [203, 221, 
226-229].  
One previously mentioned application of nitrite is in treatment of acute myocardial 
infarction. One previous study investigated this in a canine model of myocardial infarction using 
low dose intravenous nitrite given over the course of myocardial infarction development [227]. 
The study outcome of the ratio for infarct size normalized against area at risk ratio showed that 
both a 60 minute infusion of nitrite as well as a 5 minute infusion of nitrite both significantly 
reduced infarct size despite the 5 minute infusion having significantly lower overall dosage of 
nitrite as well as peak concentration, suggesting that the efficacy of nitrite in protecting against 
ischemic damage spans a wide range of concentrations [227]. Additional TUNEL analysis staining 
for cardiomyocyte apoptosis as another outcome measure for severity of damage resulting from 
the myocardial infarction showed a significantly lower number of apoptotic nuclei for both 
infusion treatment groups of nitrite [227].  
However, despite showing significant effects in cardioprotection and prevention of 
apoptosis, the effects of nitrite (which are typically thought of as being centered on vasodilation 
after conversion to nitric oxide) were not significantly associated with hemodynamic changes 
during administration as measured by changes in preload, afterload, or the pressure-rate product 
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[227]. This suggests that the protective effects of nitrite were mediated by biological pathways 
rather than by merely providing increased perfusion to surrounding areas during focal ischemia. 
Notably, functional outcomes such as ejection fraction were significantly improved by nitrite 
therapy, and presence of microvascular obstruction as qualitatively observed on magnetic 
resonance imaging as well as through measurement of endocardial blood flow using microspheres 
showed that nitrite reduced the cross-sectional area of microvascular obstruction after reperfusion 
had been achieved in the canine model. As described before, microvascular obstruction was 
characterized on serial magnetic resonance perfusion imaging as a hypointense residual region 
remaining after reperfusion of the heart. 
There were many significant implications raised by this study that directly motivated 
subsequent work in this dissertation with regards to therapeutic nitrite administration, most notably 
the time course of therapeutic effect of nitrite observed in the study as well as its effectiveness in 
treating microvascular obstruction after ischemia-reperfusion of the heart. In consideration with 
the timescale of emergent intervention for myocardial infarction, sufficiency of a 5-minute 
infusion of nitrite for significant therapeutic effect is a strongly favorable attribute for its relevance 
and potential for future application and translation. Given the emphasis on door-to-balloon time 
and emergent time dependence of the extent of ischemic damage and deteriorating patient 
outcomes, minimizing therapeutic duration for both nitrite administration and UTMC treatment 
while maintaining therapeutic efficacy is a definite priority. In line with this, other characteristics 
to prioritize for translational therapy involving nitrite and potential use with UTMC include low 
expense, rapid onset of action, short half-life, minimal systemic side effects, and biological 
efficacy not dependent solely on hemodynamic changes. 
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Another previous study investigated nitrite efficacy in protection against ischemia-
reperfusion injury through both a focal cardiac ischemia rat model as well as an ex vivo cardiac 
perfusion model [221]. For in vivo cardioprotection evaluation, a wide range of doses from 0 to 10 
mg of nitrite per kg of animal body weight was tested with the main outcome of infarct size 
normalized against area at risk. The results showed that a dosage of 4 mg per kg body weight 
resulted in the lowest normalized infarct size [221]. Additionally, timing of nitrite administration 
was evaluated both 15 minutes prior to onset of cardiac ischemia as well as 10 seconds after onset 
of reperfusion using the 4 mg per kg bodyweight dose of nitrite previously identified. The most 
optimal timings evaluated were either 15 minutes prior to ischemia or 15 minutes after ischemia, 
while the treatment group receiving nitrite 10 seconds after reperfusion showed no significant 
decreases in normalized infarct size relative to the drug-free control group. Most notably, results 
from this study showed a biphasic relationship of nitrite dose against effectiveness in reducing 
infarct size, in that both low as well as high doses of nitrite showed diminished efficacy [221]. The 
dosage of 10 mg per kg bodyweight of nitrite showed no significant differences compared to the 
control group in infarct size reduction. 
Other mechanistic investigations of this previous study also explored roles of other 
involved mediators in nitrite metabolism and their roles in the cardioprotective properties of nitrite. 
The role of hemoglobin was investigated through the use of an isolated ex vivo cardiac model of 
focal ischemia [221]. Nitrite perfusion was used similar to the in vivo model at various dosages, 
showing again similar results to the in vivo model where nitrite dosage followed a biphasic 
relationship for infarct size reduction, with recovery of left ventricular diastolic pressure following 
an inverse pattern of said relationship [221]. These results also suggest that hemoglobin acting as 
a nitrite reductase is not required for enabling the cardioprotective effects of nitrite. Another 
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enzyme target of investigation was xanthine oxidoreductase, which has also been shown to have 
nitrite reducing activity. Administration of oxypurinol, a xanthine oxidoreductase inhibitor, 
resulted in significant ablation of the protective effects of nitrite on reducing infarct size, thereby 
significantly implicating xanthine oxidoreductase as a mediator of nitrite cardioprotection. Nitric 
oxide synthase and nitric oxide itself were also investigated in inhibitory test group designs using 
L-NMA and C-PTIO respectively (a general nitric oxide synthase inhibitor and a nitric oxide 
scavenger) to demonstrate that neither nitric oxide synthase nor presence of nitric oxide itself were 
necessary for the cardioprotective effects of nitrite [221]. 
Significant findings of this study included the dose-dependent effect of nitrite on 
cardioprotection with specific titration to rodent models, optimized timing for nitrite 
administration relative to an ischemia-reperfusion model, and several mechanistic findings 
regarding nitrite efficacy. As previously discussed, xanthine oxidoreductase plays key roles both 
in nitrite metabolism as well as in the formation of reactive oxygen species, specifically the 
superoxide anion. In hypoxic and acidic conditions, activity of xanthine oxidoreductase in 
reducing nitrite is significantly increased, conditions which are found in focal tissue ischemia. 
These results support previous mechanistic findings as well. Interestingly, efficacy of nitrite was 
shown to be independent of both endogenous nitric oxide generation through nitric oxide synthase 
as well as converted nitric oxide itself. While it has been noted that nitric oxide synthase itself may 
function in a nitrite reducing capacity, inhibition of the nitric oxide synthase in this investigation 
using L-NMA without significant detraction from nitrite efficacy suggests alternative signaling 
pathways. 
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6.0 Nitro-alkenes (Nitro-fatty Acids) Physiology and Applications 
Nitro-fatty acids, or fatty acids with a nitro group modification, are a relatively new class 
of therapeutic molecules. As will be discussed in this chapter, the functional mechanisms of these 
molecules are diverse and range beyond simple nitric oxide donation, spanning into modification 
of key transcriptional factors to elicit anti-inflammatory and protective effects against ischemia-
reperfusion injury. In addition, their molecular structure, in being amphiphilic with a long acyl 
chain group, is extremely similar to traditional components of MB agents such as phospholipids 
as we previously discussed. Their application in a functionalized MB design will be discussed in 
a later chapter of this dissertation. This chapter will cover what we currently understand with 
regards to their physiology and therapeutic application, including in treatment of a variety of 
cardiovascular disease contexts as represented by animal models. Although the applications of 
nitro-fatty acids, including the settings of various clinical trials such as kidney disease or cancer 
therapy, may range beyond solely cardiovascular disease, these applications are beyond the scope 
of this dissertation and will not be discussed. 
6.1 Basic Mechanisms for Formation of Nitro-Alkenes (Nitro-Fatty Acids) 
To first understand the functions of nitro-fatty acids which arise from their specific 
chemical structure, we will first discuss basic mechanisms for the formation of these species. At 
its essence, the formation of nitro-fatty acids involves a reaction between nitric oxide and nitric 
oxide-derived oxidative species such as peroxynitrite, reactive oxygen species (which are 
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inflammatory mediators) such as superoxide or hydrogen peroxide, and unsaturated fatty acids. 
Endogenous formation of nitro-fatty acids therefore involves environmental factors previously 
discussed including nitric oxide bioavailability, tissue inflammation and oxidative stress, as well 
as presence of oxygen (or hypoxia, the lack thereof) [230-232]. Common unsaturated fatty acids 
available in biological systems include linoleic acid and oleic acid. These species are also 
especially suitable for nitration due to the presence of double bonds in their hydrocarbon chains, 
which are available targets for attack from the various nitric oxide associated species such as 
nitrogen dioxide. The result of these nitration reactions are mostly nitroalkenes or nitrohydroxy-
related molecules. The work in this dissertation pertinent to nitro-fatty acids uses only nitroalkene 
species. The reaction of fatty acid nitration itself involves multiple steps. First, the nitrogen dioxide 
molecule (or other related species) adds to the double bond of the unsaturated fatty acid, resulting 
in a beta-nitroalkyl radical. This is a fast process which may be elaborated by further modification 
and nitration if the environment is hydrophobic and has a relatively high presence of nitric oxide 
or other nitrogen oxides. A second attack from another nitrogen dioxide molecule results 
information of a nitronitrite ester, which may lose a nitrous acid molecule resulting in a nitroalkene 
with the double bond in its original position. Alternatively, hydrolysis of the nitronitrite ester may 
result in a nitrohydroxy-type molecule, which may lose a molecule of water to also result in a 
nitroalkene [230-232]. 
6.2 Basic Chemical Reactions of Nitro-fatty Acids 
As mentioned, the chemical structure and reactivity of nitroalkenes, which will be referred 
to as nitro-fatty acids for simplicity, determines the pluripotency of their impact on cellular 
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signaling and gene expression. Some of these reactions may involve an intermediate species such 
as previously described with the reaction between nitroalkenes and water to result in a 
nitrohydroxy-type molecule. Another type of reaction that nitro-fatty acids undergo involves 
release of a nitric oxide molecule. These reactions typically involve conversion to intermediate 
species such as a nitronate anion (in which the nitrated carbon gains a negative charge) and is then 
reduced to yield a nitric oxide molecule. Given that nitro-fatty acids have been observed to induce 
vasorelaxation in animal experiments is further evidence for the significance of this nitric oxide 
release, although the true biological significance of this effect outside of isolated experiments is 
still a subject of investigation [230].  
Nitro-fatty acids are stabilized by hydrophobic environments, in which equilibrium shifts 
further away from nitric oxide release. Stabilizing agents, including those used in the delivery of 
nitro-fatty acids in the work of this investigation, are organic solvents such as polyethylene glycol 
and various alcohols. Formation of micelles or liposomes with surfactant molecules such as 
phosphatidylcholine and cholesterol has also been noted to further stabilize nitro-fatty acids from 
decomposition (which includes nitric oxide release). Partitioning of nitro-fatty acids into organic 
membranes such as cell membranes or with lipoproteins follows suit with these mechanisms for 
stabilization and may promote downstream signaling mechanisms of nitro-fatty acids after 
subsequent activation by biological enzymatic mediators such as esterases or phospholipases 
[230]. Many protein modification reactions involving nitro-fatty acids are mediated through 
electrophilic adduction reactions of thiol groups and histidine residues. 
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6.3 Signaling Mechanisms of Nitro-fatty Acids 
The various mechanisms of nitro-fatty acids in signaling to modify downstream cellular 
events including gene expression and post-translational modification of proteins will be discussed 
in brief detail. Although each mechanism has been characterized through many studies, this section 
will offer a brief overview of the mechanism and implications on macro-scale cellular and tissue 
environments. 
6.3.1 Vascular Relaxation 
As extensively discussed in the previous chapter, vasorelaxation of vascular smooth muscle 
involves nitric oxide and nitric oxide donors for regulation. As mentioned, nitro-fatty acids and 
release of nitric oxide molecules do have an effect on cyclic GMP-dependent signaling. This was 
demonstrated by an ex vivo experiment involving perfusion of pre-constricted rat aortic tissue. 
Nitrohydroxy-type molecules derived from arachidonic acid have also been implicated in 
vasorelaxation. However, there are several factors which discourage this effect, mainly acting to 
stabilize nitro-fatty acid molecules either through intercalation into micelles and liposomes or in 
biological membranes. The potential for nitro-fatty acids to act as a nitric oxide donor has not been 
fully characterized given the potential for involvement of other actors including enzymes or 
activation of signaling pathways relevant to nitric oxide bioavailability and will be further 
discussed in a later subsection [233-235]. 
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6.3.2 Anti-inflammatory Mechanisms 
Nitro-fatty acids interact with several key inflammatory mediators to inhibit development 
of an inflammatory milieu, namely neutrophils and platelets. In activated neutrophils, nitro-fatty 
acids inhibit reactive oxygen species production, degranulation, and CD11b production. In 
platelets, nitro-fatty acids inhibit thrombin-mediated aggregation through increasing intracellular 
cyclic AMP levels likely through upregulation of adenylate cyclase activity. Macrophages are 
affected by nitro-fatty acids as well, both through inhibition of nitric oxide synthase isoform 2 and 
through inhibition of endothelial expression and surface migration of cellular adhesion molecules, 
including VCAM-1, E-selectin, and P-selectin. These adhesion molecules mediate the rolling, 
adhesion, and extravasation stages of monocyte localization and infiltration in the setting of 
inflammation and are key to further downstream signaling for activation of other immune cell 
types [236-239]. 
6.3.2.1 Heme Oxygenase-1 Induction 
Another mechanism by which nitro-fatty acids decrease inflammatory signaling is through 
upregulation of various mechanisms which protect against inflammatory damage. One such 
mechanism is through the upregulation of heme oxygenase-1 (HO-1). HO-1 is a key enzyme 
involved in heme catabolism, or the breakdown of heme into various metabolic byproducts such 
as biliverdin, ferrous iron, and carbon monoxide. HO-1 expression is also regulated by Nrf2, which 
will be further discussed. Carbon monoxide has been implicated as an anti-inflammatory mediator, 
as well as HO-1 itself in not only prevention of excessive nitric oxide scavenging, but also in 
inhibition against oxidative stress, cellular apoptosis, and other sub-processes of inflammation 
including edema, leukocyte adhesion and extravasation, and production of inflammatory signaling 
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mediators. Mechanisms underlying HO-1’s anti-inflammatory functions include removal of heme, 
which has been identified as a mediator of oxidative stress when not bound to a protein, production 
of bilirubin (as a metabolic byproduct), which has been associated with antioxidant and anti-
inflammatory effects, and prevention of iron toxicity through coordination of ferritin synthesis and 
storage [240, 241]. 
6.3.2.2 Nuclear factor-B inhibition 
Inhibition of nuclear factor kappa B (NF-B) is key anti-inflammatory mechanism of nitro-
fatty acids. NF-B is a transcription factor comprised of many different subunits with their 
respective governing domains. Certain NF-B subunits (p50 and p65) have critical roles in 
governing cellular survival as well as development of inflammation and are surpressed by nitro-
fatty acids. More specifically, nitro-fatty acids alkylate the p65 unit of NF-B and prevent it from 
successfully promoting inflammatory genes, resulting in downstream effects of tumor necrosis 
factor- inhibition and abrogation of lipopolysaccharide-stimulated inflammatory responses. 
Inhibition of lipopolysaccharide-based inflammatory responses also include inhibition of 
inflammatory cytokines including interleukin 6, tumor necrosis factor alpha, monocyte 
chemoattractant protein 1, as well as down-regulation of inducible nitric oxide synthase 
expression. It is noted here that these signaling mediators are selected as endpoint outcome 
measures for gene expression analysis of tissue samples taken from the ischemia-reperfusion 
animal model studied for these reasons [235, 236, 238]. 
In addition, the regulation of NF-B by nitro-fatty acids occurs at multiple levels in its 
signaling pathway beyond alkylation of the p65 subunit. Upstream events such as surface 
membrane expression of toll-like receptor 4 as well as tumor necrosis factor receptor associated 
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factor 6 recruitment are inhibited as well as inhibition of inhibitor of kappa B (IB) 
phosphorylation (which would result in its dissociation from NF-B, allowing the NF-B protein 
to translocate to the nucleus and activate the aforementioned gene expression). 
6.3.2.3 Peroxisome Proliferator-Activated Receptor Agonism 
Another mechanism by which nitro-fatty acids inhibit inflammation that is also involved 
in metabolic regulation is through activation of peroxisome proliferator-activated receptors. These 
receptors are involved in mediating fat metabolism, adipogenesis, regulation of glucose 
metabolism and storage, as well as inflammation. These peroxisome proliferator-activated 
receptors are expressed by a wide range of cell types, including endothelial cells, vascular smooth 
muscle cells, white blood cells, and adipocytes. Previous studies have shown that nitro-fatty acid 
agonism of these receptors rivals that of rosiglitazone, a thiazolidinedione which is a class of drugs 
used in treatment of type 2 diabetes. The resulting effects of nitro-fatty acid agonism of peroxisome 
proliferator-activated receptors is similar to that of thiazolidinedione agonism and include 
increased glucose uptake but also a diminished capacity to affect adipogenesis. Notably, this also 
suggests the relevance of nitro-fatty acids to treatment of type 2 diabetes given their capacity to 
potentially improve insulin sensitivity without significant weight gain (adipogenesis). Many other 
thiazolidinedione associated adverse effects including edema and increased risk for cardiovascular 
events may be avoided in utilizing nitro-fatty acids over thiazolidinediones as well. Aside from 
regulation of glucose metabolism and insulin sensitivity, nitro-fatty acid agonism of peroxisome 
proliferator-activated receptor gamma also mediates lipid metabolism as it has been associated 
with decreased plasma triglyceride levels, reductions in lipoprotein biomarkers for cardiovascular 
risk, and prevention of triglyceride accumulation in macrophages through increased expression of 
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key metabolic enzymes including hormone-sensitive lipase and adipose triglyceride lipase. Along 
these lines, nitro-fatty acids themselves may also be incorporated directly into mono-, di-, and 
triglycerides, suggesting that there may be mechanistic implications of the affinity that nitro-fatty 
acids have for these molecules. Peroxisome proliferator-activated receptors also interact with the 
NF-B transcription factor previously mentioned in that peroxisome proliferator-activated 
receptor gamma may directly interact with subunits p50 as well as p65 of NF-B to inhibit 
subsequent inflammatory signaling (which is upregulated by nitro-fatty acid agonism of 
peroxisome proliferator-activated receptors). In addition, the sumoylation (process of adding small 
ubiquitin-like modifiers) of peroxisome proliferator-activated receptor gamma results in 
transcriptional repression of inflammatory mediators such as inducible nitric oxide synthase [230, 
233, 237]. 
6.3.2.4 Nuclear Factor Erythroid 2-related Factor 2 Activation 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a mediator of cellular responses to 
oxidative damage and presence of oxidants. As a transcription factor it regulates the expression of 
a variety of antioxidant factors as a cytoprotective measure. These include NADPH quinone 
oxidoreductase 1, heme oxygenase-1, glutathione s-transferase, UDP-glucuronosyltransferase, and 
multidrug resistance-associated proteins. These proteins are involved in reduction or prevention of 
oxidative stress, detoxification of oxidative stress mediators such as hydrogen peroxide and 
peroxynitrite, conjugation of potentially harmful compounds to glutathione or glucuronic acid 
moieties to facilitate their excretion (through increasing water solubility), and increasing efflux of 
toxic compounds into bile, leading to their excretion. 
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Nrf2 is maintained in an inactive form complexed for proteosomal degradation in the cytosol by 
the activity of Kelch-like ECH-associated protein 1 (Keap1). Keap1 is the target of nitro-fatty acids 
(being lipid electrophiles), allowing dissociation of Nrf2 from its ubiquitin complex and migration 
to the nucleus, where Nrf2 may affect downstream gene transcription. Nrf2, similar to NF-B, is 
expressed in and protects many cell types from oxidative stress including vascular smooth muscle 
cells and endothelial cells [236, 242]. 
6.3.2.5 PGHS and NADPH Oxidase Modulation 
Two other mechanisms of nitro-fatty acid mediation of anti-inflammatory effects involve 
prostaglandin endoperoxide H synthase (PGHS) and NADPH oxidase (NOX). PGHS is involved 
in the formation of prostaglandins, and various isoforms of these enzymes are the target of 
nonsteroidal anti-inflammatory drugs. Prostaglandins themselves are paracrine or autocrine 
signaling molecules which have a wide variety of effects which include regulation of inflammation 
and platelet aggregation. Nitro-fatty acids have been shown to inhibit synthesis of prostaglandins 
at two separate steps in the enzymatic pathway. Activity of PGHS in platelets was also significantly 
attenuated with nitro-fatty acid administration (along with decreases in thromboxane formation, 
resulting in a decrease in platelet aggregation), giving nitro-fatty acids antiplatelet aggregation 
effects. Previous studies have also shown that these effects are not dependent on cyclic GMP or 
intracellular calcium store mobilization (which are mechanisms for nitric oxide mediated anti-
platelet aggregation effects), suggesting that nitro-fatty acids may operate through distinct 
mechanisms. 
NOX isoforms may be involved in the production and regulation of superoxide anions and 
are present in a wide variety of inflammatory cells including macrophages. Previous studies have 
shown that administration of nitro-fatty acids results in inhibition of NOX isoform 2 formation of 
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superoxide anions in activated macrophages, with potential mechanisms including prevention of 
NOX subunit migration to the cellular membrane and assembly of the final enzyme. Although this 
nitro-fatty acid mechanism is still early in a full characterization, it is also though to attenuate 
inflammation [230, 240]. 
6.4 Nitro-fatty Acids and Nitric Oxide Metabolism 
As previously discussed, nitro-fatty acids have a wide range of protein modification 
mechanisms which result in downstream effects on gene expression which make up a significant 
portion of its total therapeutic benefits. Nitric oxide donation is thought to be a less prevalent or 
significant therapeutic mechanism due to various conditions which go against the equilibrium of 
nitric oxide donation (and therefore toward nitro-fatty acid stabilization) such as incorporation into 
various hydrophobic compartments or cellular membranes. However, recent studies have shown 
that despite these factors, nitro-fatty acids may have significant ramifications on nitric oxide 
metabolism and bioavailability through other alternative means. 
One such study evaluating the effect of nitro-fatty acids on nitric oxide bioavailability 
involved its administration via osmotic pumps with outcome measures of gene expression for HO-
1 and endothelial nitric oxide synthase in a mouse model as well as in vitro for endothelial cell 
cultures [243]. The study found that there were increases in gene expression for both of the 
mentioned targets (3-fold increase for endothelial nitric oxide synthase and 1.9-fold for HO-1) in 
mouse aortic tissue [243]. Quantification of nitro-fatty acid concentration in plasma was performed 
(to ensure successful delivery and validation of results as correlated against increases in nitro-fatty 
acid concentration) and showed that administration of nitro-fatty acid at 3 mg/kg bodyweight per 
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day for 3 days resulted in approximately 28.3 nanomolar serum concentration of the nitro-fatty 
acid species. This further suggests that a nanomolar concentration in plasma is sufficient for 
significant therapeutic effects including gene transcriptional changes. These results were supported 
by gene expression results for in vitro culture of endothelial cells as well [243].  
Additionally, in vitro studies showed that endothelial cells treated with nitro-fatty acids 
showed a significant increase in endothelial nitric oxide synthase phosphorylation at the Ser1177 
site [244]. As previously discussed, this is a critical site for up-regulation of endothelial nitric oxide 
synthase activity and is a key step in other mechanistic pathways for endothelial nitric oxide 
synthase activation and subsequent nitric oxide production. Further mechanistic investigation 
showed that administration of nitro-fatty acid increased phosphorylation of Akt and p38, which 
are upstream enzyme cascade participants for nitric oxide synthase activation [244]. Time-course 
investigations showed significant phosphorylation at 7.5 minutes after treatment administration, 
which fits the timescale for the treatment later administered in the work for this dissertation. Later 
production of nitric oxide in cellular cultures was quantified as well to support the observed 
increase in nitric oxide synthase activation and demonstrated significantly increased production of 
nitric oxide with only 2.5 micromolar concentration of nitro-fatty acid administered in the culture 
medium for up to 120 minutes [244]. 
The results of this study hold significant implications for the involvement of nitro-fatty 
acid therapy in nitric oxide metabolism on multiple levels. Increased expression of HO-1 has been 
previously discussed to increase nitric oxide bioavailability due to the role of hemoglobin and free 
heme (which are degraded by HO-1) as nitric oxide scavengers [226]. Additionally, nitro-fatty 
acid has been shown to not only increase expression of nitric oxide synthase but also increase post-
translational modification of the protein directly resulting in increased activity and production of 
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nitric oxide itself. Although applications of nitro-fatty acid therapy in cardiovascular disease will 
be discussed shortly, the implications on vascular pathology are already visible, with HO-1 having 
a significant role in protection against atherosclerosis and vascular disease as well as nitric oxide 
having an anti-inflammatory effect. 
Another similar study corroborated these results in an analysis of nitro-fatty acid 
administration on gene expression and phosphorylation of key targets in nitric oxide metabolism 
[245]. Similar to the previously discussed study, in vitro cultures of endothelial cells were used 
with the addition of serial measurements of various outcomes including nitric oxide production 
(measured by the Griess method, which quantifies nitrite concentration as a byproduct of nitric 
oxide production) and mRNA expression of endothelial nitric oxide synthase, heat shock protein 
90 (Hsp90), and caveolin-1 (Cav-1). Phosphorylation of key enzymes including endothelial nitric 
oxide synthase, Akt, and ERK1/2 protein kinases was also quantified [245].  
Results for the study showed that nitro-fatty acid stimulated the production of nitric oxide 
in endothelial cells in a time-dependent manner, increasing significantly above baseline levels of 
nitric oxide in as soon as 2 hours and reaching 50% increased production of nitric oxide above 
baseline at 8 hours [245]. Controls featuring administration of the un-modified fatty acid showed 
no significant increase in nitric oxide production. Results of gene expression analysis showed that 
nitro-fatty acid treatment significantly increased expression of peroxisome proliferator-activated 
receptor gamma at early intervals (2 to 8 hours post-treatment) as well as Hsp90. Interestingly, 
results from the study showed significantly decreased endothelial nitric oxide synthase and Cav-1 
expression, which in theory contradicts previous results showing upregulation of both endothelial 
nitric oxide synthase and HO-1 expression by nitro-fatty acid administration. However, analysis 
of enzyme phosphorylation showed significantly increased phosphorylation of endothelial nitric 
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oxide synthase at the Ser1177 site (as previously discussed) as well as the Ser633 site. However, 
nitro-fatty acid administration conversely decreased phosphorylation of endothelial nitric oxide 
synthase at the Ser113 and Thr495 sites, suggesting that these sites may have additional 
significance in regulating enzymatic activity. Phosphorylation of signaling protein kinases 
including Akt at the Ser473 site and ERK1/2 at the P44-Thr202 and P42-Tyr204 sites was 
significantly increased with nitro-fatty acid administration. 
These results hold significant mechanistic implications on the effects of nitro-fatty acids 
on post-translational modification and cellular transport of endothelial nitric oxide synthase, 
especially Hsp90 and Cav-1, which are significantly involved in cellular membrane structure and 
transport. Hsp90 is a chaperone protein for endothelial nitric oxide synthase and enhances the 
effect of calmodulin binding on activation of nitric oxide synthase. This association and 
enhancement of activation has previously been demonstrated with Hsp90 and is also associated 
with other stimuli of endothelial nitric oxide synthase activity including fluid shear forces, vascular 
endothelial growth factor, and estradiol. On the other hand, Cav-1 is a structural inhibitor of the 
calmodulin complex binding site of endothelial nitric oxide synthase, and also inhibits production 
of nitric oxide. Previous studies have shown significant increases in nitric oxide synthase activity 
with gene knockout of Cav-1 in animal models. The results of altered gene expression of both 
Hsp90 and Cav-1 show that administration of nitro-fatty acids also regulates endothelial nitric 
oxide synthase activity at the level of these two additional regulators which are involved in protein 
transportation as well as calmodulin association with the enzyme, in addition to increased gene 
expression and phosphorylation of nitric oxide synthase previously demonstrated. 
For the results of endothelial nitric oxide synthase phosphorylation in this study, the 
various sites of phosphorylation and de-phosphorylation identified are all corroborative with 
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increased activity of the enzyme, although the precise functional effects of each site are still not 
clear. However, this study demonstrated that involvement of the nitro-fatty acid in altering nitric 
oxide synthase phosphorylation is more involved than previously identified. This along with the 
functional assay supporting these results with time-dependent increases in nitric oxide production 
of the in vitro cellular culture support the authors conclusion that multisite coordination of 
phosphorylation is indeed legitimate. The authors also provided additional commentary on the 
specific hypothesized mechanisms of each site individually and their interaction effects in the 
context of the enzymatic subunits of nitric oxide synthase which will not be discussed here. 
However, the reduction in mRNA expression of endothelial nitric oxide synthase itself in response 
to nitro-fatty acid stimulation is not fully characterized by the authors. The results demonstrated 
an approximately 50% reduction in endothelial nitric oxide synthase expression at 4 and 8 hours 
post-treatment, although this magnitude is significantly lower than the increases seen in other gene 
targets such as Hsp90 and peroxisome proliferator-activated receptor gamma which saw increases 
in expression up to 100% relative to control samples. 
6.5 Previous Cardiovascular Applications of Nitro-fatty Acids 
Given the previously discussed downstream functions of nitro-fatty acids relevant to 
oxidative stress, nitric oxide bioavailability, and endothelial function, there are many potential 
therapeutic applications of nitro-fatty acids to cardiovascular disease. Previous studies have 
administered nitro-fatty acids to animal disease models of several pertinent varieties which will be 
discussed in this sub-section.  
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One such study investigated the therapeutic effects of nitro-fatty acids in a mouse model 
of atherosclerosis [246]. The disease model was characterized by apolipoprotein E deficiency in 
transgenic mice, leading to the development of atherosclerotic lesions in blood vessel walls. 
Natural atherosclerosis is mediated by a variety of inflammatory mediators, and its pathogenesis 
typically involves endothelial expression of inflammatory cell adhesion markers, derangement of 
lipid metabolism, and immune cell accumulation of said lipids and forming vascular deposits 
which develop into atherosclerotic lesions or plaques. Given the role of nitro-fatty acids in 
reducing inflammation through modification of gene expression, therapeutic potential was 
identified in this study. Results from the study showed successful reduction in atherosclerotic 
lesion formation for the disease model mice compared to untreated disease mice by 32%. However, 
nitro-fatty acid administration did not affect overall metabolism of lipids as characterized by 
plasma concentrations of various lipid species including total cholesterol concentration and plasma 
triglyceride levels, as well as glucose. Use of immunofluorescent imaging showed that for the 
vascular lesions which did develop in the nitro-fatty acid treated disease mice, there was a 
significantly decreased extent of infiltration and recruitment of monocytes and neutrophils to the 
lesion site. These cells are recruited and localized by expression of VCAM-1, MCP-1, and ICAM-
1 on endothelial surfaces. Given that expression of these markers falls under the governance 
affected by nitro-fatty acids (as previously discussed), this diminished immune cell localization is 
supported by previous investigations. The effects of nitro-fatty acid on production and 
accumulation of various mediators of oxidative stress were investigated as well, characterized by 
levels of superoxide anion and peroxynitrite, with successful reduction of these measures in nitro-
fatty acid treated disease animals. Lastly, conversion of macrophages to lipid-laden foam cells is 
a key step in the formation and maturation of atherosclerotic lesions with disease progression. To 
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characterize this, the study investigated the extent of lipid accumulation as well as STAT-1 
phosphorylation (a key factor in this conversion of cell phenotype), showing that both these factors 
are reduced in nitro-fatty acid treated disease animals. 
Particularly relevant to the work involving nitro-fatty acids in this dissertation, another 
previous study evaluated the therapeutic efficacy of nitro-fatty acids in a mouse model of focal 
cardiac ischemia and reperfusion injury [235]. Not only did this study demonstrate that 
administration of NFA at several different time points relative to ischemia-reperfusion injury result 
in significantly improved outcomes in terms of infarct size to area-at-risk ratios as well as 
morphological analysis, gene expression measurement of several key factors in inflammation and 
oxidative stress revealed protective effects of NFA as well. 
Aside from these two applications, other cardiovascular applications of NFAs in animal 
pre-clinical models include effects of NFA on neointimal formation after vascular injury, ischemic 
preconditioning, inflammatory insult from exogenous stimuli such as LPS, fibrosis and fibrotic 
remodeling after vascular injury, and hypertension [234, 247-249]. 
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7.0 Nitrite Co-therapy with Ultrasound-targeted Microbubble Cavitation 
This chapter is derived from a published manuscript as follows: 
Gary, Z. Y., Istvanic, F., Chen, X., Nouraie, M., Shiva, S., Straub, A. C., & Pacella, J. J. 
(2020). Ultrasound-Targeted Microbubble Cavitation with Sodium Nitrite Synergistically 
Enhances Nitric Oxide Production and Microvascular Perfusion. Ultrasound in Medicine & 
Biology, 46(3), 667-678. 
 
7.1 Introduction 
Cardiovascular disease (CVD) is the leading cause of death in the United States. With 
coronary artery disease (CAD) accounting for over 40% of all cases, it is estimated that an acute 
myocardial infarction (AMI) occurs every 40 seconds [160]. Contemporary treatment for AMI is 
percutaneous coronary intervention (PCI), which focuses on restoring patency of the infarcted 
artery to reestablish perfusion to the ischemic bed [250].  However, a major obstacle to myocardial 
reperfusion post-PCI is microvascular obstruction (MVO). MVO is a combination of distal 
obstruction by microthrombotic debris, oxidative stress, and inflammation which occurs in up to 
60% of AMI cases and is associated with worsened patient outcomes independent of age, infarct 
size, and ejection fraction [162, 165, 166, 168, 169, 172, 177]. MVO also directly correlates with 
decreased post-AMI ejection fraction and is the leading independent contributor to post-AMI 
congestive heart failure and major adverse cardiovascular events [171, 175, 251].  
Recently we have demonstrated that ultrasound-targeted microbubble cavitation (UTMC) 
may be used to relieve MVO [184]. UTMC utilizes imaging-guided ultrasound sonication of 
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intravenously injected lipid microbubbles (MBs) which causes MB expansion and contraction.   
This results in mechanical disruption of microthrombi, relief of MVO, and restoration of 
microvascular blood volume (MBV).  In addition to these physical mechanisms of microthrombi 
disruption, MB oscillation also results in generation of intravascular shear stress stimulating 
release of endothelial derived nitric oxide (NO); our group has shown that UTMC increases 
endogenous NO bioavailability, which was shown to be a key contributor to its therapeutic efficacy 
[96, 190, 252].  
Decreased NO bioavailability is a known major contributor to the development of MVO 
due to vascular vulnerability to ischemic injury, increased propensity for platelet and neutrophil 
aggregation, and decreased protection against reactive oxygen species [167, 253]. AMI patients 
with coronary artery disease are especially vulnerable due to pre-existing endothelial dysfunction 
and a milieu of oxidative stress [254, 255]. NO holds a crucial role in numerous pathways that 
may protect against MVO and its sequelae: decreasing tissue reactive oxygen species (ROS), 
platelet aggregation and adhesion, inflammatory cell adhesion, and increasing endogenous 
endothelial tPA release [203]. 
NO bioavailability may be increased through administration of nitrite (NO2
−), an exogenous 
NO donor with increased activity during hypoxia and acidosis, conditions found in MVO. 
Numerous preclinical and clinical studies have demonstrated the cardioprotective role of nitrite in 
AMI, where it consistently reduced infarct size, myocardial dysfunction, and occurrence of major 
adverse cardiovascular events when administered during PCI for AMI [222, 226, 227]. Previous 
studies have also shown that nitrite may further enhance endogenous NO production, which may 
potentially lead to synergistic interactions with UTMC therapy [210]. 
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Therefore, in this study, we sought to investigate the potential for therapeutic enhancement 
of UTMC with co-administration of intravenous nitrite. We hypothesized that, compared to UTMC 
alone, their combination would result in further increases in NO bioavailability and microvascular 
blood volume (MBV) and accompanying decreases in ROS activity.  This was tested in a series of 
experiments during UTMC and nitrite combination therapy in normal rat hindlimb 
microcirculation. Blockade of endogenous NO production with N-Nitro-L-Arginine methyl ester 
(LNAME) was also used to parcel dependence on endothelial nitric oxide synthase (eNOS). 
During these studies, NO concentration was measured, and ROS activity was evaluated using H2O2 
concentration and protein carbonylation. To determine whether the specific source of exogenous 
NO had an effect on the above measures, the experiments were repeated with sodium nitroprusside 
(SNP), a direct NO donor. 
7.2 Methods 
7.2.1 Lipid Microbubble Agents 
The therapeutic phospholipid MBs used for UTMC therapy were synthesized in-house and 
measured as described by our previous work [190]. For contrast perfusion imaging, DEFINITY® 
MBs (Lantheus Medical Imaging, North Billerica, MA) were prepared at full concentration with 
mean diameter of 1.1-3.3 m and approximate concentration of 1.21010 microbubbles/mL for 
infusion at 2 mL/hr. 
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7.2.2 Animal Preparation 
All animal studies in this investigation received prior approval by the Institutional Animal 
Care and Use Committee at the University of Pittsburgh. The rat hindlimb model, previously 
developed in our laboratory, was used for modeling of healthy microvasculature of the 
gastrocnemius muscle [190]. In rats weighing 275±20 g, anesthesia was induced by inhalation of 
isoflurane (2.5%). An arterial cannula (PE-10, Becton Dickinson, Franklin Lakes, NJ) was placed 
into the right femoral and advanced into the abdominal aorta for infusion of therapeutic MBs 
directly into the left hindlimb for first pass delivery. The femoral arterial cannulation site was also 
used for infusion of sodium nitrite (4 mg/kg, Sigma-Aldrich, St. Louis, MO) and/or LNAME (10 
mg/kg, Sigma-Aldrich, St. Louis, MO). The right internal jugular vein was cannulated (24G, 0.75 
inches long) to deliver DEFINITY® MBs (Lantheus Medical Imaging, Inc., North Billerica, MA) 
at 2 mL/hr for contrast imaging. 
 
 




Figure 2: Specific arrangement of US transducers in hindlimb model 
 
 
Figure 3: Anatomic landmarks and US view of gastrocnemius muscle 
A simplified diagram (left) of the local major feeding vessels (red lines) and gastrocnemius muscle (rough 
pink outline) is shown with the corresponding contrast US image (right) with labeled vessels and treatment 
US beam approximate location shown in a red dashed circle. 
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7.2.3 Ultrasound Therapy and Perfusion Imaging 
All therapeutic ultrasound (US) was delivered using a 1 MHz single-element transducer 
12.7 mm in diameter (A303S, 0.5 inch, Olympus NDT, Waltham, MA) with calibration performed 
in free field. The transducer was driven by an arbitrary function generator (AFG3252, Tektronix, 
Beaverton, OR) connected to a radio frequency power amplifier (800A3B, Amplifier Research, 
Souderton, PA). The therapy transducer was placed vertically with the rat hindlimb and coupled 
to depilated skin using acoustic gel (transducer orientations shown in Figure 2). The therapeutic 
pulse consisted of a long tone 5,000 cycle duration with a pulse interval of 3 seconds at a peak 
negative acoustic pressure of 1.5 MPa. Ultrasound perfusion imaging was performed using a 
clinical scanner (Siemens, Sequoia, 15L8 probe) during infusion of DEFINITY®. The syringes 
holding the MBs were rotated gently throughout delivery to maintain uniform MB suspension.  
Burst-replenishment imaging was performed in contrast pulse sequence (CPS) mode at 7 
MHz with mechanical index of 0.2 and framerate of 5 Hz, and a 5-frame burst pulse at an MI of 
1.9 was used to completely clear MBs from the field of view. The dynamic range (60 dB), gain (0 
dB), and linear compression curve were fixed throughout the study. Replenishment of 
DEFINITY® MBs to the target microvasculature was recorded in cine-loops for processing of 
perfusion kinetics. 
7.2.4 Image Acquisition and Processing 
Positioning of the imaging transducer was perpendicular to the treatment transducer such 
that the junction of the saphenous and popliteal arteries was clearly visible on the right side of the 
image with blood flow through these major vessels proceeding from right to left. White line 
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artifacts visualized in the hindlimb at this imaging position represent strong reflection by bone or 
cartilage and were excluded from the region of interest for perfusion analysis. 
Image analysis was performed using recorded cine-loops in MATLAB following a 
previously described approach to obtain a measure of peak microvascular blood volume (MBV) 
as a correlate of vasodilatory status and microvascular perfusion [190]. The justification and 
derivation of this method of using a mono-exponential regression for quantification of 
microvascular blood volume has previously been documented [256, 257]. For each animal, MBV 
measurements at post-treatment time points were normalized against the pre-treatment baseline 
measurement. 
 
Figure 4: Contrast US image of gastroc. with microvascular ROI 
The contrast US image of the gastrocnemius muscle is shown (with major feeding vessels labeled in red 
numbers) and the selected region-of-interest for microvascular analysis shown in blue with major feeding 
vessels excluded. 
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7.2.5 Measurement of Hindlimb Nitric Oxide and Hydrogen Peroxide 
For real-time measurement of intramuscular NO, a calibrated porphyrinic membrane 
catheter probe (amiNO-IV, Innovative Instruments Inc., Tampa, FL) was inserted into the left 
gastrocnemius muscle in the treatment area of the therapeutic US beam. The probe signal was 
allowed to equilibrate for 30 min prior to drug infusion and treatment. NO concentration was 
recorded up to 30 min post-UTMC therapy, followed by background subtraction and normalization 
against the start of the observation interval. Due to a lack of absolute NO quantification for in vivo 
probe calibration, all measurements are presented as relative changes in concentration as 
represented by change in current (in pA) detected by the probe. Additionally, a similar probe 
sensitive to tissue H2O2 was calibrated and placed in a separate cohort (HP250, Innovative 
Instruments Inc.). H2O2 concentration was recorded for 7 min post-UTMC therapy.  
7.2.6 Measurement of Protein Carbonylation 
Protein carbonylation was measured as an indicator of damage from oxidative stress and 
production of ROS. To avoid tissue damage from catheter probe placement, tissue samples were 
collected from animals receiving the experimental protocol previously described without NO nor 
H2O2 probe placement. 5 animals received combination nitrite and UTMC therapy, while 5 animals 
received UTMC therapy only. For each animal, tissue from the gastrocnemius muscle of the treated 
hindlimb in the region directly beneath the therapeutic US transducer and tissue from the ipsilateral 
biceps femoris muscle (not directly treated by UTMC) were excised 7 minutes after UTMC 
therapy and snap frozen in liquid nitrogen.  
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The tissue samples were then homogenized and prepared for quantification of protein 
carbonylation using a standard 2,4-dinitrophenylhydrazine assay (Sigma-Aldrich). Total protein 
content was evaluated using a BCA assay (Sigma-Aldrich) on the tissue homogenates used. The 
resulting protein carbonylation per unit mass protein measurements were normalized against the 
control group receiving no treatment. Each animal served as its own control as tissue samples taken 
from UTMC treated and untreated regions of the same hindlimb were compared in a carbonylation 
ratio. 
7.2.7 Measurement of Nitrite in Blood and Muscle Tissue 
To verify the successful infusion and delivery of nitrite to the rats receiving combination 
therapy, nitrite concentration in blood samples were measured using ozone-based 
chemiluminescence. Prior to euthanasia, a catheter was inserted into the rat carotid artery for 
collection of blood into a tube with EDTA for anticoagulation. Blood samples were spun down in 
a centrifuge and the plasma layer was isolated for assay use, as previously described [258, 259]. 
For muscle tissue samples, specimens were collected from the treated gastrocnemius muscle and 
ipsilateral biceps femoris muscle in animals receiving combinations of UTMC and nitrite therapy 
7 minutes after treatment. All tissue samples were snap frozen in liquid nitrogen and homogenized 
in a nitrite preservation solution prior to analysis with ozone chemiluminescence. Tissue nitrite 
measurements were normalized against protein concentration measured by a BCA assay (Sigma-
Aldrich) while intravascular nitrite was normalized against sample volume. 
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Figure 5: Simplified schematic of experimental groups 
7.2.8 Experimental Protocol 
Nitrite (4 mg/kg iv, ~ 0.25 mL volume) was delivered as a slow bolus in saline into the 
femoral site over 15 seconds, 5 min prior to UTMC. LNAME was delivered with the nitrite in the 
same saline bolus (10 mg/kg iv) in the appropriate groups to inhibit the activity of eNOS. For 
UTMC therapy, treatment US was delivered during the infusion of treatment MBs at the femoral 
site (2108 treatment microbubbles/mL, 1.5 mL/hr) via syringe pump for 2 min. Placement of the 
therapeutic US transducer was confirmed by visualization of MB destruction by the therapeutic 
pulses in the perfusion image during treatment. Microvascular tissue perfusion was then measured 
by bust-replenishment imaging cine-loops during DEFINITY® infusion at baseline (prior to drug 
administration and UTMC), 3, 6, 10, and 30 min post-UTMC. Heart rate, respiratory rate, and O2 
saturation were continuously monitored. After the 30-minute observation interval, the animals 
were euthanized by isoflurane overdose followed by heart excision. 
To observe the effects of peak negative US pressure and MB concentration on 
microvascular perfusion and NO perfusion, three different conditions of each parameter were used 
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in the combination therapy of UTMC and sodium nitrite. For the effect of US peak negative 
pressure, therapeutic MB delivery concentration was kept constant at 1109 microbubbles/mL 
infused at a rate of 3 mL/hr. Peak acoustic pressures of 1.5 MPa, 0.75 MPa, and 0.33 MPa were 
used. For the effect of MB concentration, therapeutic US peak negative pressure was maintained 
at 1.5 MPa. MB concentrations of 1109 and 5108 microbubbles/mL at 3 mL/hr, and 2108 
microbubbles/mL at 1.5 mL/hr were used. 
Similar to the experimental protocol for nitrite co-therapy with UTMC, sodium 
nitroprusside (SNP) was given in the pre-treatment bolus at a dosage of 8 µg/kg in saline, followed 
by a 5 min waiting period and 2 min of UTMC therapy. A MB concentration of 1109 
microbubbles/mL given at 3 mL/hr was used for UTMC. Burst-replenishment cine-loops were 
obtained at baseline, 3, 6, 10, and 30 minutes post-treatment and processed for total MBV. Changes 
in local NO concentration were also measured over 30 minutes post-treatment. 
7.2.9 Statistical Analyses 
For the factorial design between UTMC, nitrite, and LNAME administration, effects on 
MBV and change in NO concentration were analyzed using a mixed effects model (with random 
intercept for each animal and restricted maximum likelihood) using Stata 14.2 (StataCorp., College 
Station, TX). Remaining data were analyzed using one-way and two-way repeated measures 
ANOVA followed by Tukey’s HSD post-hoc test and both paired and unpaired t-tests performed 
using GraphPad Prism (GraphPad Software, La Jolla, California) with significance considered at 




7.3.1 Effects of UTMC and Nitrite on NO and Microvascular Blood Volume 
Figure 6 shows still frame contrast images for peak plateau video intensities obtained 30 s 
post-UTMC for experimental groups without LNAME at baseline and 3, 6, 10, and 30 min after 
treatment. MBV for all treatment groups are shown in Figure 7.  
There was a significant three-way interaction effect between UTMC, nitrite, and L-NAME 
on change in MBV over the 30 min observation interval (p < 0.0001) (Figs 7A, C). At the 3 min 
time point specifically, the UTMC only group showed a transient decrease in MBV below baseline, 
likely indicating a post-UTMC microvascular spasm (p < 0.0001) previously observed by our 




Figure 6: Effect of UTMC nitrite combination therapy on microvascular blood volume 
Contrast-enhanced still-frame ultrasound images of the treated hindlimb gastrocnemius region are shown for 
all groups after UTMC (2×108 MB/mL at 1.5 mL/hr for 2 min) at 1.5 MPa negative peak acoustic pressure. 
Images were taken 30 sec after burst in the reperfusion sequence at baseline, 3, 6, 10, and 30 min after the 2 
min treatment period. Note the transient decrease in image intensity at 3 min for the UTMC group (red 









However, addition of nitrite to UTMC eliminated this event and instead resulted in 
significantly increased MBV (p < 0.0001). With the addition of LNAME (Fig 7C, D), which 
removes eNOS dependent NO, both UTMC LNAME and UTMC LNAME nitrite showed 
significant decreases in MBV (p < 0.0001 for both), suggesting eNOS dependence of the UTMC-
nitrite interaction effect.  
Change in concentrations of intramuscular NO versus time are presented in Figure 2B and 
D. There was a significant three-way interaction effect between UTMC, nitrite, and L-NAME on 
changes in NO concentration over 30 min (p < 0.0001). No change in NO concentration was seen 
in the control group.  In both UTMC alone and nitrite alone, there was a mild increase in NO above 
baseline. However, when UTMC was combined with nitrite, there was a marked, synergistic 
increase in intramuscular NO (Fig. 7B).  In congruence with the MBV data, LNAME reversed 
these NO enhancing effects. Specifically, UTMC combined with LNAME caused a marked 







Figure 7: Changes in MBV and NO concentration after UTMC nitrite therapy 
Changes in MBV (A and C) and NO concentration (B and D) are shown. Asterisk indicates p < 0.0001 
compared to control. The transient decrease in MBV in the UTMC group at 3 min was reversed with the 
addition of nitrite, while addition of N-Nitro-L-Arginine methyl ester (LNAME) resulted in persistent and 
exacerbated decrease. UTMC with nitrite resulted in greatly increased NO over individual treatments. 
Addition of LNAME to UTMC resulted in decreased NO which was partially rescued by addition of nitrite. 
There was a significant three-way interaction effect between factors of UTMC, nitrite, and LNAME (p < 
0.0001) for both change in MBV and NO concentration. All error bars indicate standard deviation. 
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7.3.2 Effect of US Pressure and MB Dose on UTMC Nitrite Co-therapy 
 
Figure 8: Effect of US pressure and MB dosage 
For animals receiving UTMC nitrite therapy, changes in MBV and NO concentration for varied US pressures 
with constant MB dosage of 1×109 MB/mL, 3 mL/hr for 3 min (A and B) and varied MB doses at a constant 
1.5 MPa peak negative US pressure (C and D) are shown. While there was a significant effect of varying US 
pressure on MBV and NO concentration, the effect of MB dosage for the levels shown was not significant. 
Asterisk (*) indicates p < 0.05 compared to other groups. Dagger (†) indicates all groups are significantly 
different from each other (p < 0.0005). Error bars indicate standard deviation. 
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7.3.2.1 Effect of US Dose 
As shown in Figure 8A, there was a significant effect of varying US pressure on MBV for 
the tested levels of 1.5, 0.75, and 0.33 MPa (p < 0.0005). In post-hoc testing, the 1.5 MPa group 
had significantly higher MBV than both other groups at 6 and 10 min (p < 0.05). Only the 1.5 MPa 
group had significantly higher MBV than baseline at all subsequent time points (p < 0.001). 
For the 0.33 MPa group NO concentration was significantly lower than both the 1.5 and 
0.75 MPa groups from 12 min onward (p < 0.0005, Figure 8B). While NO concentration in the 
1.5 MPa group exceeded the 0.75 MPa group at 14 min onward (p < 0.0005). The 0.75 MPa group 
increased significantly above baseline at 10 min while the 1.5 MPa did so at 8 min (p < 0.0001). 
7.3.2.2 Effect of MB Dose 
There was no significant effect of varying MB dosage on MBV for the groups investigated 
(Figure 8C). All groups increased in MBV significantly above BL at 3 and 6 min post-treatment 
(p < 0.005), while only the 1109 microbubbles/mL at 3 mL/hr and the 2108 microbubbles/mL at 
1.5 mL/hr increased significantly above BL at 10 and 30 min (p < 0.0001). 
For NO concentration, there was a significant MB effect on NO concentration as the group 
receiving 1107 MBs briefly rose above the other two groups from 8 to 12 min post-treatment (p 
< 0.0001, Figure 8D). Both the 1108 and the 5107 MBs groups increased significantly above 
baseline after 10 min (p < 0.0001) while the 1107 MBs increased above baseline at 2 min post-
treatment (p < 0.0001). 
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7.3.3 Effect of UTMC Nitrite Therapy on Oxidative Stress 
 
Figure 9: Protective effects of nitrite with UTMC therapy on oxidative stress 
Change in hydrogen peroxide concentration (A) show that addition of nitrite to UTMC prevented early 
increases in hydrogen peroxide seen in UTMC alone in the first seven minutes after treatment. Extent of 
protein carbonylation is presented as a concentration for each group (B), and as a carbonyl content ratio (C). 
The carbonyl content ratio was obtained by taking the ratio of carbonyl concentration of a muscle tissue 
sample within the US treatment region (gastrocnemius) to one outside the US treatment region in the same 
rat hindlimb (thigh). For each group in (B) and (C), n = 5 animals. Addition of nitrite with UTMC therapy 
resulted in no increase in carbonylation seen in UTMC without nitrite. Asterisk (*) signifies p < 0.005 against 
all other groups (left) or compared group (middle, right). Error bars indicate standard deviation. (Gastroc. = 
gastrocnemius) 
7.3.3.1 Hydrogen Peroxide Concentration 
There was a significant interaction effect between nitrite and UTMC on H2O2 concentration 
(p < 0.0001) with results shown in Figure 9A. Nitrite alone did not result in significant increase 
in H2O2 concentration. UTMC alone resulted in significant increases in H2O2 concentration from 
1 min onward compared against control, nitrite alone, and UTMC with nitrite (p < 0.0005 for all). 
Addition of nitrite to UTMC resulted in significantly decreased H2O2 concentration compared to 
all other groups up to 3 min post-treatment (p < 0.05), with no significant difference up to 7 min.  
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Relative to each group’s own baseline value, UTMC alone increased H2O2 concentration 
significantly at all later time points (p < 0.005) while UTMC with nitrite reduced H2O2 
concentration at 2 and 3 min (p < 0.005). 
7.3.3.2 Protein Carbonylation 
Carbonyl concentration (nanomolar amount per gram protein) for groups receiving 
combinations of UTMC and nitrite therapy were normalized against the mean control group value 
(Figure 9B). Significance differences in carbonyl concentration were seen between groups (p < 
0.0005) using one-way ANOVA. The group receiving UTMC without nitrite had significantly 
higher normalized carbonyl concentration than the control group and the UTMC nitrite 
combination group (p < 0.005). There was no significant change in normalized carbonyl 
concentration between the UTMC nitrite group or either the nitrite only or the control group.  
When normalizing each animal’s UTMC treated region against its UTMC untreated region 
as a paired control, carbonylation ratios were obtained for the groups with and without nitrite 
(Figure 9C). Animals which did not receive nitrite had significantly higher carbonylation ratios 
(UTMC treated over untreated) than those which did receive nitrite (p < 0.005). 
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7.3.4 Comparison of Nitrite with SNP during UTMC Therapy 
 
Figure 10: Contrast US imaging comparing NO donor efficacy at higher MB dose 
Contrast-enhanced still-frame ultrasound images are shown after 2 min of ultrasound-targeted microbubble 
cavitation (UTMC) at 1×109 MB/mL at 3 mL/hr for 2 min and 1.5 MPa pressure. Images were taken 30 sec 
after burst in the reperfusion sequence at baseline (BL), 3, 6, 10, and 30 min after the 2 min treatment period. 
In the UTMC group, microvascular spasm is observed at 3 and 6 min after treatment (red arrow). This is also 
noted in the UTMC sodium nitroprusside (SNP) group, although spasm size is notably smaller.  
7.3.4.1 Microvascular Blood Volume 
Still-frame perfusion images for UTMC, UTMC with SNP, and UTMC with nitrite at 
baseline, 3 min, and 6 min post-treatment are shown in Figure 10.  A higher treatment MB dosage 
was used to compare against results in our previous work [190].  
As indicated in Figure 11A, at 3 min UTMC alone had significantly lower MBV relative 
to baseline (p < 0.0001). Although UTMC with SNP had higher MBV than UTMC alone at 3 min 
(p < 0.05), UTMC with nitrite had significantly higher MBV than both groups (p < 0.005). 
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7.3.4.2 NO Concentration 
For NO concentration (Figure 11B), UTMC alone increased significantly above baseline 
from 26 min onward (p < 0.0005). UTMC with SNP increased above baseline from 18 min onward 
with the exception of the 26 min timepoint (p < 0.0005). UTMC with nitrite increased above 
baseline from 10 min onward (p < 0.0005). UTMC with SNP had significantly higher NO 
concentration than UTMC alone at the 8- and 10-min time points (p < 0.05), while UTMC with 
nitrite had significantly higher NO concentration than both other groups from 12 min onward (p < 
0.0005). 
 
Figure 11: Effect of SNP compared to nitrite on MBV and NO concentration 
Change in MBV (top) and NO concentration (bottom) are shown for UTMC and NO donor co-therapies. 
While a decrease in MBV with UTMC was observed at 3 min, this was mitigated with SNP and reversed with 
nitrite co-therapies. In addition, a significant increase in NO was only observed for UTMC with nitrite. 
Dagger (†) indicates all groups are significantly different (p < 0.005). Asterisk (*) indicates p < 0.0005 against 
other groups. 
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7.4 Discussion and Conclusions 
Our previous work has demonstrated that UTMC restores microvascular perfusion in an in 
vivo model of MVO, with endogenous NO bioavailability playing a significant role in its efficacy 
[184, 190]. We sought to enhance the effects of UTMC using nitrite, an exogenous NO source, in 
this exploratory study. To better understand the mechanistic interactions between UTMC and 
nitrite, this study was performed in normal hindlimb microvasculature to prevent potential 
confounding factors or pathologic interference in the NO signaling pathways seen during MVO. 
Although we recognize that endothelial health cannot be assumed in many potential applications 
of UTMC, including vasculopathies, AMI, and sickle cell disease, the therapeutic interactions and 
synergies described here will serve as a foundation for potential future studies in such disease 
models.  
We tested this hypothesis using a factorial design between UTMC, nitrite, and LNAME 
administration in a healthy rat hindlimb and found a significant three-way interaction effect of the 
treatment factors on microvascular perfusion and NO concentration. While UTMC and nitrite 
synergistically increase microvascular perfusion and NO concentration, this effect is diminished 
by LNAME administration, suggesting eNOS dependence. However, administration of nitrite 
alone resulted in significant increases in MBV regardless of LNAME administration, which 
supports previous characterization of nitrite as an eNOS independent contributor to NO 
bioavailability and vasodilation [216].  
After establishing a synergistic effect between UTMC and nitrite, we then sought to 
characterize how US peak negative acoustic pressure and MB dosage used in UTMC nitrite co-
therapy would affect MBV and NO concentration. Previously, we have demonstrated that high 
(1.5 MPa) US peak negative pressure led to increased clot destruction in an in vitro MVO flow 
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loop model, which solely investigated the mechanical mechanisms of UTMC and the interactions 
of the MB and microthrombi [187]. This increased clot destruction was ascribed to higher 
pressures resulting in non-linear MB expansion and collapse, with large changes in MB radius, 
delivering increased energy per time as well as other physical phenomenon such as microjet 
formation [260]. In addition, higher acoustic pressure also induced continuous cavitational activity 
which persisted for up to 5 ms of the US tone burst [187].  
Taken together, these MB behaviors translate to increased shear force exposure of the 
vascular endothelium.  In the current work, we demonstrated that this results in a dose response 
relationship between peak negative pressure and increases in MBV and NO concentration, 
supporting a causal relationship.  
While the 0.33 MPa group saw slight, numerical increases (not statistically significant) in 
MBV, no increase in NO concentration was observed. At these acoustic pressures, the predicted 
shear stress generated by the oscillating MB should exceed the limit required to stimulate 
endothelial NO production (3-9 Pa).  We recognize the possibility that the amount of NO produced 
may have been below the sensitivity of our intramuscular NO probe.  
No significant effect of MB dose on MBV or NO were observed in UTMC nitrite co-
therapy. All of the doses investigated resulted in similar increases in MBV and NO concentration. 
This observation may be due to the fact that we have exceeded a threshold concentration of MBs, 
beyond which further increases do not result in further enhancement of MBV or NO production. 
A wider range of dosages may be further characterized in future studies.  
Next, we sought to characterize the effects of UTMC and UTMC nitrite therapy on various 
measures of reactive oxide species production and oxidative stress because these environmental 
factors are potentially deleterious in the setting of MVO [261]. To do so, we measured real-time 
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intramuscular H2O2 concentration and post-UTMC tissue carbonyl content as surrogate indicators 
of ROS production and oxidative stress [262, 263]. Both of these are well characterized and stable 
over the observation period of our animal model and were evaluated in the 7 min post-UTMC 
window [264]. A 7 minute observation period was selected because 1) an approximately 3 min 
transient decrease in MBV was seen in the UTMC only group suggestive of microvascular spasm 
and 2) recovery of MBV back toward baseline which occurs at approximately 6 minutes was 
blunted by the addition of LNAME to UTMC, indicating that lack of endogenous NO is a major 
contributor to recovery of microvascular blood volume. Thus, the mechanistic basis for this 
phenomenon, of which ROS production and oxidative stress are potential components, would be 
observed in this 7-minute time window. Increased production of ROS and oxidative stress are 
directly related to higher levels of NO scavenging and endothelial dysfunction [265].  
However, whether this increase in ROS is the direct cause of the post-UTMC transient 
microvascular spasm, or a byproduct remains unclear. Our results showed that there is a nearly 
immediate increase in intramuscular H2O2 concentration after UTMC, relative to control. 
However, addition of nitrite to UTMC completely eliminated this increase in ROS concentration. 
This suggests that nitrite has protective effects on local ROS concentration after UTMC, by 1) 
greater clearance of local ROS from the treatment site from the enhanced microvascular perfusion, 
preventing its accumulation, and/or 2) greater direct conversion of ROS to other species by 
increased local NO.  
Previous studies have also observed the formation of hydrogen peroxide after UTMC, 
associating it with transient permeabilization of cell membranes without jeopardizing cell viability 
[106, 266]. However, the study was performed under low diagnostic power US and stable MB 
oscillation, rather than the high-pressure US, inertial MB cavitation of our present study, 
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suggesting that the changes in hydrogen peroxide seen in these two studies may represent different 
phenomena.  
To further validate the protective effects of nitrite in the setting of UTMC, we measured 
protein carbonylation as a marker of damage from ROS in muscle tissue samples within the same 
animal at both UTMC treated and untreated locations [262]. These results were congruent with 
those of H2O2 concentration, where UTMC alone resulted in a significant increase of protein 
carbonyl content relative to an untreated site on the same animal. Both absolute values of protein 
carbonyl content and animal-matched carbonyl ratios between treated and untreated sites indicated 
that addition of nitrite prevented any increase in carbonyl content. This together with our H2O2 
concentration results support nitrite co-therapy as a protective measure against ROS production 
and oxidative stress accompanied by long-tone burst, high pressure UTMC.  
To determine whether the synergistic effect between UTMC and nitrite seen in our trials is 
due to nitrite-specific molecular pathways or general NO donor activity, we compared nitrite 
administration to SNP, another exogenous NO donor which directly releases molecular NO. In this 
experiment, a higher dose of injected MB was used to consistently replicate the post-UTMC 
transient microvascular spasm previously noted and compared against our previous results 
featuring the same concentration [190]. Although addition of SNP prevented any transient decrease 
in MBV at the 3 min time point, the subsequent increase in MBV as seen with nitrite co-therapy 
was markedly less.  
Similarly, although SNP co-therapy prevented the transient decrease in NO concentration 
seen with high-MB dose UTMC, it did not synergistically increase NO concentration above levels 
seen with UTMC alone. Although these results were obtained using a single dosage of SNP, they 
support that the synergistic effects seen in UTMC nitrite therapy are specific to nitrite rather than 
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a general exogenous NO donor.  Furthermore, they reinforce that lack of NO contributes to post 
UTMC recovery of microvascular blood volume. 
Enhancement of tissue perfusion with therapeutic US has previously been characterized in 
a variety of healthy and disease models over a range of US settings [267, 268]. Tissue perfusion is 
enhanced by focal shear stress stimulation of the microvascular endothelium caused by MB 
oscillation and destruction (inertial cavitation) when stimulated by US. The downstream cellular 
responses that occur after US stimulation include eNOS and nitric oxide-dependent changes in 
perfusion kinetics and purinergic signaling pathways through release of extracellular ATP [269-
271].  
One pathway that may be involved in the downstream signaling of UTMC cavitation events 
is that of AMP-activated protein kinase (AMPK) with eNOS, a potential mechanism for the 
synergy between UTMC and nitrite. In this proposed pathway, exogenous nitrite produces NO via 
two arms: 1) direct conversion of nitrite to NO via reductive mechanisms (eNOS independent) and 
2) nitrite-AMPK-eNOS-NO pathway [204, 209]. That is, AMPK is activated by both nitrite and 
shear stress, each of which results in eNOS phosphorylation and production of NO [210, 214].  
UTMC provides an external source of intravascular shear through MB oscillations which may also 
activate AMPK, which would result in phosphorylation of eNOS to yield even greater NO 
production.  Additionally, AMPK may also be stimulated via calcium/calmodulin-dependent 
protein kinase pathways, which may also be involved in shear mechanotransductive signaling 
[207, 208, 212, 213]. Therefore, through shear responsiveness, the AMPK pathway could further 
increase NO bioavailability and explain synergism observed between nitrite and UTMC. 
An additional potential explanation for the synergy between nitrite and UTMC may be that 
UTMC enhances the local concentration of nitrite at the treatment site. Because nitrite is not only 
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a source of NO but also a vasodilatory agent, this could explain the changes in MBV and NO 
concentration observed. To exclude this possibility, both blood and tissue nitrite concentrations 
were measured in rats receiving all combinations of UTMC and nitrite therapy and there were 
found to be no significant differences in blood or tissue nitrite concentration between rats which 
did and did not receive UTMC.  Therefore, a UTMC-induced increase in local nitrite concentration 
to explain this observed synergy is unlikely. 
In this study, long tone burst US at high MI was used for UTMC with nitrite co-
administration. These settings were determined to be the most effective for sonothrombolysis in 
our previous MVO animal model with no significant adverse effects such as microvessel damage 
and red blood cell extravasation [184].  We have also previously characterized the imaging US 
used to have no effects on the outcome measures of this study [190]. Although we have made some 
progress toward characterizing how this may be tuned according to various ultrasound settings of 
UTMC, further optimization may be performed to explore a wider range of US settings, 
modulating other components of the US pulse, and investigating longer observation intervals to 
determine whether changes in NO concentration may be further sustained similar to our previous 
work [190]. Although previous in vitro studies have demonstrated the presence of inertial 
cavitation for US peak negative pressures above 0.6 MPa, this study did not include in vivo passive 
cavitation detection and hence confirmation of inertial cavitation [187]. Additionally, in vivo 
absolute calibration of the NO measurement system, resulting in expression of NO concentration 
in relative terms only. 
A wider range of MB dosages may be investigated for a potentially greater effect on 
outcomes of NO and MBV. This study was a preliminary exploration into lower MB 
concentrations used for this hindlimb model, with the range ceiling guided by previous successful 
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dosages and the floor being an order of magnitude lower [190]. Although the highest MB dosage 
exceeds clinically approved concentrations, our previous histological studies for the US acoustic 
pressure and MB dosage used indicate there were no overt adverse effects including vessel trauma 
or hemorrhage [184]. Given that even the lowest concentration used showed significant increases 
in both MBV and NO, even lower concentrations would be warranted to fully characterize the 
dose-effect relationship in future work.  
Although we have characterized the combination therapy effects in a healthy hindlimb 
setting, further development and testing in an MVO model will be necessary to determine whether 
these synergistic benefits are translatable to improved therapeutic efficacy. Additionally, we have 
demonstrated the capacity of UTMC with nitrite to increase local NO concentration. The specific 
biological mechanisms for the increased NO production may also be further characterized, 
specifically the role of the eNOS-AMPK pathway and its interactions with nitrite. Additionally, 
our use of LNAME to inhibit activity of all NOS isoforms may be further refined by inhibition of 
specific isoforms to account for the contributions of iNOS and nNOS to the increased NO 
concentration observed.  
While we used SNP as an alternative exogenous NO donor comparison against sodium 
nitrite, the respective dosages of each NO donor were taken from previous studies on their 
application to pathological states and are not chemically equivalent [221, 272, 273]. This is also 
made difficult by their differing mechanistic pathways and interconversion to other species in the 
bloodstream. Additionally, SNP efficacy is vulnerable to systemic NO scavenging, which we 
attempted to account for by direct intra-arterial injection into the treated hindlimb. Additional 
characterization of these dosages may further inform their combination effects on UTMC therapy. 
 167 
In this study, we have demonstrated the synergistic interaction between nitrite and UTMC 
therapy in increasing MBV and NO bioavailability. We have shown that this interaction effect is 
partially dependent on eNOS activity, but the specific mechanisms are yet unclear. In addition, the 
combination of nitrite with UTMC appears to mitigate oxidative stress. These new insights may 
further inform the biomechanisms of UTMC and potential application of this combination therapy 
to reperfusion of MVO following AMI. 
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8.0 Nitro-fatty Acid Microbubble Characterization and Application 
8.1 Introduction 
Cardiovascular disease is a leading cause of death in the United States, with over 1 million 
Americans estimated to have a new or recurrent acute myocardial infarction (AMI) this year [160]. 
Contemporary treatment for AMI is percutaneous coronary intervention (PCI), which aims to 
restore perfusion to the myocardium through recanalization of the epicardial vessels to effect 
maximal myocardial salvage [250]. Although mortality from AMI has decreased in recent years, 
post-MI congestive heart failure is increasing due to microvascular obstruction (MVO) and 
inadequate restoration of microvascular perfusion, ultimately limiting myocardial salvage [180]. 
MVO is a phenomenon in which myocardial tissue remains hypo-perfused after PCI even 
with patent upstream epicardial vessels; it occurs due to a combination of distal micro-
embolization, ischemia-reperfusion injury, and activation of inflammatory cascades. Other 
mechanisms of MVO include tissue edema causing vessel compression and local vasospasm [162, 
165, 167, 169, 170, 179, 253]. MVO occurs in up to 60% of all STEMI patients receiving PCI, and 
results in decreased LV function, and is an independent predictor for major adverse cardiac events, 
which include cardiac death, stroke, myocardial infarction, and heart failure requiring 
hospitalization [166, 176, 251]. MVO is also associated with increased infarct size and LV 
remodeling, with persistence of MVO being a stronger predictor for functional recovery than 
transmural infarct extension [166, 171, 172, 174, 175]. 
Previous strategies at treating or preventing MVO included administration of vasodilators 
and antiplatelet therapy, thrombus aspiration and embolic protection devices, and even use of 
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hyperoxemic intracoronary reperfusion therapy [178]. However, even with these various 
strategies, no definitive therapeutic consensus for MVO has arisen, and a number of clinical trials 
have yielded conflicting results [167, 176, 179]. Therefore, there is a need for an acute therapy 
capable of resolving MVO and its sequelae due to the unpredictable and rapidly catastrophic nature 
of acute cardiac events. 
Use of therapeutic ultrasound for thrombolysis has become a rising subject of investigation. Our 
lab has previously demonstrated the efficacy of ultrasound-targeted microbubble cavitation 
(UTMC) in treatment of MVO and improvement of tissue perfusion [184, 190]. This technique 
involves image-guided ultrasound sonication of intravenously injected lipid microbubble (MB) 
contrast agents, resulting in microbubble oscillation (cavitation) which generates intravascular 
shear forces. UTMC produces both mechanical and biological effects in disrupting microthrombi 
to restore perfusion and activating endothelial NO pathways for local vasodilation [187, 190, 252]. 
In addition to thrombolysis, UTMC may also be used as a means for targeted delivery of 
therapeutics through use of loaded MBs, resulting in site-specific concentration of the therapeutic 
at higher efficiency than through systemic administration, while also reducing off-target effects 
[274-278]. UTMC is an ideal solution for MVO because it is a minimally invasive, theranostic 
technique that may visualize regions of MVO using MB contrast agents while simultaneously 
delivering image-guided ultrasound pulses. However, while UTMC has shown great promise in 
disrupting microthrombi and increasing myocardial perfusion, the numerous inflammatory 
mechanisms associated with MVO remain unaddressed. 
To this end, nitro-fatty acids (NFAs) are endogenous signaling molecules formed from 
oxidative reactions between NO and nitrite-derived species and unsaturated fatty acids [232]. 
These molecules have been previously  investigated in a wide range of inflammatory conditions 
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due to their role in post-translational modification of various anti-inflammatory signaling pathways 
[230, 233, 235-237, 245, 279, 280], resulting in decreased production of reactive oxide species, 
inhibition of pathogenic macrophage conversion and activation, inhibition of fibrotic and 
hyperplastic processes, and prevention of endothelial dysfunction [249, 281-283]. All of these 
effects are clinically relevant to the prevention and treatment of MVO, especially as NFAs have 
been demonstrated to be cardioprotective in the setting of focal cardiac ischemia [235, 284]. NFAs 
also present potential therapeutic interactions with UTMC from their capacity to increase nitric 
oxide bioavailability through multiple mechanisms. These include direct dissociation of NO 
molecules from the parent NFA molecule through the Nef chemical reaction, which then mediate 
cGMP-dependent signaling pathways [285]. In addition, NFAs have been shown to increase eNOS 
mRNA and protein expression as well as serine-1177 phosphorylation, resulting in increased 
cellular distribution and activity of eNOS [243].   
Although NFAs have demonstrated their therapeutic value through previous trials featuring 
both longitudinal and acute systemic administration, targeted local delivery of NFAs for immediate 
concentration at tissue specific sites has not been explored [239]. Given their relatively rapid onset 
of effectiveness and lack of adverse effects from overdosing, NFAs are a strong candidate for 
targeted therapy in the context of MVO. The molecular structure of NFAs is also highly similar to 
the phospholipid species found in the lipid shell of the therapeutic MBs used in UTMC.  
Another advantage of delivering NFA through loaded MBs in UTMC is the ability to 
concentrate payloads of NFA at the specific site of MVO. Previous literature has shown that the 
inhibition of various inflammatory signaling reactions by NFAs are both time-dependent and 
dosage-dependent in inflammatory and endothelial cells [233]. This coupled with previous 
successes of reducing inflammation and preserving myocardium in a myocardial ischemia model 
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with systemically administered NFA suggests the strong potential of further improving the efficacy 
of this therapy through rapidly concentrating NFAs at the site of the myocardial insult [235]. This 
further complements the rapid-onset and localized nature of MVO.  
Therefore, the combination of NFA with therapeutic MBs used in UTMC may allow for 
the anti-inflammatory and cardioprotective effects of NFA to be focused at the specific location of 
MVO while supplementing the mechanical effects of UTMC on thrombolysis and perfusion. Site 
specific oscillation of NFA-loaded MBs and release of NFA within the microcirculation at the 
target site will create a region of concentrated NFA. Moreover, in conjunction with the increased 
vascular permeability and “leaky” endothelium associated with MVO, local delivery of NFA to 
the surrounding interstitium would be expected, although this is not necessary for effectiveness of 
the NFA.   
We hypothesize that a novel therapeutic MB with a shell composition containing NFAs 
may further augment the therapeutic efficacy of UTMC for MVO. In this study we synthesized a 
novel NFAB agent and characterized it for successful and stable incorporation of NFAs as well as 
other MB contrast agent parameters including MB stability, physical characteristics, and acoustic 
behavior. We then applied the NFABs to our previously characterized rat hindlimb model, which 
mimics the microvascular structure of the heart and allows for adequate US contrast-enhanced 
microvascular perfusion imaging, in both a healthy state and a model of ischemia-reperfusion 
injury. We hypothesized that our novel NFAB agent would result not only in the significant 
improvements in hemodynamic parameters as previously characterized, but also improvements in 




Figure 12: Simplified schematic of experimental procedures 
8.2.1 Nitro-fatty Acid Microbubble Synthesis and Characterization 
Nitro-fatty acid microbubbles (NFABs) were synthesized with a combination of 1,2-
distearoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids Inc., Alabaster, AL), 1,2-Distearoyl-
sn-Glycero-3-Phosphoethanolamine-N-(Methoxy(Polyethylene glycol)-2000) (Avanti Polar 
Lipids), polyoxyethylene-40 stearate (Sigma Aldrich, St. Louis, MO), and 9-nitro-oleic acid, the 
nitro-fatty acid. All components were combined in a glass vial with chloroform in a 
29.1:5.2:43.8:21.9 molar ratio before the resulting solution was vaporized under an argon gas 
stream before vacuum storage. The dehydrated lipids were then rehydrated in acidic saline with a 
head of perfluorobutane gas prior to sonication (XL2020, Qsonica LCC, Neton, CT). The resulting 
NFABs were then washed 3 times in acidic saline to remove unsonicated lipids from solution 
before being aliquoted into sealed glass vials containing perfluorobutane. 
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The NFABs were characterized for concentration, size distribution, and loaded NFA content. All 
measurements were taken serially over up to 6 days post-synthesis to allow for tracking of stability 
in storage and loss of NFA content over time. Concentration and size distribution were measured 
using a Coulter Counter (Multisizer 3 Beckman Coulter). NFA content was measured using liquid 
chromatography and mass spectrometry of the final NFAB solution as well as the solution 
subnatant for quantification of free NFA. Free NFA was subtracted from the overall solution NFA 
measurement resulting in a concentration of only NFA loaded onto NFABs. 
 
8.2.2 Other Microbubbles Used 
As a comparison to the NFABs, in-house lipid MBs were synthesized using the same lipid 
components in absence of NFA using the same procedure and quantification for size and 
concentration. For contrast-enhanced US imaging, DEFINITY® MBs (Lantheus Medical 
Imaging, North Billerica, MA) were used without dilution. These MBs have a mean diameter of 
1.1-3.3 m and approximate concentration of 1.21010 microbubbles/mL in solution. 
 
8.2.3 Animal Preparation 
The animal studies performed in this investigation all received prior approval by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh. The rat hindlimb 
model previously developed in our laboratory was used for modeling of both healthy 
microvasculature and microvasculature experiencing ischemia-reperfusion injury [191]. 
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Briefly, anesthesia was induced using 2.5% inhaled isoflurane in Sprague-Dawley rats weighing 
275±20 g. The right femoral artery and right internal jugular vein were then cannulated for 
intravascular access. The distal right femoral artery was ligated, and the infusion line was advanced 
to the level of the iliac bifurcation for direct access to the left femoral artery. The jugular access 
was used to delivery DEFINITY® MBs for contrast-enhanced US imaging undiluted at a rate of 
2 mL per hr. The left femoral access was used to deliver treatment MBs and therapeutic agents. 
Treatment groups for the experiments included free NFA alone (with a vehicle of 85:15 
polyethylene glycol to ethanol), free NFA with unmodified treatment MBs co-infusion, and NFAB 
infusion only. 
8.2.4 Ultrasound Therapy and Perfusion Imaging 
For the UTMC treatment, therapeutic US was administered using a single-element 
transducer operating at 1 MHz frequency (A303S, 0.5 inch, Olympus NDT, Waltham, MA). Along 
with the transducer, an arbitrary function generator (AFG3252, Tektronix, Beaverton, OR) and 
radio frequency power amplifier (800A3B, Amplifier Research, Souderton, PA) were used. This 
treatment transducer was fixed vertically above the gastrocnemius region of the left rat hindlimb 
(with the rat placed in right lateral decubitus position) at a distance of approximately 2 cm from 
the hindlimb surface according to the focal length of the transducer and was coupled to the 
hindlimb using acoustic gel.  
The therapeutic US pulse itself consisted of 5000 cycles of 1 MHz tone with a peak 
negative acoustic pressure of 1.5 MPa. There was a 3 second interval between each pulse of 5000 
cycles. The pulse was administered for 2 treatments of 10 minutes during infusion of the 
appropriate MB and therapeutic agent combination for each treatment group. Each individual 
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treatment was followed by contrast-enhanced US imaging using a clinical imaging probe 
(Siemens, Sequoia, 15L8 probe) and infusion of DEFINITY® MBs. It is noted that all MBs were 
infused using automated syringe pumps and all MB syringes were constantly rotated during 
administration to maintain MBs in suspension and avoid excess flotation.  
Contrast-enhanced US imaging was performed using the burst-replenishment technique in 
contrast pulse sequence mode at 7 MHz frequency with a mechanical index of 0.2 and framerate 
of 5 frames per second. For the burst at the start of imaging, a 5-frame pulse with mechanical index 
of 1.9 was used to extinguish all contrast MBs from the field of view. After the burst, reperfusion 
of the hindlimb view with contrast MBs was recorded for further processing and analysis of 
hemodynamic parameters in cine-loops. All other US parameters including dynamic range (60 
dB), gain (0 dB), and linear compression curve were kept constant throughout the studies for all 
treatment groups. 
8.2.5 Image Acquisition and Processing 
The imaging US transducer was positioned perpendicular to the longitudinal axis of the rat 
tibia and parallel to the working surface (also perpendicular to the treatment transducer axis). The 
transducer was manipulated such that the junction of the saphenous and popliteal arteries was 
visible in the field of view and the skin thickness was minimized. Occasional artifacts potentially 
representing bone reflections were permitted but ultimately excluded from any regions of analysis. 
Processing of all recorded cine-loops from burst-replenishment imaging was performed 
using in-house code in MATLAB as described previously. Briefly, microvasculature regions of 
interest were selected for the gastrocnemius microvasculature such that skin, bone, and major 
vessels (saphenous and popliteal) were excluded. Image brightness (converted from a 16-bit scale 
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to 60 dB range) of the region of interest was analyzed over the appx 30 second duration of each 
cine-loop and fit to an exponential regression. The coefficient of the exponential regression was 
taken to be the plateau value for the image brightness (due to saturation of the field of view with 
contrast MBs after allowing adequate reperfusion) while the coefficient in front of the exponent of 
the regression equation was taken to be an inverse time constant (accounting for the steepness of 
the increase of the brightness to the plateau value over time). Hemodynamically, the plateau value 
was taken to be the microvascular blood volume (representing the saturated reperfusion of contrast 
MBs in the hindlimb view) while the inverse time constant multiplied by the plateau value resulted 
in the microvascular blood flow rate (units of brightness per second later converted to dB per 
second). 
8.2.6 Healthy Hindlimb Model Experimental Protocol 
Treatment groups for the healthy hindlimb model were centered around analysis of tissue 
delivery of the loaded NFA and included free NFA alone, NFA with co-infusion of unmodified 
MB UTMC, and UTMC with NFABs. Dosage of NFA in all treatment groups was equalized based 
on the measured amount of NFA quantified in 1E9 NFABs, which was taken to be the treatment 
dosage. Similarly, all treatment MBs (regardless of NFA loading) were equalized in dosage to 1E9 
MBs per overall treatment (2 times 10-minute treatments). All treatment infusions (NFA or MB 
infusions) were administered via the femoral cannulation at 3 mL per hr. All imaging MB infusions 
were administered via the internal jugular cannulation at 2 mL per hr. 
Placement of the therapeutic transducer over the gastrocnemius muscle was confirmed by 
visual inspection and one pulse of MB destruction in the field of view prior to treatment. After 
each 10-minute treatment, infusion of imaging MBs was performed during burst-replenishment 
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imaging and cine-loop recording. Rat physiologic parameters including heart rate, respiratory rate, 
and oxygen saturation were continuously monitored. After the second 10-minute treatment, the rat 
was euthanized by isoflurane overdose followed by heart excision. Following euthanasia, tissue 
samples were obtained from the UTMC-treated gastrocnemius muscle tissue as guided by US 
imaging markers. Tissue samples were also collected from the ipsilateral quadriceps femoris 
muscle as a control for the UTMC treatment receiving the same systemic perfusion of infused 
agents without targeted US stimulation. All tissue samples were then immediately frozen in liquid 
nitrogen and stored at minus 80 degrees Celsius. 
8.2.7 Ischemia-Reperfusion Injury Model Experimental Protocol 
The general protocol for the ischemia-reperfusion injury model remains the same as the 
healthy hindlimb model with a few exceptions. Prior to treatment, the left femoral artery was 
ligated using a suture, resulting in isolated hindlimb ischemia. This is distinct from the right 
femoral artery which was the site for cannulation into the aorta iliac bifurcation. After an hour of 
hindlimb ischemia, the suture was removed, allowing for reperfusion of the hindlimb for half an 
hour. After this half hour, treatment proceeded as with the healthy hindlimb model. After the 
second 10-minute treatment and perfusion imaging, a 2-hour wait was instated to allow for 
development of pathophysiologic changes in gene expression before the animal was sacrificed and 
tissue samples were collected. 
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8.2.8 Measurement of NFA in NFABs and Tissue Samples 
For samples of NFABs, both the MBs in saline solution and samples of the saline subnatant 
alone were measured for NFA content. Subnatant NFA concentration was subtracted from overall 
MB solution NFA concentration to give concentration of incorporated NFA only. For tissue 
samples, skeletal muscle tissue was taken from the treatment site (gastrocnemius muscle) and a 
control site (quadriceps femoris muscle) on the ipsilateral hindlimb. Differential of NFA between 
the two sites was obtained by subtraction of their respective NFA concentrations. The protocol for 
NFA concentration quantification using liquid chromatography/mass spectrometry is documented 
in previous literature [235]. 
8.2.9 Measurement of Gene Expression 
Skeletal muscle tissue samples from the same treatment and control locations previously 
described were also obtained and frozen in liquid nitrogen prior to mRNA isolation and assessment 
for expression using real-time PCR. Target genes included intercellular adhesion molecule 1 
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and monocyte chemotactic protein 1 
(MCP-1). These target genes have been previously validated as markers upregulated in the 
ischemia-reperfusion injury pathologic response and regulated by successful NFA treatment [235]. 
8.2.10 Statistical Analyses 
All statistical analyses were performed in Prism (GraphPad Prism version 8.00, GraphPad 
Software, La Jolla, California, USA). Analyses were performed as either one-way ANOVAs or 
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two-way repeated measures ANOVAs when appropriate. Post-hoc analyses for two-way repeated 
measures ANOVAs were performed using Tukey’s HSD while t-tests were used for one-way 
ANOVAs. For pairwise analyses, t-tests of the pairwise differences were performed between 
groups. 
8.3 Results 
8.3.1 Nitro-fatty Acid Microbubble Characterization 
8.3.1.1 Size, Concentration, Distribution 
NFAB size and distribution measurements from Coulter counter analysis are shown in 
Figure 13 and include results from an example batch up to 4 days post-synthesis. Quantitatively 
there were no significant differences in mean and standard deviation of NFAB diameter (3.0  1.5 
micrometers) over the 4 days measured, with NFAB concentration dropping only to 85% of the 
original concentration from day 1 onward. The distribution curves depict a unimodal population 




Figure 13: Coulter counter measurement of NFABs 
Samples of NFABs from the same synthesis batch were serially sampled for measurement in a Coulter 
counter for distributions of MB counts over MB diameters, showing stability of the size and size distribution 
up to 4 days post-synthesis. 
 
Figure 14: Quantification of loaded NFA for NFABs 
Samples of NFABs in saline were quantified for NFA concentration using LC/MS methods. Subnatant 
samples with no NFABs were also quantified for concentration of free, unincorporated NFA which was then 
subtracted from total NFA concentration, resulting in the shown measurements. 
8.3.1.2 Nitro-fatty Acid Content 
Loaded NFA content for three batches of NFABs were serially measured up to 4 days post-
synthesis in triplicate with results shown in Figure 14. The average concentration was 
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approximately 82.9  5.8 nmol of NFA per 1E9 MBs after subtraction of the subnatant unloaded 
NFA content. Because the therapeutic dose for MBs previously established in the rat hindlimb 
model is 1E9 MBs delivered, the loaded NFA content of 1E9 MBs was taken as the equivalent 
dosage for free NFA infusion and free NFA with normal MB UTMC. Although statistics were not 
performed due to the low sample size, future experiments include increasing the replicate number 
for a more representative sampling of loaded NFA concentration.  
 
8.3.1.3 High-speed Microscopy Imaging 
High-speed microscopy during US stimulation of NFABs is shown in Figure 15 in the form 
of a still-frame series at 1.5 MPa. Given that a negative peak acoustic pressure of 1.5 MPa is well 
within the regime for inertial cavitation, images of the oscillating NFABs reflect these differences. 
For the 1.5 MPa still-frame series, several morphological changes in the oscillating NFABs are 
present. Namely, destruction of the MB and loss of spherical structure are immediately noticeable 
in each rarefactive phase visualized. In addition, separation of the expanded mother MB into 
several daughter MBs is also visible and is one of the potential mechanisms of efficacy for UTMC. 
Behavior of NFABs at 1.5 MPa suggest that these novel MBs behave similarly to other unmodified 
lipid MBs under US stimulation and will function appropriately in UTMC and sonothrombolysis. 
 182 
 
Figure 15: High speed imaging of NFABs stimulated by US at 1.5 MPa 
Frame by frame analysis (10-25 million frames per second) of NFABs show typical lipid MB behaviors as 
expected in inertial cavitation, including collapse and formation of daughter MBs. 
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8.3.2 Healthy Hindlimb Model 
 
Figure 16: Burst-replenishment still-frame images from contrast-enhanced US imaging 
Still-frame observational analysis at 5 seconds post-burst show drastic differences in replenishment between 
NFAB+UTMC and Free NFA+UTMC groups. Much of the microvascular bed is yet to be replenished in the 
latter, suggesting possible microvascular slowing or previously discussed microvascular spasm, while the 
former group shows full replenishment of the microvasculature exceeding baseline levels. TX1 for treatment 
1, TX2 for treatment 2 imaging periods after a 10 minute treatment. 
8.3.2.1 Perfusion Changes in Contrast-enhanced Ultrasound Imaging 
Burst-replenishment imaging representative still-frames at 5 seconds post-burst for the two 
UTMC-treated healthy hindlimb groups are shown in Figure 16. As the main difference between 
these two groups is the compartment of incorporation of NFA into the MB structure versus co-
infusion with unmodified MBs, differences between these groups was taken to represent the effect 
of incorporating NFA into the lipid MB shell.  
The NFAB group showed not only a greater area coverage of contrast-visualized 
reperfusion as well as a greater image intensity compared to the baseline state. The free NFA co-
infusion group with regular UTMC does not show greater intensity compared to baseline, as well 
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as incomplete reperfusion at 5 seconds post-burst. Although this is not representative of a persistent 
hypoperfused region given that at 30 seconds post-burst, the hypointense region was successfully 
reperfused, this abridged comparison further emphasizes the improved speed of microvascular 
reperfusion seen in the NFAB treatment group. Still-frame visualization demonstrated increased 
speed of microvascular perfusion of the NFAB group that was further reinforced by quantification 
of microvascular perfusion using region-of-interest selection. 
Quantification of the hindlimb cine-loops using an exponential regression for region-of-
interest image intensity is presented in Figures 17 and 18. Although both the NFAB and free NFA 
co-infusion with UTMC groups showed increases in microvascular blood volume, only the NFAB 
group demonstrated increased microvascular flow rate as well. As control, free NFA alone did not 
affect hindlimb microvascular perfusion. These results suggest that while UTMC itself had a 
significant effect on increasing blood volume, the incorporation of NFA into the MB shells offered 
additional hemodynamic benefits. 
 
Figure 17: Changes in microvascular blood volume 
Changes in microvascular blood volume show similar increases from baseline for both NFA+UTMC and free 
NFA + UTMC groups after treatments 1 and 2. Three asterisks indicates p<0.001 between the bracketed 






Figure 18: Change in microvascular flow rate 
Only the NFAB+UTMC group demonstrated significantly increased microvascular blood flow rate compared 
to other treatment groups. Three asterisks indicate p<0.001. TX1 for treatment 1, TX2 for treatment 2 
imaging periods after a 10 minute treatment. 
8.3.2.2 Tissue Delivery of Nitro-fatty Acid 
Tissue concentrations of NFA at both US treated and untreated sites for the three groups 
are shown in Figure 19 as differences in concentration between the two sites. Free NFA alone 
showed no difference in concentration (as no UTMC was applied to the hindlimb in this group), 
while NFA co-infusion with regular UTMC and NFAB UTMC showed sequentially increasing 
differences in concentration. Incorporation of NFA into the lipid MB resulted in approximately 




Figure 19: Change in tissue concentration of NFA 
Change in NFA concentration was taken as a difference between US treated and untreated regions on the 
ipsilateral hindlimb on the same animal. All samples were analyzed as pairwise differences of treated minus 
untreated concentrations of NFA. 
8.3.3 Ischemia-reperfusion Injury Model 
8.3.3.1 Perfusion Changes in Contrast-enhanced Ultrasound Imaging 
Still-frames from the burst-replenishment cine-loops are shown in Figure 20 for the NFAB 
and NFA co-infusion with standard UTMC groups. The NFAB group showed significant increases 
in perfusion compared to the post-IR state while the NFA co-infusion group showed no 
improvements with potentially even decreases in perfusion.  
Quantitative analysis of hindlimb perfusion showed that only the NFAB group had 
significant increases in microvascular blood volume as well as microvascular blood flow after each 
treatment (Figures 21 and 22). In addition, the free NFA only group and the NFA co-infusion 
group showed decreased mean microvascular blood flow after each treatment below the flow rate 
immediately after ischemia-reperfusion injury. 
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Figure 20: Contrast-enhanced US still-frame images 
TX1 for treatment 1, TX2 for treatment 2 imaging periods after a 10 minute treatment. 
Still-frame images were taken from burst-replenishment contrast-enhanced cine-loops at 5 seconds post-
burst. Note the complete replenishment of microvasculature in the NFAB+UTMC group while the free 
NFA+UTMC group shows a decrease in microvascular perfusion. 
 
Figure 21: Changes in microvascular blood volume in the IR model 
Significant increases in microvascular blood volume are only seen in the NFAB+UTMC group for the IR 
model after each treatment. Compared to the healthy hindlimb model, no significant increases in 
microvascular blood volume were seen in the free NFA+UTMC group after the post-IR imaging interval. 
Asterisk indicates p<0.05 for bracketed groups. TX1 for treatment 1, TX2 for treatment 2 imaging periods 
after a 10 minute treatment. 
 188 
 
Figure 22: Changes in microvascular blood flow rate in the IR model 
Similar to microvascular blood volume, only the NFAB+UTMC group showed significant increases in 
microvascular blood flow rate compared to all other groups. Dagger indicates p<0.05 against all other groups. 
TX1 for treatment 1, TX2 for treatment 2 imaging periods after a 10 minute treatment. 
8.3.3.2 Gene Expression Changes 
Results of gene expression analysis for all target genes are shown in Figure 23. For I-
CAM1, V-CAM1, MCP, and TNF-, only the NFAB group resulted in significantly lower gene 
expression in the treatment sample compared to the control sample. In addition, the treated NFAB 
sample showed a lower level of gene expression than treated samples from all other groups. 
Although the NFA only and NFA co-infusion groups showed lower mean relative treatment group 




Figure 23: Gene expression changes with NFAB UTMC treatment 
Changes in gene expression for key genes in inflammation and recruitment of leukocytes are shown for 
skeletal muscle tissue samples taken from control (no US treatment) and US treated sites on the ipsilateral 
hindlimb from the same animal. Only the NFAB+UTMC group showed significant reductions in mRNA 
expression for the target genes in the treatment site compared to the other groups. Both control and 
treatment sites were subjected to the same IR injury. Asterisk indicates p<0.05 between bracketed groups. 
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8.4 Discussion and Conclusions 
In this study a newly developed NFA microbubble agent was characterized and applied in 
UTMC therapy in both healthy and disease hindlimb models. To our knowledge this is the first 
MB functionalization of NFAs as well as the first application of NFAs in UTMC therapy. Not only 
was the novel NFAB agent shown to be stable in terms of MB properties and loading of the NFA, 
ultra-high-speed microscopy analysis of the NFABs showed similar acoustic responses under US 
stimulation as previous lipid MB agents. Results from the healthy hindlimb model showed that not 
only did NFAB UTMC result in increased microvascular flow rate compared to a co-infusion of 
free NFA with standard MB UTMC, it also resulted in increased skeletal muscle tissue 
concentration of NFA in the treatment site. For the ischemia-reperfusion injury hindlimb model, 
NFAB UTMC again resulted in significantly improved hemodynamic parameters compared to all 
other treatment groups, as well as reduced levels of gene expression for signaling mediators of 
inflammation and oxidative stress, demonstrating the improved efficacy of NFAB UTMC in 
delivering targeted benefits of NFAs over NFA co-infusion with standard lipid MBs. 
In comparing the contrast-enhanced perfusion US imaging results of this study with 
previous investigations of UTMC, similarities were noted with our previous study using nitrite in 
adjunctive administration with UTMC [191]. However, while nitrite is a known reservoir of nitric 
oxide bioavailability and has several identified mechanisms of chemical conversion to nitric oxide 
especially in environments of hypoxia and acidosis, NFAs have been noted to only directly serve 
as a nitric oxide donor in strongly aqueous environments that are not similar to the biological 
vascular environment [217, 226]. Therefore, the mechanism of enhanced perfusion by NFAs is 
unlikely to result from direct donation of nitric oxide.  
 191 
This is also supported by our results showing that infusion of free NFA alone had no 
significant effects on hindlimb perfusion. However, previous investigations have shown that NFAs 
may have other mechanisms of enhancing nitric oxide bioavailability. These include upregulation 
of heme oxygenase-1 (HO-1) and endothelial nitric oxide synthase (eNOS) gene expression and 
increased phosphorylation of eNOS at several sites including the Ser1177 site, which is known to 
regulate enzymatic activity [243, 244]. HO-1 serves to metabolize hemoglobin, which scavenges 
free NO as well [241]. Given that previous studies on in vitro endothelial NO production after 
NFA administration already showed significant increases at 2 hours post-treatment, these 
mechanisms of gene expression upregulation and post-translational modification of eNOS are 
more likely feasible in the timescale of the treatments in this investigation.  
In addition, our previous studies suggest that UTMC plays a role in increasing NO 
bioavailability through interactions with endogenous NO production given the blunting effect of 
eNOS inhibitors on UTMC-associated increases in perfusion [190]. In addition, nitrite was also 
shown to have positive interactions with eNOS NO production, which served as a mechanistic 
explanation for the synergy in both NO production and increased perfusion when administered 
with UTMC [191]. Similar to this precedent, both UTMC and NFAs may have positive interactions 
on eNOS activity for increased NO bioavailability. Future studies may investigate the specific 
mechanisms further including measurement of eNOS phosphorylation and various protein kinase 
phosphorylation as well as in vivo measurement of NO bioactivity. 
Comparison of the NFAB UTMC results against the free NFA co-infusion with standard 
MB UTMC showed significant increases in perfusion with NFABs. Because the total dosage of 
NFA between these two groups was equalized against the quantified amount of NFA loaded onto 
the NFABs, the differences between these two groups is most likely attributed to the mechanistic 
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advantages of NFA incorporation into the lipid shell itself. Previous studies on MB-based 
therapeutic delivery have shown that attachment of the therapeutic agent on MBs themselves does 
result in improved localization in the UTMC target site [275, 276, 286]. However, because this 
study is the first to our knowledge utilizing bioactive therapeutic lipids, we can only assume from 
previous MB delivery treatments that similar principles would apply in this context. Therefore, 
mechanisms including sonoporation and sono-printing may apply with this application. Given that 
NFAs have known mechanisms of incorporation into biological membranes leading to nuclear 
translocation and alteration of gene expression, said mechanisms of UTMC may suffice for 
successful delivery and signal transduction of the NFAs. However, to fully analyze the effects of 
UTMC on facilitating effects of NFA co-infusion as well as to isolate the effects of UTMC alone, 
further experimental groups of normal UTMC alone, NFA vehicle alone, and a non-nitrated fatty 
acid such as oleic acid alone are needed and planned for future study. 
With regards to alterations in gene expression, we have demonstrated that NFAB UTMC 
resulted in significantly decreased expression of several gene targets relevant to inflammation and 
ischemia-reperfusion injury, especially compared against the NFA co-infusion with standard 
UTMC, which did not show significant changes in levels of gene expression between treatment 
and control sites within the same animal. Although this is further evidence for the improved 
efficacy of NFAs when incorporated into NFABs, our results for NFA alone and NFA co-infusion 
show significantly reduced therapeutic efficacy that is likely due to our experimental design when 
compared against previous studies evaluating the effects of NFAs on gene expression.  
Specifically, a previous study on focal cardiac ischemia analyzing effects of nitro-oleic 
acid on several similar target genes as in the present investigation implemented a period of 24 
hours between treatment and tissue sample collection [235]. Given that our protocol only waited 
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2 hours between conclusion of treatments and tissue collection, the increased time in the previous 
study may have allowed for significantly more therapeutic activity of the NFAs as well as 
incubation of further pathologic gene expression changes in the untreated tissue samples.  
However, because our treatment groups included several groups which all involved 
administration of the same cumulative NFA dose, a shorter incubation time in this investigation 
was used to improve sensitivity between these groups in detecting significant group effects. In 
addition, given the ease with which nitro-fatty acids may traverse between multiple biological 
compartments, reducing the incubation time further reduces the equilibration effect of NFA 
diffusion, which was also potentially significant in detecting changes in NFA tissue concentration 
between groups with the same NFA dosage. 
Although this study has yielded results demonstrating the potential therapeutic value of 
NFABs in UTMC, there were several limitations. Regarding NFAB characterization, cavitation 
detection in vivo was not implemented, although cavitation was visually confirmed with ultra-
high-speed microscopy and frequency decomposition analysis. Additional optimization of NFAB 
design and composition may be performed. For NFAB UTMC therapy, additional observation 
intervals may be implemented both to improve characterization of short and long-term tissue 
loading kinetics as well as extend characterization of gene expression and hemodynamic parameter 
changes. Stability of NFABs in the circulatory environment was not assessed, although satisfactory 
visualization of NFABs on contrast-enhanced US imaging was confirmed. Mechanistic analyses 
identifying the source of hemodynamic changes were also not performed and may include live in 
vivo detection of changes in NO concentration. Future work includes additional measures and 
genetic targets characterizing oxidative stress and inflammation and application of NFAB UTMC 
in animal models of cardiac pathology such as an MVO model with microthrombi injection. 
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In all, NFAB UTMC is a combination of two treatments leading to greatly expanded 
therapeutic potential. Although this study was limited to a hindlimb model of ischemia-
reperfusion, previous mechanistic studies of NFAs have demonstrated its value in treatment of 
other types of cardiovascular pathology. Given that the strength of UTMC lies in not only in 
delivering and concentrating other therapeutic agents at a target site in a rapid manner but also 
eliciting mechanotransductive intravascular responses, other applications of NFAB UTMC 
specifically may include treatment of myocardial infarction, microvascular obstruction, and during 
post-infarct recovery. Localized inflammatory vascular pathologies such as peripheral vascular 
disease, atherosclerosis, and restenosis may also benefit from NFAB UTMC given the many anti-
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